1980-82 Fellow, Department of Internal Medicine, Division of Rheumatology and Division of Geriatrics, University of Washington School of Medicine, Seattle, WA

1980-81 Chief Resident, Department of Internal Medicine, University of Washington School of Medicine, Seattle, WA

Fellow, Department of Internal Medicine, Division of Rheumatology, University of Washington School of Medicine, Seattle, WA

1979-80 Senior Resident, Department of Internal Medicine, University of Washington

School of Medicine, Seattle, WA

1978-79 Junior Resident, Department of Internal Medicine, University of Washington

School of Medicine, Seattle, WA

1977-78 Intern, Department of Internal Medicine, University of Washington School of

Medicine, Seattle, WA

PROFESSIONAL EXPERIENCE

6/01-present Rheumatology and Internal Medicine, Seattle Rheumatology Associates, Seattle,

6/01-present Director, Division of Rheumatology Clinical Research, Swedish Medical Center, Seattle, WA

1982-present Clinical Professor, University of Washington, Seattle, WA

1985-5/01 Rheumatology and Internal Medicine, Minor & James Medical, Seattle WA

1996-12/00 Medical Director, Division of Clinical Research, Minor & James Medical, Seattle WA

1982-1985 Rheumatology and Internal Medicine, Seattle, WA

BOARD CERTIFICATION

1982 American Board of Rheumatology

1980 American Board of Internal Medicine

LICENSURE TO PRACTICE

State of Washington License # MD00016710

PROFESSIONAL ORGANIZATIONS

2012 Assessment of SpondyloArthritis international Society (ASAS)

2009 The Rheumatology Education Group (TREG)

2006 International Myopain Society

2005 Consortium of Rheumatology Researchers of North America (CORRONA)

(Executive board, scientific steering committee, director – psoriatic arthritis and spondyloarthritis arm of registry)

2004 Spondyloarthritis Research and Therapy Network (SPARTAN)

2003 Outcome Measures in Rheumatology Clinical Trials (OMERACT)

(Steering committee; co-chair psoriatic arthritis, chronic pain/fibromyalgia, single joint assessment working groups; member biomarker working group)

2003 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

(Founder and immediate past president)

1996 American Society of Bone & Mineral Research

1982 King County Medical Society

1982 American College of Rheumatology

1978 American College of Physicians

HOSPITAL APPOINTMENTS

TEACHING ACTIVITIES

Teaching Physician, Family Practice and Internal Medicine Residency Program, Swedish Medical Center, Seattle, WA

Teaching Physician, Family Practice and Internal Medicine Residency Program, Providence Medical Center, Seattle, WA

Clinical Professor, University of Washington Hospitals

T32 grant Mentor for Clinical Research for Rheumatology Fellows, University of Washington

Staff Physician, Swedish Medical Center, Seattle, WA

CONSULTANT ACTIVITY

2016-present Consultant, Clinical Development, Vitaeris

2015-present Consultant, Clinical Development, SUN Pharmaceuticals

2014-present Consultant, Clinical Development, Boehringer Ingelheim

2014-present Consultant, Clinical Development, Zynerba

2013-present Consultant, Clinical Development, Dermira

2012-present Consultant, Clinical Development, Cell Therapeutics

2011-present Consultant, Clinical Development, Portola

2010-present Consultant, Clinical Development, Novartis

2010-present Consultant, Clinical Development, ICON

2009-present Consultant, Clinical Development, Celgene

2009-present Consultant, Clinical Development, NicOx

2009-present Consultant, Clinical Development, Crescendo Bioscience

2009-present Consultant, Clinical Development, AnaMar

2008-present Consultant, Clinical Development, Biocryst

2007-present Consultant, Clinical Development, Roche

2007-present Consultant, Clinical Development, Dharma

2006-present Consultant, Clinical Development, PanGenetics

2006-present Consultant, Clinical Development, Jazz Pharmaceutical

2006-present Consultant, Clinical Development, Genentech

2006-present Consultant, Clinical Development, Fralex

2006-present Consultant, Clinical Development, Bristol Myers Squibb

2006-present Consultant, Clinical Development, Biovail

2006-present Consultant, Clinical Development, Allergan

2006-present Consultant, Clinical Development, Alder

2005-present Consultant, Clinical Development, UCB

2004-present Consultant, Clinical Development, Schering Plough

2004-present Consultant, Clinical Development, Pierre Fabre

2004-present Consultant, Clinical Development, Nastech

2004-present Consultant, Clinical Development, Lilly

2004-present Consultant, Clinical Development, Genentech

2004-present Consultant, Clinical Development, Regeneron

2003-present Consultant, Clinical Development, Trubion Pharmaceuticals

2003-present Consultant, Clinical Development, Forest Pharmaceuticals

2003-present Consultant, Clinical Development, BiogenIdec

2003-2006 Consultant, Clinical Development, Xcyte Therapeutics

2002-present Consultant, Clinical Development, Seattle Genetics

2002-present Consultant, Clinical Development, Combimatrix

2002-present Consultant, Clinical Development, Centocor

2002-present Consultant, Clinical Development, Amgen

2002-present Consultant, Clinical Development, Abbott

2001-present Consultant, Clinical Development, Targeted Genetics

2001-present Consultant, Clinical Development, Serono

2001-present Consultant, Clinical Development, Pharmacia

2001-present Consultant, Clinical Development, Pfizer

2001-present Consultant, Clinical Development, MedImmune

2001-present Consultant, Clinical Development, Cypress Bioscience

2001-2002 Consultant, Clinical Development, Zorion

2000-present Consultant, Clinical Development, Zymogenetics

2000-present Consultant, Clinical Development, Wyeth

2000-present Consultant, Clinical Development, Genelab Technologies

2000-2002 Consultant, Clinical Development, Immunex

1999-present Consultant, Clinical Development, Centocor

1999-present Consultant, Clinical Development, Aventis

1997-2004 Consultant, Clinical Development, Histatek

1995-2001 Medical/Research Consultant, Osteoporosis and Bone Health Center,

Minor & James Medical, Seattle, WA

1994-present Consultant, Clinical Development, MyoRx/EBOC

1989-2002 Medical/Research Consultant, Center for Comprehensive Care, Seattle, WA

INTERNATIONAL/NATIONAL WORKING GROUPS

2012-present Co-chair, OMERACT pain working group

2011-present Member, Treat-to-Target in Spondyloarthritis and Psoriatic Arthritis working group

2011-present Member, IMMPACT-ACTION working group on methodology of pain assessment

2009-present Co-chair, ACR-EULAR Psoriatic Arthritis responder index committee

2009-present Member, ACR-EULAR Rheumatoid Arthritis classification criteria committee

2008-present Member, OMERACT working group on fatigue

2007-present Member, OMERACT working group on soluble biomarkers

2003-present Member, OMERACT working group on patient participation

2003-present Co-chair, OMERACT special interest group on single joint assessment

2003-present Co-Chair, OMERACT working group on fibromyalgia

2003-present Co-Chair, OMERACT working group on psoriatic arthritis

FDA ADVISORY

2015 Mock opponent for Pfizer tofacitinib in psoriasis

2013 Presenter in two-day FDA Advisory Committee meeting on ankylosing spondylitis/axial spondyloarthritis – request by Abbvie and UCB to expand indication for anti-TNF therapy to AxSpA. In preparation, participated in four mock meetings for the two companies

2001-present Have advised biopharmaceutical companies on FDA submissions ranging from pre-IND through phase 3 and have served as external consultant to in-person meetings between companies and FDA for submissions in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis

ADVISORY BOARDS

2016-present Abbvie PsA-AS Advisory Board (JAKi, TNFi-IL17i)

2015-present SUN Pharma PsA Advisory Board (IL23i)

2015-present SUN Pharma AS Advisory Board (IL23i)

2015-present Boehringer Ingelheim PsA Advisory Board (IL23i)

2015-present Boehringer Ingelheim AS Advisory Board (IL23i)

2015-present Mallinckrodt PsA Advisory Board

2015-present Zynerga OA-FM Advisory Board

2014-present UCB Psoriasis Advisory Board

2014-present Pfizer Psoriasis Advisory Board

2014-present Pfizer Global Data Advisory Board

2014-present Boeringer Ingelheim Psoriatic Arthritis, Spondyloarthritis Advisory Board

2014-present Zynerba Fibromyalgia Advisory Board

2014-present Theravance Fibromyalgia Advisory Board

2013-present Daiichi Sankyo Fibromyalgia Advisory Board

2012-present Abbvie Psoriatic Arthritis Advisory Board

2012-present UCB Spondyloarthritis Advisory Board

2012-present UCB Psoriatic Arthritis Advisory Board

2012-present Pfizer Spondyloarthritis Advisory Board (co-chair)

2012-present Celgene Psoriatic Arthritis Advisory Board

2012-present Lilly Psoriatic Arthritis Advisory Board

2012-present Lilly Ankylosing Spondylitis Advisory Board

2012-present Novartis Psoriatic Arthritis Advisory Board

2012-present Novartis Axial Spondyloarthritis Advisory Board

2011-present Novartis Immunoscience National Advisory Board

2011-present Pfizer Psoriatic Arthritis Advisory Board

2011-present Pfizer JAK inhibitor MOA Advisory Board (PsA)

2011-present BMS Psoriatic Arthritis Advisory Board

2010-present BMS RA National Advisory Board

2010-present Genentech Ocrelizumab RA National Advisory Board

2009-present Pfizer JAK-3 RA National Advisory Board

2009-present Pfizer Fibromyalgia Education Advisory Board

2008-present Lilly National Academic Pain Advisory Board

2008-present UCB Fibromyalgia Advisory Board

2005-present Forest Fibromyalgia Advisory Board

2006-present Alder Biopharma Rheumatology Advisory Board

2005-present National Fibromyalgia Association Medical Advisory Board

2007-present Seattle Genetics Autoimmune Disease Advisory Board

2007-present Abbott Spondyloarthropathy Advisory Board

2007-present Boehringer-Ingelheim Fibromyalgia Advisory Board

2007-present Roche Global RA Advisory Board (tocilizumab)

2007-present Wyeth Fibromyalgia Advisory Board

2006-present Abbott, Treatment Resistant Depression Advisory Board

2006-present Allergan, Fibromyalgia Advisory Board

2006-present Genentech Publication Advisory Board

2006-present Fralex Fibromyalgia Advisory Board

2006-present Jazz Pharmaceutical, Fibromyalgia Advisory Board

2005-present Genentech, RA National Advisory Board, Rituximab

2005-present Genentech, Phase IV RA Advisory Board, Rituximab

2005-present Amgen, Global Bone Erosion Advisory Board

2005-present UCB, PsA/Psoriasis Advisory Board

2005-present National Psoriasis Foundation medical advisory board

2005-present National Fibromyalgia Association Medical Advisory Board

2005-present Genentech/BiogenIDEC, Steering Committee National RA Education

2005-present UCB, RA Advisory Board

2005-present BMS Psoriatic Arthritis Global Advisory Board

2004-present Centocor, IRT Advisory Board

2004-present Centocor, CNTO 104 Rheumatology Scientific Advisory Board

2004-present Genentech/IDEC Regional Advisory Board: Rituximab in RA

2004-present Serono, International Psoriasis and Psoriatic Arthritis Advisory Board

2004-present Abbott, RA National Advisory Board: Adalimumab

2004-present Genentech, Psoriasis and Psoriatic Arthritis National Advisory Board: Efalizumab

2004-present Lilly, Fibromyalgia Advisory Board

2004-present Wyeth, Early Arthritis Advisory Board

2004-present Pfizer, Pregabalin Mechanism of Action Advisory Board

2003-present Trubion, Rheumatology Scientific Advisory Board

2003-present Centocor North American Advisory Board

2003-present Xcyte, Rheumatology Scientific Advisory Board

2003-present Bristol-Myers, CTLA4IG Mechanism of Action Advisory Board

2003-present National Psoriasis Foundation Medical Advisory Board

2003-present Amgen-Wyeth Ankylosing Spondylitis Advisory Board

2002-present Biogen Psoriatic Arthritis Advisory Board

2002-present Novartis, TARGET Steering Committee

2002-present Abbott Psoriatic Arthritis Advisory Board

2002-present Xoma Psoriatic Arthritis Advisory Board

2002-present American Academy of Dermatology Advisory Board re.dermatologist education about biologics

2002-present Amgen(Immunex)/Wyeth, National Advisory Board (Enbrel®)

2002-present Amgen(Immunex)/Wyeth, Regional Advisory Board (Enbrel®)

2002-present Amgen(Immunex)/Wyeth, RADIUS Faculty and Advisory Board

2001-present Targeted Genetics, Rheumatology Scientific Advisory Board

2001-present Cypress Bioscience Fibromyalgia Advisory Board

2001-present National Psoriasis Foundation Clinical Advisory Board

2001-present Medimmune Psoriatic Arthritis Advisory Board

2001-present Amgen(Immunex)/Wyeth Ayerst, Psoriatic Arthritis and Psoriasis Advisory Board

2000-present Pfizer, Fibromyalgia Advisory Board

2000-present Aventis, Psoriatic Arthritis Advisory Board

1998-present Proctor & Gamble/Hoechst Marion Roussel, Alliance for Better Bone Health, Northwest Regional Expert Consultant Board

1998-present Proctor & Gamble/Hoechst Marion Roussel, Alliance for Better Bone Health, National Primary Care Consultant Panel

1998-present Immunex/Wyeth Ayerst, Patient Compliance Advisory Board

JOURNAL REVIEW BUREAUS

Journal of Rheumatology

Annals of the Rheumatic Diseases

Journal of Clinical Investigation

Journal of Musculoskeletal Medicine

Arthritis & Rheumatology

Seminars in Arthritis & Rheumatism

Arthritis Care & Research

Nature Reviews Rheumatology

SPEAKERS BUREAUS

National Psoriasis Foundation, Abbvie, Amgen, Bristol Myers Squibb, Celgene, Crescendo, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB

SERVICE/VOLUNTEER ACTIVITIES

2004-present Volunteer for medical missions in Central and South America, Amigos de

Amistad y Salud

2003-present Washington Osteoporosis Coalition, founder and board of directors

1999-present Director, Northwest Arthritis Institute (non-profit education and research foundation)

1997-2005 Management Board, Lupus Foundation, Washington State Chapter

1988-present Medical Advisory Board, Lupus Foundation, Washington State Chapter

1994-1996 Professional Education Committee, Arthritis Foundation, Washington State

Chapter

1990-1996 Coach, Seattle Youth Soccer Association

1989-93 Executive Committee, Arthritis Foundation, Washington State Chapter

1989-93 Chair, Education Committee, Arthritis Foundation, Washington State Chapter

1989-93 Management Board, Arthritis Foundation, Washington State Chapter

1973 Taught course on International Health to Stanford undergraduates

1973 Operated medical clinics in Antigua, Guatemala

1970-71 Operated medical clinic in a remote area of the Sierra Madre mountains, Sinaloa,

Mexico

HONORS & AWARDS

“Opponent” for Thoradur Love PhD defense, University of Iceland, Reykjavik, Iceland - 2013

Recognized in The Best Doctors in America, 1992, 2000, 2002, 2007, 2010, 2011, 2012, 2013

Recognized in The Best Doctors in Washington, 1992, 2000, 2002, 2003, 2005, 2006, 2007, 2008,

2010, 2011, 2012, 2013, 2014, 2015

Medical Communicator Award of the American College of Rheumatology, 1993 (awarded

annually to the physician who most effectively and dynamically presents Rheumatology

subjects to the public).

Lifetime Member, National Registry of Who’s Who, 2000

BIBLIOGRAPHY:

TEXTBOOKS and MONOGRAPHS

Adebajo A, Gladman D, Helliwell P, Mease P (eds.) Textbook of Psoriatic Arthritis. Springer. London. 2016.

Mease PJ, Helliwell PS (eds). Atlas of Psoriatic Arthritis. Springer-Verlag, London, 2008.

Grant-Kels M, Rothe M, Mease P (eds). Clinics in Dermatology: Rheumatology and Dermatology Part I. Elsevier, 2006.

Mease PJ, Helliwell P (eds). Atlas of Psoriatic Arthritis. Current Medical Group, London, 2005.

Mease PJ, Lebwohl M (eds). Psoriatic arthritis: a disease of skin and joints. The national center for advanced medical education. A division of CMEinfo.com. 2005.

BOOK CHAPTERS

Mease PJ. “Neurobiology of Pain” Doherty M (ed.) Textbook of Osteoarthritis. Oxford University Press. London. 2016.

Mease PJ. “Biologic Therapy of Psoriatic Arthritis” Adebajo A, Gladman D, Helliwell P, Mease P (eds.) Textbook of Psoriatic Arthritis. Springer. London. 2016.

Mease PJ. “Biologic Treatments for Psoriatic Arthritis Apart from TNF Inhibition” FitzGerald O, Gladman D (eds.) Textbook of Psoriatic Arthritis. Oxford University Press, London 2016.

Mease PJ. “Management of Psoriatic Arthritis.” Hochberg M, Silman A, Smolen J, et al. (eds). Rheumatology. Mosby Elsevier, Philadelphia, 2011.

Mease P. “Psoriatic Arthritis” Stone JH (ed). Myths and Pearls in Rheumatic Disease. Springer, New York, 2009.

Mease PJ (ed). Fibromyalgia, An Issue of Rheumatic Disease Clinics. Elsevier, Philadelphia, 2009.

Mease PJ. “Psoriatic Arthritis.” Radeke, Boehncke WH (eds). Biologics in General Medicine. Springer-Verlag, Heidelberg, 2007.

Mease PJ. “Psoriatic Arthritis.” Lipsky P, Smolen J (eds). Contemporary Targeted Therapies in Rheumatology. Taylor & Francis, 2007.

Mease PJ. “Biologic Therapy of Psoriatic Arthritis.” Ritchlin C, Fitzgerald O (eds). Psoriatic Arthritis. Mosby Elsevier, Philadelphia, 2007.

Mease PJ, Menter A. “Psoriatic Arthritis: Understanding its pathophysiology and improving its diagnosis and management.” Medscape 2006.

Mease PJ. “TNF-a inhibitors in psoriatic arthritis.” Gordon KB, Ruderman EM (eds). Psoriasis and psoriatic arthritis: an integrated approach. Springer-Verlag, Heidelberg 2005.

Mease PJ. “The Management of Psoriatic Arthritis.” Mease PJ, Helliwell P (eds). Atlas of Psoriatic Arthritis. Current Medical Group, London, 2005.

Mease PJ. “Psoriatic Arthritis Update.” Schiff MH (ed). Making a Difference in Rheumatology: Early and Treatment=Better Outcomes for Today’s Patients. Veritas Institute for Medical Education, Inc, 2004.

Menter A, Mease PJ. “Pathogenesis and Treatment of Psoriasis.” Schiff MH (ed). Making a Difference in Rheumatology: Early and Aggressive Treatment=Better Outcomes for Today’s Patients. Veritas Institute for Medical Education, Inc, 2004.

Mease PJ, contributing author for 50 Cases in Rheumatology, Weaver A (ed). Remedica, London, 2002.

Mease PJ. “Psoriatic Arthritis/ Psoriasis.” Smolen JS, Lipsky PE (eds). Targeted Therapies in Rheumatology. Martin Dunitz, London, 2003.

Mease PJ “Rheumatologic Issues.” Agostini R (ed). Medical and Orthopedic Issues of Active and Athletic Women. Hanley & Belfus, Philadelphia 1994.

Mease PJ “Culture variations in health care.” Transcultural Study Guide, Volunteers in Asia Press, 1973.

JOURNAL ARTICLES

Mease P, Gottlieb AB, Berman A, et al. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase 2b Study of Adults with Active Psoriatic Arthritis.

Arthritis Rheumatol. 2016 Apr 5. doi: 10.1002/art.39700. [Epub ahead of print]

Taylor AM, Phillips K … Mease P. Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain. 2016 Apr 7. [Epub ahead of print]

Taylor AM, Taylor JO, Mease PJ, et al. Reply. J Rheumatol. 2016 Apr;43(4):826-7.

van der Heijde D, Landewé RB, Mease PJ, et al. Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Mar 25. doi: 10.1002/art.39685. [Epub ahead of print]

Mease PJ. Do Biologic-treated Psoriatic Arthritis Patients with Spondylitis Respond Differently with or without Concomitant Methotrexate from Patients without Spondylitis? J Rheumatol. 2016 Mar;43(3):471-3.

Kalyoncu U, Ogdie A, Mease P, et al. Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. RMD Open. 2016 Mar 3;2(1):e000217. doi: 10.1136/rmdopen-2015-000217. eCollection 2016.

Mease PJ, Collier DH, Saunders KC, et al. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015 Dec 30;1(1):e000181. doi: 10.1136/rmdopen-2015-000181. eCollection 2015.

Deodhar A, Mease PJ, Reveille JD, et al. Frequency of axial spondyloarthritis diagnosis among patients seen by United States rheumatologists for evaluation of chronic back pain. Arthritis Rheumatol. 2016 Jan 27. doi: 10.1002/art.39612. [Epub ahead of print]

Mease PJ, Genovese MC, Mutebi A, et al. Improvement in psoriasis signs and symptoms assessed by the psoriasis symptom inventory with brodalumab treatment in patients with psoriatic arthritis. J Rheumatol. 2016 Feb;43(2):343-9.

Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis: Treatment recommendations for psoriatic arthritis 2015. Arthritis Rheumatol. 2016 Jan 8. doi: 10.1002/art.39573. [Epub ahead of print]

Kristensen LE, Lie E, Mease PJ, et al. Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: A cohort study from southern Sweden. J Rheumatol. 2016 Jan;43(1):81-7.

Stuart PE, Nair RP … Mease PJ. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015 Dec 3;97(6):816-36.

Mease PJ. Biologic Therapy for Psoriatic Arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):723-38.

Mease PJ, McGinnis IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015 Oct;373(14):1329-1339.

Kavanaugh A, Gladman D, Mease PJ, et al. Clinical responses in joint and skin outcomes and patient-reported outcomes are associated with increased productivity in the workplace and at home in psoriatic arthritis patients treated with certolizumab pegol. Value Health. 2015 Nov;18(7):A654.

Mease P. A short history of biological therapy for psoriatic arthritis. Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):104-8.

Mease P, Deodhar A, Fleischmann R, et al. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open. 2015 Jun 25;1(1):e000119. eCollection 2015.

Glinatsi D, Bird P … Mease PJ. Validation of the OMERACT psoriatic arthritis magnetic resonance imaging score (PsAMRIS) for the hand and foot in a randomized placebo-controlled trial. J Rheumatol. 2015 Dec;42(12):2473-9.

Wolfe F, Fitzcharles MA, Mease PJ, et al. A comparison of physician based and patient based criteria for the diagnosis of fibromyalgia. Arthritis Care Res (Hoboken). 2015 Sep 28. doi: 10.1002/acr.22742. [Epub ahead of print]

Maxwell LJ, Wells GA, Mease PJ, et al. Current state of reporting pain outcomes in Cochrane Reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda. J Rheumatol. 2015 Sep 15. pii: jrheum.141423. [Epub ahead of print]

Turina MC, Ramiro S, Mease P, et al. A psychometric analysis of outcome measures in peripheral spondyloarthritis. Ann Rheum Dis. 2015 Aug 5. [Epub ahead of print]

Weinblatt ME, Mease P, Mysler E, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and inadequate response to methotrexate: results from a phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging, multinational study. Arthritis Rheumatol. 2015 Oct;67(10):2591-600.

Wilson HD, Mutebi A, Mease PJ, et al. Reliability and validity of the psoriasis symptom inventory in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1750-6. doi: 10.1002/acr.22653.

McGinnis IB, Mease PJ, Kirkham A, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28.

Taylor A, Phillips K, Mease PJ, et al. ‘Is chronic pain a disease in its own right? Discussions from a pre-OMERACT 2014 workshop on chronic pain. J Rheumatol. 2015 Jul 1. [Epub ahead of print]

Schaefer C, Mann R … Mease P. The comparative burden of chronic widespread pain and fibromyalgia in the United States. Pain Pract. 2015 May 16. [Epub ahead of print]

Van den Bosch F, Kavanaugh A, Mease PJ, et al. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations. J Rheumatol. 2015 Jun;42(6):952-9.

Mease P, Sieper J, Van den Bosch F, et al. Reply to Henning Zeidler and Anand Malaviya. Arthritis Rheumatol. 2015 Jun 19. doi: 10.1002/art.39229. [Epub ahead of print]

Mease P, Sieper J, Van den Bosch F, et al. Response to editorial on article on efficacy and safety of adalimumab in patients with active nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015 Jun 19. [Epub ahead of print]

Kavanaugh A, van der Heijde D, Mease P, et al. Patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy demonstrate less radiographic progression: Results through 5 years of the randomized, placebo-controlled, GO-REVEAL study. Arthritis Care Res (Hoboken). 2015 Mar 16. [Epub ahead of print]

Østergaard M, Bird P, Mease PJ, et al. The OMERACT MRI in arthritis working group - update on status and future research priorities. J Rheumatol. 2015 Dec;42(12):2470-2.

Phillips K, Taylor A, Mease PJ, et al. Developing outcome measures for mechanisms of chronic musculoskeletal and rheumatologic pain: future directions for the OMERACT pain working group. J Rheumatol. 2015.

Phillips K, Taylor A, Mease P, et al. Harmonizing pain outcome measures: Results of a nominal group technique on pain domains at the Pre-OMERACT meeting on Partnerships for Consensus on Patient-important Outcomes domains between the Cochrane Musculoskeletal Group (CMSG) and OMERACT. J Rheumatol. 2015 Aug 1. [Epub ahead of print]

Tillett W, Eder L, Mease P, et al. Enhanced patient involvement and the need to revise the core set - report from the Psoriatic Arthritis working group at OMERACT 2014. J Rheumatol. 2015 Nov;42(11):2198-203.

Mease PJ. Psoriatic arthritis: current strategies for diagnosis and treatment. Practical Pain Management. Vol 15, Iss 1. 2015.

Keen HI, Hensor EMA, Mease PJ, et al. Ultrasound assessment of response to intra-articular therapy in osteoarthritis of the knee. Rheumatology (Oxford). 2015 Aug;54(8):1385-91.

Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015 Mar;27(2):127-33.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015 Mar;42(3):479-88.

Mease P, Sieper J, Van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with non-psoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015. 67(4):914-23.

van der Heijde D, Breban M ... Mease PJ. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology (Oxford). 2015 Jul;54(7):1210-9.

Mease P. Apremilast: A phosphodiesterase 4 inhibitor approved for treatment of psoriatic arthritis. Rheumatol Ther. 2014; 1:1-20. DOI 10.1007/s40744-014-0005-4.

Mease PJ, Armstrong AW. Effective management of psoriasis and psoriatic arthritis: Insights on current and emerging therapies and enhanced professional collaboration. Semin Arthritis Rheum. 2014 Dec;44(3):e7-8.

Mease PJ, Clauw DJ, Trugman JM, et al. Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study. J Pain Res. 2014;7:679-687. eCollection 2014.

Sieper J, Landewé R, … Mease PJ. Effect of certolizumab pegol over 96 weeks in patients with axial spondyloarthritis: results from a phase 3 randomized trial. Arthritis Rheumatol. 2015 Mar;67(3):668-77.

Boyle DL, Soma K, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015 Jun;74(6):1311-6.

Acosta Felquer ML, Coates LC … Mease PJ. Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol. 2014 Nov;41(11):2277-85.

Deodhar A, Reveille J … Mease P. The concept of axial spondyloarthritis: SPARTAN and ASAS joint statement in response to FDA’s comments and concerns. Arthritis Rheumatol. 2014;66(10):2649-56.

Helliwell P, Coates L … Mease P. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res (Hoboken). 2014;66(12):1759-66.

Mease PJ, Gladman DD, Helliwell P, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2014;71(4):649-55.

Mease PJ, Palmer RH, Wang Y. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials. J Clin Rheumatol. 2014;20(4):195-202.

Gottlieb AB, Armstrong AW, Mease PJ, et al. The international dermatology outcome measures initiative as applied to psoriatic disease outcomes: A report from the GRAPPA 2013 meeting. J Rheumatol. 2014;41(6):1227-9.

de Wit M, Campbell W, Mease PJ, et al. Patient participation in psoriasis and psoriatic arthritis outcome research: A report from the GRAPPA 2013 annual meeting. J Rheumatol. 2014;41(6):1206-11.

Mease PJ, Garg A, Helliwell PS, et al. Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 annual meeting. J Rheumatol. 2014;41(6):1249-51.

Kavanaugh A, Gladman D, Mease P, et al. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis. 2015 Jan;74(1):44-51.

Duffin KC, Garg A, Mease PJ, et al. Psoriasis and psoriatic arthritis educational initiatives: an update from the 2013 GRAPPA annual meeting. J Rheumatol. 2014;41(6):1240-3.

FitzGerald O, Mease PJ, Helliwell PS, et al. GRAPPA 2013 annual meeting, rheumatology updates: psoriatic arthritis (PsA) biomarker project, arthritis mutilans, PsA-peripheral spondyloarthritis epidemiology project. J Rheumatol. 2014;41(6):1244-8.

Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti–interleukin-17 receptor monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014 Jun 12;370(24):2295-306.

Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014; 74(4):423-41.

Tugwell P, Boers M, Mease PJ, et al. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "Truth": content, face, and construct validity. J Rheumatol. 2014;41(5):1000-4.

Wells G, Beaton DE, Mease PJ, et al. Updating the OMERACT filter: discrimination and feasibility. J Rheumatol. 2014;41(5):1005-10.

Kirwan JR, Boers M, Mease PJ, et al. Updating the OMERACT filter: core areas as a basis for defining core outcome sets. J Rheumatol. 2014;41(5):994-9.

D'Agostino MA, Boers M, Mease PJ, et al. Updating the OMERACT filter: implications for imaging and soluble biomarkers. J Rheumatol. 2014;41(5):1016-24.

Kavanaugh A, McInnes IB, Mease P,et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689-94.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al.Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020-6.

de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014 Nov;94(6):627-34.

Gross RL, Schwartzman-Morris JS, Mease PJ, et al. A comparison of malignancy incidence among psoriatic and rheumatoid arthritis patients in a large US cohort. Arthritis Rheumatol. 2014;66(6):1472-81.

Coates LC, Fitzgerald O, Mease PJ, et al. Development of a disease activity and responder index for psoriatic arthritis -- report of the psoriatic arthritis module at OMERACT 11. J Rheumatol. 2014. 41(4):782-91.

van der Heijde D, Fleischmann R, Wollenhaupt J ... Mease P. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73(1):233-7.

Peng X, Robinson RL, Mease P, et al. Long-term evaluation of opioid treatment in fibromyalgia. Clin J Pain. 2015 Jan;31(1):7-13.

Favarato MH, Mease P, Gonçalves CR, et al. Hypertension and diabetes significantly enhance the risk of cardiovascular disease in patients with psoriatic arthritis. Clin Exp Rheumatol. 2014. 32(2):182-7.

Gladman D, Fleischmann R, … Mease PJ. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of the RAPID-PsA study. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1085-92.

Mease P. Methotrexate in psoriatic arthritis. Bull Hosp Jt Dis. 2013;71 Suppl 1:S41-5.

Mease P. Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis? Clin Exp Rheumatol. 2013;31(4 Suppl 78):S59-62.

Landewé R, Braun J … Mease PJ. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014. 73(1):39-47.

Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-35.

Clauw DJ, Mease PJ, Palmer RH, et al. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Res Ther. 2013 Aug 16;15(4):R88.

Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014 Jan;73(1):48-55.

Keystone E, Landewé R, van Vollenhoven R ... Mease P. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis. 2013 Aug 5. doi: 10.1136/annrheumdis-2013-203695. [Epub ahead of print]

Mease PJ. GRAPPA Educational Initiatives: A report from the GRAPPA 2012 Annual Meeting. J Rheumatol. 2013 Aug;40(8):1457-8.

Callis Duffin K, Armstrong AW, Mease PJ. Psoriasis and Psoriatic Arthritis Video Project: An Update from the 2012 GRAPPA Annual Meeting. J Rheumatol. 2013 Aug;40(8):1455-6.

Fitzgerald O, Mease PJ. Biomarkers: Project Update from the GRAPPA 2012 Annual Meeting. J Rheumatol. 2013 Aug;40(8):1453-4.

Helliwell PS, Mease PJ, Fitzgerald O, et al. Peripheral Spondyloarthritis and Psoriatic Arthritis; Overlaps and Distinctions: A Report from the GRAPPA 2012 Annual Meeting. J Rheumatol. 2013 Aug;40(8):1446-9.

Mease PJ, Garg A, Gladman DD, et al. Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2012 Annual Meeting. J Rheumatol. 2013 Aug;40(8):1442-5.

Gladman DD, Helliwell PS … Mease PJ. Dermatology Screening Tools: Project Update from the GRAPPA 2012 Annual Meeting. J Rheumatol. 2013 Aug;40(8):1425-1427.

Mease PJ, Boehncke WH, Gladman DD. Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol. 2013 Aug;40(8):1407-9.

Mease PJ, Farmer MV, Palmer RH, et al. Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Ther Adv Musculoskelet Dis. 2013. 5(3):113-26.

Deodhar A, Mease P. Development and presentation of the first SPARTAN-GRAPPA educational symposium. Am J Med Sci. 2013 Jun;345(6):423-5.

Robinson RL, Kroenke K … Mease P. Longitudinal Observation of Treatment Patterns and Outcomes for Patients with Fibromyalgia: 12-Month Findings from the REFLECTIONS Study. Pain Med. 2013 Jun 11. doi: 10.1111/pme.12168. [Epub ahead of print]

Smolen JS, Braun J … Mease P. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014. 73(1):6-16.

Schoels MM, Braun J … Mease P. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014. 73(1):238-42.

Kavanaugh A, McInnes IB, Mease P, et al. Patient reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: Findings through 2 years of the GO-REVEAL trial. Arthritis Care Res (Hoboken). 2013 May 10:NA. doi: 10.1002/acr.22044. [Epub ahead of print]

Rigby WF, Mease PJ, Olech E, et al. Safety of Rituximab in Combination with Other Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: An Open-label Study. J Rheumatol. 2013;40(5):599-604.

Furst DE, Fleischman R, Mease P, et al. Documentation of off-label use of biologics in Rheumatoid Arthritis. Ann Rheum Dis. 2013;72 Suppl 2:ii35-51.

Furst DE, Keystone EC, Mease P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013;72 Suppl 2:ii2-34.

Coates LC, Fitzgerald O, Mease P, et al.; on behalf of the GRACE collaboration. Reduced joint counts misclassify psoriatic arthritis patients with oligoarthritis and miss significant active disease. Arthritis Rheum. 2013;65(6):1504-9.

Mease PJ, Heckaman M, Kary S, et al. Application and Modifications of Minimal Disease Activity Measures for Patients with Psoriatic Arthritis Treated with Adalimumab: Subanalyses of ADEPT. J Rheumatol. 2013;40(5):647-52.

Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol. 2013;25(3):287-96.

Armstrong AW, Parsi K, Mease PJ, et al. Standardizing training for psoriasis measures: effectiveness of an online training video on psoriasis area and severity index assessment by physician and patient raters. JAMA Dermatol. 2013 May 1;149(5):577-82.

Wagner CL, Visvanathan S, Mease PJ, et al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Ann Rheum Dis. 2013;72(1):83-8.

Mease PJ. Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis? J Rheumatol. 2012 39(12):2235-7.

Garg A, Gladman DD, Mease PJ. On defining musculoskeletal inflammation: a report from the GRAPPA 2011 annual meeting. J Rheumatol. 2012;39(11):2214-5.

Mease P. Update on treatment of psoriatic arthritis. Bull NYU Hosp Jt Dis. 2012;70(3):167-71.

Callis Duffin K, Armstrong AW, Mease PJ. Psoriasis and psoriatic arthritis video project: an update from the GRAPPA 2011 annual meeting. J Rheumatol. 2012;39(11):2198-200.

Fitzgerald O, Ritchlin CT, Mease PJ. Biomarkers of radiographic progression in psoriatic arthritis: a report from the GRAPPA 2011 annual meeting. J Rheumatol. 2012;39(11):2189-92.

Helliwell PS, FitzGerald O, Mease PJ, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). AnnRheumDis. 2012; 0:1-6.

Helliwell PS, Fitzgerald O, Mease PJ, et al. GRAPPA responder index project (GRACE): a report from the GRAPPA 2011 annual meeting. J Rheumatol. 2012;39(11):2196-7.

Cañete JD, Mease P. The link between obesity and psoriatic arthritis. Ann Rheum Dis. 2012;71(8):1265-6.

Mease PJ, Gladman DD. Prologue: 2011 group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA). J Rheumatol. 2012;39(11):2181-3.

Sieper J, van der Heijde D, Mease PJ, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomized placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815-22.

Mohs R, Mease P, Arnold LM, et al. The effect of duloxetine treatment on cognition in patients with fibromyalgia. Psychosom Med 2012;74(6):628-634.

Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis. 2013;72(11):1777-85.

Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol Suppl. 2012 Jul;89:90-93.

Mease P. Spondyloarthritis: Is methotrexate effective in psoriatic arthritis? Nat Rev Rheumatol. 2012;8(5):251-252.

Keystone EC, Combe B … Mease P, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford). 2012;51(9):1628-38.

Furst DE, Keystone EC … Mease P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71 Suppl 2:i2-i45.

Bennett R, Russell IJ … Mease P, et al. Evaluation of patient-rated stiffness associated with fibromyalgia: a post-hoc analysis of 4 pooled, randomized clinical trials of Duloxetine. Clin Ther. 2012 Mar 13. [Epub ahead of print]

Reich K, Ortonne JP … Mease P, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomised, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180-90.

Tak PP, Mease PJ, Genovese MC, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor:results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 2012;64(2):360-370.

Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71(7):1183-1189.

Helliwell PS, Fitzgerald O, Mease PJ. Development of Composite Measures for Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting. J Rheumatol. 2012;39(2):398-403.

Fitzgerald O, Helliwell P, Mease P, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. Ann Rheum Dis. 2012;71(3):358-362.

Espinoza LR, Toloza SM … Mease PJ, et al. Global partnering opportunities and challenges of psoriasis and psoriatic arthritis in Latin America: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39(2):445-447.

Woodcock JL, Mease PJ, Callis Duffin K. Psoriasis and psoriatic arthritis video project: an update from the 2010 GRAPPA annual meeting. J Rheumatol. 2012;39(2):421-422.

Mease PJ. Distinguishing inflammatory from noninflammatory arthritis, enthesitis, and dactylitis in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39(2):415-417.

Robinson RL, Kroenke K, Mease P, et al. Burden of illness and treatment patterns for patients with fibromyalgia. Pain Med. 2012;13(10):1366-76.

Garg A, Gladman DD, Mease PJ. The need to define musculoskeletal inflammation: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39(2):413-414.

Mease PJ, Gladman DD. Prologue: 2010 group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA). J Rheumatol. 2012;39(2):391-393.

Arnold LM . . . Mease PJ, et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum. 2012;64(3):885-894.

Mease PJ. Measures of psoriatic arthritis: tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander/Newcastle enthesitis index (MEI), Leeds enthesitis index (LEI), spondyloarthritis research consortium of Canada (SPARCC), Maastricht ankylosing spondylitis enthesis score (MASES), Leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI). Arthritis Care Res. 2011;63(S11):S64-85.

Sarzi-Puttini P, Atzeni F, Mease PJ. Chronic widespread pain or fibromyalgia? That is the question. Best Pract Res Clin Rheumatol. 2011;25(2):131-132.

Sarzi-Puttini P, Atzeni F, Mease PJ. Chronic widespread pain: from peripheral to central evolution. Best Pract Res Clin Rheumatol. 2011;25(2):133-139.

Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rheumatol. 2011;25(2):285-297.

Sarzi-Puttini P … Mease PJ, et al. Multidisciplinary approach to fibromyalgia: what is the teaching? Best Pract Res Clin Rheumatol. 2011;25(2):311-319.

Mease PJ. Psoriatic arthritis - treatment update. Bull NYU Hosp Jt Dis. 2011;69(3):243-249.

Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of health assessment questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumol 2011;38(11):2461-2465.

Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford). 2011;50(12):2223-2232.

Furfaro N, Mease PJ. Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: Practical applications for rheumatology healthcare providers. J Am Acad Nurse Pract. 2011;23(9):479-492.

Coates LC, Mumtaz A … Mease PJ, et al. Development of a disease severity and responder index for psoriatic arthritis (PsA) -- Report of the OMERACT 10 PsA special interest group. JRheumatol. 2011;38(7):1496-1501.

Mease PJ, Clauw DJ, Christensen R, et al. The OMERACT fibromyalgia working group. toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol. 2011;38(7):1487-1495.

Mease PJ. The potential roles for novel biomarkers in rheumatoid arthritis assessment. Clin Exp Rheumatol. 2011;29(3):567-574.

Mease PJ, Hanna S, Frakes EP, Altman RD. Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment. J Rheumatol. 2011;38(8):1546-1551.

Arnold LM, Clauw DJ, McCarberg BH, Mease PJ, et al. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc. 2011;86(5):457-464. Review.

Strand V, Smolen JS, van Vollenhoven RF, Mease P, et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis. 2011;70(6):996-1002.

Mease PJ. Certolizumab pegol in the treatment of rheumatoid arthritis. Rheumatology. 2011;50(2):261-270.

Gottlieb AB… Mease P, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol. 2011;10(3):289-300.

Keystone EC… Mease P, et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trial. J Rheumatol. 2011;38(6):990-996.

Mease PJ, Gladman DD (eds). Annual meeting of the group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA). J Rheumatol. 2011; 38(3)522-525.

Callis Duffin K, Mease P. Psoriasis and psoriatic arthritis video project 2010: A report from the GRAPPA annual meeting. J Rheumatol. 2011;38(3):562-563.

Coates LC… Mease PJ, et al. Summary of the international federation of psoriasis associations (IFPA) meeting: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38(3):530-539. Review.

Furst DE, Keystone EC … Mease P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011;70 Suppl 1:i2-36.

Mease PJ. Inflammatory musculoskeletal disease: Identification and assessment. J Rheumatol. 2011;38(3):557-561.

Helliwell PS… Mease PJ, et al. Composite measures in psoriatic arthritis: A report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38(3):540-545.

Mease PJ, Gladman DD. Prologue: 2009 group for research and assessment of psoriasis and PsA (GRAPPA). J Rheumatol. 2011;38(3):522-525.

Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70 Suppl 1:i77-84. Review.

Mease PJ, Spaeth M, Clauw DJ, et al. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res (Hoboken). 2011;63(6):821-826.

Wolfe F… Mease P, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: A modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol. 2011;38(6):1113-1122.

Cauli A… Mease PJ, et al. GRAPPA 3PPsA Study Group. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38(5):898-903.

Mease PJ, Zimetbaum PJ, Duh MS, et al. Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: evidence from french health data. Ann Pharmacother. 2011;45(2):179-188.

Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled phase II trial. Arthritis Rheum. 2011;63(4):939-948.

Keen HI, Mease P, Bingham CO III, et al. Systematic review of MRI, US and scintigraphy as outcomes measure for structural pathology in interventional therapeutic studies of knee arthritis: a focus on responsiveness. J Rheumatol. 2011;38(1):142-154.

Keystone E… Mease P, et al. Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better long-term outcomes: post-hoc analysis of a randomized controlled trial. J Rheumatol. 2011;38(6):990-996.

Marangell LB . . . Mease P, et. al. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: Secondary analyses of four pooled randomized controlled trials of duloxetine. Pain, 2011;152(1):31-37.

Mease PJ. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology, 2011;50(2):261-270.

Wolfe F … Mease P, et al. Reply to the letter to the editor. Arthritis Care Res (Hoboken). 2011;63(2):309–310.

Coates LC… Mease PJ, et al. Summary of the international federation of psoriasis associations (IFPA) meeting: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38(3):530-539.

Callis-Duffin KC, Mease PJ. Psoriasis and psoriatic arthritis video project 2010: a report from the GRAPPA annual meeting. J Rheumatol, 2011;38(3):562-563.

Aletaha D… Mease P, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2769-2781.

Arnold L, Mease P, Silverman S. Pregabalin: an alpha2-delta ligand for the management of fibromyalgia. Am J Manag Care. 2010;16(5 Suppl):S138-143.

Bradley LA, Wohlreich MM, Wang F, Gaynor PJ, Robinson MJ, D’Souza DN, Mease PJ. Pain response profile of patients with fibromyalgia treated with duloxetine. Clin J Pain. 2010;26(6):498-504.

Choy EH… Mease P. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2010;36(10):2230-2234.

Coates LC… Mease PJ, et al. Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010;37(2):448-452.

Dominguez P, Gladman DD, Helliwell P, Mease PJ, Husni ME, Qureshi AA. Development of screening tools to identify psoriatic arthritis. Curr Rheumatol Rep. 2010;12(4):295-299.

Friedewald VE, Ganz P … Mease PJ, et al. AJC editor’s consensus: rheumatoid arthritis and atherosclerotic cardiovascular disease. Am J Cardiol. 2010;106(3):442-447.

Furst DE… Mease P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 69(Suppl 1):i2-29, 2010.

Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH.Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther. 2010;12(3):R113.

Gladman DD, Tom BD, Mease PJ, Farewell VT. Informing response criteria for psoriatic arthritis: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. J Rheumatol. 2010;37(12):2559-2565.

Gladman DD… Mease PJ, et al. Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol. 2010;37(2):453-461.

Goldenberg DL… Mease P, et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Medicine. 2010;11(2):180-194.

Hazes JMW… Mease P. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford). 2010;49(10):1900-1910.

Heald AE… Mease PJ. Single-joint outcome measures: Preliminary validation of patient-reported outcomes and physical examination. J Rheumatol. 2010;37(5):1042-1048.

Humphrey L, Arbuckle R, Mease P, et al. Fatigue in fibromyalgia: a conceptual model informed by patient interviews. BMC Musculoskelet Disord. 2010;11:216.

Husdon JI… Mease PJ, et al. What makes patients with fibromyalgia feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of 4 randomized placebo-controlled trials of duloxetine. J Rheumatol. 2010;36(11):2517-2522.

Husni ME, Mease PJ. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep. 2010;12(4):281-287.

Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: Results from the SUNRISE trial. J Rheumatol. 2010;37(5):917-927.

Mease PJ, Russell IJ, Kajdasz DK, et al. Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum. 2010;39(6):454-464.

Mease PJ, Signorovitch J, Yu AP, et al. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: A pooled analysis of randomized clinical trials. Dermatology. 2010;220(1):1-7.

Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol. 2010;37(6):1221-1227.

Mease PJ. Improving the routine management of rheumatoid arthritis: the value of tight control. J Rheumatol. 2010;37(8):1570-1578.

Mease PJ. Psoriatic Arthritis: Pharmacotherapy Update. Curr Rheumatol Rep. 2010;12(4):272-280.

Mease PJ. Psoriatic Arthritis: Update on Pathophysiology, Assessment, and Management. Bulletin of the NYU Hospital for Joint Diseases. 2010;68(3):191-198.

Mease, PJ, Wei N, Fudman EJ, et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 study. J Rheumatol. 2010;37(4):692-703.

Reddy SM… Mease PJ, et al. Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. J Rheumatol. 2010;37(12):2566-2572.

Ritchlin CT… Mease PJ, et al. Biomarkers in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. J Rheumatol. 2010;37(2):462-467.

Taylor WJ, Mease PJ, Adebajo A, Nash PJ, Feletar M, Gladman DD. Effect of psoriatic arthritis according to the affected categories of the International Classification of Functioning, Disability and Health. J Rheumatol. 2010;37(9):1885-1891.

Weisman M... Mease P, et al. Current controversies in spondyloarthritis: SPARTAN. J Rheumatol. 2010;37(12):2617-2623.

Wolfe F... Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600-610.

Chandran V… Mease PJ, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arth Rheum. 2009;61:1235-1242.

Choy EH, Mease PJ. Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). Rheum Dis Clin North Am. 2009;35:329-337.

Choy EH, Mease PJ, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis from five clinical trials. Clin Rheumatol. 2009;28:1035-1044.

Frank KM… Mease PJ, et al. Investigation of the cause of death in a gene-therapy trial. N Eng J Med. 2009;361(2):161-169.

Gladman DD, Helliwell PS, Mease PJ, et al. GRAPPA at the European League Against Rheumatism (EULAR) 2008. J Rheumatol. 2009;36(3):656-658.

Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976-986.

Keen HI… Mease PJ. Assessing single joints in arthritis clinical trials. J Rheumatol. 2009;36:2092-2096.

Mease PJ. Fibromyalgia: key clinical domains, comorbidities, assessment and treatment. CNS Spectr. 2009;14(12 Suppl 16):6-9.

Maksymowych WP… Mease PJ, et al. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol. 2009;36:1792-1799.

Maksymowych WP… Mease PJ, et al. Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria. J Rheumatol. 2009;36:1785-1791.

Mease PJ, Ory P, Sharp, JT, et al. Adalimumab for long term treatment of psoriatic arthritis: two-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis. 2009;68(5):702-709.

Mease PJ, Reich KD; Alefacept in Psoriatic Arthritis Study Group. Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009;60:402-411.

Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: Lessons learned from other rheumatologic conditions. Semin Arthritis and Rheum. 2009;38(4):320-335.

Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, soluble-blind, placebo-controlled trial. J Rheumatol. 2009;36(2):398-409.

Mease P. Examining the link between RA and CVD. Supplement to Rheumatology News: 7-8, 2009.

Mease PJ, Hobbs K, Chalmers A, et al. Local delivery of a recombinant adeno-associated vector containing a tumor necrosis factor-α antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann Rheum Dis 68:1247-54, 2009.

Mease PJ. Fibromyalgia. Preface. Rheum Dis Clin North Am 35:xiii-xiv, 2009.

Mease P, Arnold LM, Choy EH, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009;36(10):2318-2329.

Mease PJ. Further strategies for treating fibromyalgia: The role of serotonin and norepinephrine reuptake inhibitors. The American Journal of Medicine 122:S44-55, 2009.

Mease P, Buskila D, Sarzi-Puttini. The fibromyalgia conundrum. Clinical and Experimental Rheumatology 27:S2-4, 2009.

Mease PJ, Choy EH. Pharmacotherapy of fibromyalgia. Rheum Dis Clin North Am 35:359-372, 2009.

Mease PJ. Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol 21(4):348-355, 2009.

Ritchlin CT… Mease PJ, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68:1387-1394, 2009.

Smolen JS, Landewé RB, Mease PJ, et al. Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. Ann Rheum Dis 68(6):797-804, 2009.

Strand V, Mease P, Burmester GR, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 11(6):R170, 2009.

Syversen SW, Mease PJ, et al. Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. J Rheum 36:1769-1784, 2009.

van der Heijde D… Mease PJ, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68(6):922-929, 2009.

Prodinger WM…Mease P, et al. Measuring health in patients with fibromyalgia: content comparison of questionnaires based on the International Classification of Functioning, Disability and Health. Arth Rheum 59(5):650-658, 2008.

Mease PJ. Spondyloarthritis update: New insights regarding classification, pathophysiology, and management. Bulletin of the NYU Hospital for Joint Disease 66:203-209, 2008.

Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab-results of the dose ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial. J Rheum 35(1):20-30, 2008.

Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheum 35(3):502-514, 2008.

Mease PJ. B-cell targeted therapy in autoimmune disease: rational, mechanisms and clinical application. J Rheum 35(7):1245-1255, 2008.

Cohen SB… Mease PJ, et al. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J Rheum; 35(81):4-30, 2008.

Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient Delphi exercises. Arthritis Care Res. 59(7):952-960, 2008.

Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136(3):419-431, 2008.

Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136(3):432-444, 2008.

Gladman D… Mease PJ, et al. Clinical and genetic registries in psoriatic disease. J Rheumatol. 2008;35(7):1458-1463.

Mease PJ. Assessment tools in psoriatic arthritis. J Rheumatol. 2008;35(7):1426-1430.

Quereshi AA… Mease PJ, et al. Psoriatic arthritis screening tools. J Rheumatol. 2008;35(7):1423-1425.

Sanchez-Guerrero J… Mease PJ, et al. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol. 2008;35(8):1567-1575.

Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Education and Counseling 73(1):114-120, 2008.

Davis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: From the bench to the clinic. Semin Arthritis Rheum 38(2):83-100, 2008.

Keystone EC… Mease, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis patients: Results from the RAPID 1 study. Arth Rheum 58(11):3319-3329, 2008.

Mease PJ, Seymour K. Fibromyalgia: Should the treatment paradigm be monotherapy or combination pharmacotherapy. Curr Pain Headache Reports 12: 399-405, 2008.

Mease PJ, Seymour K. Treatment options for fibromyalgia. Pain Practitioner 18: 26-35, 2008.

Furfaro N, Mease PJ. Nursing considerations for infusion therapy in rheumatoid arthritis versus malignancy. Journal of Infusion Nursing 31 (6): 350-360, 2008.

Furst DE… Mease P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67(Suppl III):iii2–iii25, 2008.

Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 30(11):1988-2004, 2008.

Papp K… Mease P, et al. Efalizumab for the treatment of psoriatic arthritis. Journal of Cutaneous Medicine and Surgery 11(2):57-66, 2007.

Gladman D, Mease PJ, Healy P, et al. Outcome measures in psoriatic arthritis. J Rheumatol 34:1159–1166, 2007.

Gladman D, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 34(5):1167-1170, 2007.

Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in the treatment of patients with psoriatic arthritis who had failed disease-modifying antirheumatic drug therapy. J Rheumatol 34(5):1040-1050, 2007.

Gladman D…Mease PJ, et al. International Spondyloarthritis Inter-Observer Reliability Exercise – The INSPIRE study I. Assessment of spinal measures. J Rheumatol. 2007;34(8):1733-1739.

Gladman D…Mease PJ, et al. International Spondyloarthritis Inter-Observer Reliability Exercise – The INSPIRE study: II. Assessment of peripheral joints, enthesitis and dactylitis. J Rheumatol. 2007;34(8):1740-1745.

Horn E, Gordon K, Mease P. The first world psoriasis and psoriatic arthritis conference. Journal of Investigative Dermatology 127(7): 1566-1567, 2007.

Mease P, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. J Rheumatol 34(6):1415-1425, 2007.

Mease P, Seymour K. Fibromyalgia syndrome update: Emerging pharmacologic treatments. J Musculoskeletal Med 24:436-445, 2007.

Giles JT, Mease P, Boers M, et al. Assessing single joints in arthritis clinical trials. J Rheumatol. 2007;34(3):641-647.

Keeling SO… Mease PJ, et al. Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. J Rheumatol. 2007;34(3):623-633.

Lassere MN… Mease P, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of quantitative hierarchical levels of evidence schema. J Rheumatol. 2007;34(3):607-615.

Gladman D, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness is psoriatic arthritis trial. Arthritis Rheum 56(2):476-488, 2007.

Furst DE… Mease P, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, Ann Rheum Dis 66: iii2 - iii22, 2007.

Mease PJ. Current treatment in psoriatic arthritis and other spondyloarthritides. Rheumatic Disease Clin North Am 32:11-20 2006

Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 11:1491-1504, 2006.

Fransen J, Antoni C, Mease P, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of data from randomized, controlled trials of two TNF inhibitors. Ann Rheum Dis 65:1373-1378, 2006 Oct.

Johnsen AK, Schiff MH, Mease PJ, et al. Comparison of 2 doses of etanercept (50 vs. 100mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol. 2006;33:659-664.

Mease P, Menter A. Quality of life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. Journal of American Academy of Dermatol. 54: 685-704, 2006.

Gottlieb AB, Mease PJ, Jackson JM, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologist’s offices. J Dermatolog Treatment 17(5):279-287, 2006.

Mease PJ, Gladman D, Keystone EC, et al. Alefacept (Amevive®) in combination with methotrexate for the treatment of psoriatic arthritis: results for a randomized, double-blind, placebo-controlled study. Arth Rheum 54: 1638-1645, 2006.

Taylor W…Mease PJ, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arth Rheum 54: 2665-2673, 2006.

Mease PJ. Infliximab (Remicade) in the treatment of psoriatic arthritis. Therapeutics and Clinical Risk Management 2: 133-148, 2006

Mease PJ. Adalimumab in the treatment of arthritis. Therapeutics and Clinical Risk Management 2: 389-400, 2006.

Gladman D, Mease PJ. Towards international guidelines for the management of psoriatic arthritis. J Rheumatol 33:1228-1230, 2006.

Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression inpatients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33: 712-721, 2006.

Mease PJ, van der Heijde D. Joint damage in psoriatic arthritis: How is it assessed and can it be prevented? Int J Adv Rheumatol 4(2):38-48, 2006.

Mease PJ. Psoriatic arthritis update. Bulletin of the NYU Hospital for Joint Disease 64: 25-31, 2006.

Myers W, Gottlieb A, Mease P. Psoriasis and psoriatic arthritis. Clinics in Dermatology 24:438-447, 2006.

Mease P. Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Current Rheumatology Reports 8:348-354, 2006.

Mease PJ, Goffe B. Diagnosis and treatment of psoriatic arthritis. J Am Acad Derm 52:1-19, 2005.

Mease PJ: Recent advances in the management of psoriatic arthritis. Curr Opin Rheumatol 16:366-370,2004.

Furst DE, Breedveld FC, Kalden JR…Mease PJ, et al. Updated consensus statement on biological agents, specifically tumor necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis. 2005;64 Suppl 4: iv2-14.

Crofford LJ, Rowbotham MC, Mease PJ. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arth Rheum 52: 1264-1273, 2005.

Mease PJ. TNF antagonists in the treatment of psoriasis and psoriatic arthritis. European Pharmacy Letter HPE. 19:47-48, 2005.

Mease PJ. Targeting therapy in psoriatic arthritis. Drug Discovery Today. 1:389-396, 2005.

Mease PJ, Gladman D, Krueger G. Prologue (ARD supplement on psoriatic arthritis). Ann Rheum Dis. 64:ii1-ii2, 2005.

Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondyloarthropathies – to lump or split? Ann Rheum Dis 64: ii9-ii13, 2005.

Gladman D, Antoni C, Mease PJ, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64: ii14-ii17, 2005.

Mease PJ, Antoni CE, Gladman D, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 64: ii49-ii54, 2005.

Ory P, Gladman D, Mease PJ. Imaging in psoriatic arthritis. Ann Rheum Dis 64: ii55-ii57, 2005.

Mease PJ, Behrens F, Boehncke W-H, et al. Discussion: Assessment of psoriatic arthritis. Ann Rheum Dis 64: ii69- ii73, 2005.

Mease PJ, Antoni CE. Psoriatic arthritis treatment: Biologic response modifiers. Ann Rheum Dis 64: ii78-ii82, 2005.

Mease PJ, Boehncke W-H, Gladman DD, et al. Discussion: Treatment of psoriatic arthritis. Ann Rheum Dis: ii91-ii92, 2005.

Gladman D, Strand V, Mease PJ, et al. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis 64: ii115-ii116, 2005.

Gladman D, Mease PJ, Smolen J. Epilogue (ARD Supplement on psoriatic arthritis). Ann Rheum Dis 64: ii117, 2005.

Mease PJ, Ginzler EM, Gluck OS, et al. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol. 2005;32: 616-621.

Gelfand JM, Gladman D, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53: 573, 2005.

Mease PJ, Gladman D, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arth Rheum 52:3279-3289, 2005.

Mease PJ. Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheum 75: 6-21, 2005.

Mease PJ. Psoriatic arthritis therapy advances. Curr Opin Rheumatol 17: 426-432, 2005.

Fleischmann RM…Mease PJ, et al. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med Res Opin 21:1181-1190. 2005.

Gendreau M,…Mease PJ, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32: 1975-1985.

Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol. 2005;32(11):2270-2277.

Gladman D, Mease PJ, Krueger G, et al. Outcome measures in psoriatic arthritis. J Rheumatol. 2005;32(11):2262-2269.

Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 15: 1491-1504, 2005.

Fiorentino DF, Mease PJ. The skin in psoriatic arthritis. Int J of Adv in Rheumatol 3(4):110-117, 2005.

Gladman D, Helliwell P, Mease P, et al. Assessment of patients with psoriatic arthritis. A review of currently available measures. Arth Rheum 50: 24-35, 2004.

Furst DE...Mease P, et al. Updated consensus statement on biological agents, specifically tumor necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 64 Suppl 2: i12-12, 2004.

Callen J…Mease P, et al. AAD (American Academy of Dermatology) consensus statement on psoriasis therapies. J Am Acad Dermatol. 49:897-899, 2003.

Kaltwasser JP…Mease PJ, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arth Rheum 50:1939-1950, 2004.

Petri M, Mease Pj, Merrill JT, et al. Effects of prasterone on disease activity and symptoms on women with active systemic lupus erythematosus. Arth Rheum 50: 2858-2868, 2004

Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50(7):2264-72.

Mease PJ, Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheum 31: 1356-1361, 2004.

Mease PJ. Recent advanced in the management of psoriatic arthritis. Curr Opin Rheumatol 16:366-370, 2004.

Mease P. TNFa therapy in psoriatic arthritis and psoriasis: How and why does it work? Ann Rheum Dis 63: 755-758, 2004.

Mease PJ. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Letter. 8(1):1-4, 2003.

Mease PJ. Disease-modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment. Curr Opin Rheumatol 15(3):205-212, 2003.

Mease PJ. Current treatment of psoriatic arthritis. Clinics Rheumatic Disease 29:495-511, 2003.

Mease PJ. Tumor necrosis factor in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61:298-304, 2002.

Mease PJ. Psoriatic arthritis: The role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheum. 20 (suppl 28): 116-121, 2002.

Mease PJ. Etanercept: a new era in the treatment of psoriatic arthritis. [Review] [48 refs] American Journal of Managed Care. 8(6Suppl):S181-193,2002.

Husni ME. Maier AL. Mease PJ. Overman SS. Fraser P. Gravallese EM. Weinblatt ME. Etanercept in the treatment of adult patients with Still's disease. Arthritis & Rheumatism. 46(5):1171-1176, 2002.

Mease PJ. Etanercept in the management of psoriatic arthritis and psoriasis. J of musculoskeletal medicine supplement, S45-S49 May 2001.

Mease PJ. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis 60:iii37-iii40, 2001.

Hertzman PA, Clauw DJ, Duffy J…Mease PJ, et al. Rigorous new approach to constructing a “gold-standard” for validating new diagnostic criteria as exemplified by the eosinophilia myalgia syndrome. Arch Int Med 161:2301-2306, 2001.

Mease PJ, Goffe B, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385-390, 2000.

Moreland LW. . .Mease PJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Internal Medicine 130:478-486, 1999

Moreland LW. . . Mease PJ, et al. Long-term treatment of rheumatoid arthritis with Etanercept (tumor necrosis factor receptor p75 Fc fusion protein, Enbrel®). Lancet, 1999.

Wolfe F…Mease PJ, et al. The fibromyalgia syndrome: A consensus report on fibromyalgia and disability. J Rheum 23: 534-539, 1996.

Hertzman P….Mease PJ, et al. Eosinophilia myalgia syndrome: Guidelines for patient care. J Rheum 22: 161-163, 1995.

Hertzman P, Clauw D, Kaufman L, Vargas J, Silver R, Thacker H, Mease P, Espinoza L, Pincus T: The eosinophilia-myalgia syndrome: Status of 205 patients and results of treatment 2 years after onset. Ann Intern Med 122:851-855, 1995.

Culpepper RC, Williams RG, Mease PJ, et al. Eosinophilia myalgia syndrome: Investigation of Washington cases. Wash Pub Health 16-18, Winter 1991.

Culpepper RC, Williams RG, Mease PJ, et al. Natural history of the eosinophilia myalgia syndrome. Ann Int Med 115: 437-442, 1991.

Katon WJ, Buchwald DJ, Simon GE, Russo JE, Mease PJ: Psychiatric illness in patients with chronic fatigue and those with rheumatoid arthritis. J Gen Int Med 6:227-285, 1991.

Buchwald DJ, Blair J, Mease PJ: Treatment of chronic fatigue syndrome with acupuncture. Intl J Clinical Acupuncture 2: 231-236, 1991.

Mease PJ, Willkens RF: Treatment of acute gout with oxaprozin. Sem Arth Rheum 15 (Suppl 2): 86-89, 1986.

Mease PJ. Ochs HD. Corey L. Dragavon J. Wedgwood RJ. Echovirus encephalitis/myositis in X-linked agammaglobulinemia. New England Journal of Medicine. 313(12):758, 1985 Sep 19.

Fretwell MD, Pearlman RA, Vestal RE, Mease PJ, Hazard WR: Fever and delirium in three elderly patients. A discussion of possible cimetidine toxicity, cimetidine pharmacology, and the application of decision analysis to cimetidine therapy. Medical Grand Rounds 1:223-238, 1982.

Mease PJ, Ellsworth JG, Killen PD, Willkens RF: Zomepirac, interstitial nephritis, and renal failure. Ann Int Med 97:454, 1982.

Mease PJ, Ochs HD, Wedgewood RJ: Successful treatment of ECHO-virus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. NEJM. 304:1278-1281, 1981.

ABSTRACTS

Mease PJ; Gladman DD; Gomez-Reino JJ, et al. Long-term (104-week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. Australian Rheumatology Association (ARA) Annual Scientific Meeting, Darwin, Australia. Apr-May 2016.

McInnes IB, Kirkham B, Mease P, et al. Secukinumab Provides Rapid and Sustained Reductions in Dactylitis, Enthesitis, and Nail Psoriasis in Patients with Psoriatic Arthritis: 52-week Results of the FUTURE 2 study. 25th Congress European Academy of Dermatology and Venereology (EADV), Vienna, Sept. 2016.

McInnes IB, Mease P, Hall S, et al. Secukinumab Provides Sustained Improvement in Psoriatic Arthritis in both Anti‒TNF-Naïve and Anti-TNF Exposed Patients: 52-Week Results From the FUTURE 2 study. 25th Congress European Academy of Dermatology and Venereology (EADV), Vienna, Sept. 2016.

Mease PJ, van der Heijde D, Ritchlin CT, et al. A randomized, double-blind, active- and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease modifying antirheumatic drugs with active psoriatic arthritis. Deutschen Gesellschaft fur Rheumatologie (DGRh) - 44 Kongress, Frankfurt, Aug. 2016.

Strober BE, Gottlieb A, Mease PJ, et al. Tofacitinib safety data from global clinical trials in rheumatoid arthritis and chronic plaque psoriasis. American Academy of Dermatology (AAD) 74th Annual Meeting, Washington, DC, USA, March, 2016.

Gladman DD, Kavanaugh A ... Mease PJ. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase III, randomized, controlled trials. Canadian Rheumatology Association (CRA) Annual Scientific Meeting & APHA Annual Meeting, Fairmont Chateau Lake Louise, Alberta, Canada, Feb. 2016.

Mease P, Palmer JB, Etzel CJ, et al. Patient reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from Corrona registry. Winter Clinical Dermatology congress, Hawaii, Jan. 2016.

Mease P, Palmer JB, Etzel CJ, et al. Patient reported outcomes in psoriatic arthritis patients by extent of body surface area affected by psoriasis: results from Corrona registry. Winter Clinical Dermatology congress, Hawaii, Jan. 2016.

Gladman DD, Hall S ... Mease PJ. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase III, randomized, controlled trials. Australian Rheumatology Association (ARA) Annual Scientific Meeting, Darwin, Australia. Apr-May 2016.

Khraishi M , Hoepken B ... Mease PJ. Sustained improvements in skin outcomes following certolizumab pegol treatment of psoriatic arthritis patients with prior anti-TNF exposure or severe skin involvement at baseline. Regional Congress, Spanish Congress of Rheumatology (SER), Barcelona, Spain, May 2016.

Mease PJ, van der Heijde D, Ritchlin CT, et al. A randomized, double-blind, active- and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease modifying antirheumatic drugs with active psoriatic arthritis. Canadian Rheumatology Association (CRA) Annual Scientific Meeting & APHA Annual Meeting, Fairmont Chateau Lake Louise, Alberta, Canada, Feb. 2016.

Soriano E, Gottlieb A, Mease P, et al. Secukinumab Safety and Tolerability in Patients With Active Psoriatic Arthritis and Psoriasis: Results From A Pooled Safety Analysis of Seven International Phase 3 Trials. Congress of the Pan American League of Associations for Rheumatology (PANLAR), Panama City, Panama, Apr. 2016.

Kavanaugh A, Kivitz A, Mease P, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti‒TNF-Naïve Patients and those previously exposed to Anti-TNF therapy: 52-week results from an International Phase 3 Trial. Congress of the Pan American League of Associations for Rheumatology (PANLAR), Panama City, Panama, Apr. 2016.

Mease PJ, et al. Clinical characteristics and disease outcomes in psoriatic arthritis patients by extent of body surface area affected by psoriasis: results from Corrona registry. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015. Arthritis Rheumatol 2015;67:S10.

Kavanaugh A, Gladman D … Mease P. Clinical responses in joint and skin outcomes are associated with increased productivity in the workplace and at home in psoriatic arthritis patients treated with certolizumab pegol. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, Karki C, Etzel CJ, et al. Clinical Characteristics and Disease Activity in Psoriatic Arthritis Patients with Dactylitis or Enthesitis: Results from Corrona Registry. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Brown MA, Bird PA … Mease PJ. Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA) American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, van der Heijde D, Mittal M, et al. Quality of Life in Patients with Active Peripheral SpA is Similarly Impaired as in other rheumatic diseases and influenced by disease activity but not disease duration. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, Kavanaugh A, Coates LC, et al. The Prediction of Long-Term Minimal Disease Activity and Its Benefits in Patients with Psoriatic Arthritis. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, van der Heijde D, Ritchlin CT, et al. A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naïve to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Wolfe F, Fitzcharles M … Mease PJ. A Comparison of Physician Based and Patient Based Criteria for the Diagnosis of Fibromyalgia. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Roy Fleischmann R, Mease PJ, Schwartzman S, et al. Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Ritchlin CT, Gottlieb AB … Mease PJ. Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, Gottlieb AB, Menter A, et al. All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Kavanaugh A, McInnes IB, Mease PJ, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Gottlieb AB, Mease PJ, Cuchacovich RS, et al. Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Genovese MC, Mease PJ, Greenwald M, et al. Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Sheth P, Mease PJ, Li Y, et al. The Majority of Patients with Moderate to Severe Psoriatic Arthritis Had Existing Structural Damage, Predisposing Them to Further Progression, Which Was Markedly Inhibited By Adalimumab. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Kavanaugh A, Gladman D, Mease PJ, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase 3, Randomized, Controlled Trials. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Kavanaugh A, Adebajo AO, Mease PJ, et al. Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1). American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, Lesperance T, Accortt N, et al. Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Gladman DD, Kavanaugh A, Mease PJ, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, Adebajo AO, Gladman DD, et al. Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

van Den Bosch F, Mease PJ, Sieper J, et al. Early Clinical Response Is a Better Predictor of Long-Term Remission Than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, Wollenhaupt J, Hall S, et al. Assessment of Disability Levels in a Cohort of 1,489 Patients with Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data from Three Phase III, Randomized, Controlled Trials. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Mease PJ, McInnes IB, Gottlieb AB, et al. Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis and Psoriasis: Results from a Pooled Safety Analysis. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Deodhar AA, Sieper J, Mease PJ, et al. Effect of Weight on Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015. American College of Rheumatology (ACR) Annual Meeting, San Francisco CA, Nov. 2015, Arthritis Rheumatol 2015;67:S10.

Kavanaugh A, Adebajo AO ... P.J. Mease. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (PALACE 1). 52nd National Congress of the Italian Society of Rheumatology (SIR) , Nov. 2015, Rimini.

Mease PJ, Fleischmann R, Wollenhaupt J, et al. Long-term safety and efficacy of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure. Dutch Rheumatology Congress (NVR 2015), Amsterdam, Sept. 2015.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Society of Dermatology Physician Assistants-Fall (SDPA Fall 2015), Orlando FL, Nov. 2015.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Las Vegas Dermatology Seminar (LVDS 2015), Las Vegas NV, Nov. 2015.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Fall Clinical Dermatology Conference (FCDC 2015), Las Vegas NV, Oct. 2015.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Maui Derm NP+PA Fall Meeting, Washington DC, Sept. 2015.

Kavanaugh A, Adebajo AO ... P.J. Mease. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (PALACE 1). French Society of Rheumatology (SFR) 2015 annual conference. Paris, December 2015.

Mease PJ, van der Heijde D, Ritchlin CT, et al. A randomized, double-blind, active- and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naïve to biologic disease modifying antirheumatic drugs with active psoriatic arthritis. American Academy of Dermatology (AAD) 2015.

Gottlieb A, Mease P, McInnes I, et al. Secukinumab inhibits radiographic progression in patients with psoriatic arthritis: results of phase 3 FUTURE 1 study stratified by concomitant methotrexate use. 24th European Academy of Dermatology and Venereology (EADV) Congress, Copenhagen, Oct. 2015.

Gottlieb A, McInnes P, Mease P, et al. Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: results from two phase 3 randomised, multicentre, double-blind, placebo-controlled studies (FUTURE 1 and 2). 24th European Academy of Dermatology and Venereology (EADV) Congress, Copenhagen, Oct. 2015.

Gottlieb A, McInnes P, Mease P, et al. Secukinumab improves signs and symptoms of psoriatic arthritis: results of phase 3 FUTURE 2 study stratified by concomitant methotrexate use. 24th European Academy of Dermatology and Venereology (EADV) Congress, Copenhagen, Oct. 2015.

Mease P, Palmer JB, Etzel CJ, et al. Patient reported outcomes in psoriatic arthritis patients by extent of body surface area affected by psoriasis: results from Corrona registry. Academy of Managed Care Pharmacy (AMCP), Orlando, Oct. 2015.

Mease P, Palmer JB, Etzel CJ, et al. Patient reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from Corrona registry. Academy of Managed Care Pharmacy (AMCP), Orlando, Oct. 2015.

Mease P, McInnes IB, Mpofu S, et al. Secukinumab inhibits radiographic progression in patients with psoriatic arthritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (FUTURE 1). Brazilian Congress of Rheumatology, Curitiba, October, 2015.

Mease P, McInnes IB, Mpofu S. Secukinumab efficacy in anti-TNF-naive and anti-TNF-IR patients with psoriatic arthritis: results of a phase 3 multicenter, double-blind, placebo-controlled study (FUTURE 2). Brazilian Congress of Rheumatology, Curitiba, October, 2015.

Kavanaugh A, Gladman D … Mease P. Clinical responses in joint and skin outcomes and patient-reported outcomes are associated with increased productivity in the workplace and at home in psoriatic arthritis patients treated with certolizumab pegol. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress, Milan, Italy, Nov. 2015.

Mease PJ, et al. Efficacy (week 24) in asian patients, secukinumab. Asia Pacific League of Associations for Rheumatology (APLAR), 2015 Congress, Chennai, India, Sept. 2015.

Schett G, Kavanaugh A … Mease PJ. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (PALACE 1). German Rheumatology Conference (DGRh), Bremen, Germany, September, 2015.

Wollenhaupt J, Kavanaugh A, Mease PJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: results from 3 phase 3, randomized, controlled trials. German Rheumatology Conference (DGRh), Bremen, Germany, September, 2015.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study. International Federation of Psoriasis Associations (IFPA) Congress, Stockholm, July 2015.

Gottlieb AB, McInnes IB, Mease P, et al. Secukinumab improves signs and symptoms of active psoriatic arthritis: results from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using a subcutaneous dosing regimen (FUTURE 2). International Federation of Psoriasis Associations (IFPA) Congress, Stockholm, July 2015.

Mease P, Kirkham B, McInnes IB, et al. Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: results from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (FUTURE 2). International Federation of Psoriasis Associations (IFPA) Congress, Stockholm, July 2015.

Haraoui B, Gladman DD, Mease PJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase III, randomized, controlled trials. Laurentian Conference of Rheumatology; Mont Tremblant, QC, Canada, May 2015.

Mease PJ, Kavanaugh A, Coates LC, et al. The prediction and benefits of minimal disease activity in patients with psoriatic arthritis in the ADEPT trial. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Mease PJ, van der Heijde D, Mittal M, et al. Quality of life in patients with active peripheral spondyloarthritis is similarly impaired as in other rheumatic diseases and influenced by disease activity but not disease duration. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Schaefer C, Adams E ... Mease PJ. Multisite prospective observational study of fibromyalgia patients in the U.S. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Mease PJ, Mittal M, Joshi A, et al. Value of treating both skin and joint manifestations of psoriatic arthritis: post-hoc analysis of the ADEPT clinical trial. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Brown MA, Bird PA, Mease P, et al. Baseline MRI/CRP as predictors of response to etanercept in the management of patients with non-radiographic axial spondyloarthritis. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Mease PJ, McInnes IB, Richards H, et al. Secukinumab safety and tolerability in patients with active psoriatic arthritis: pooled safety analysis of two phase 3, randomized, controlled trials. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Mease PJ, Genovese MC, Greenwald MW, et al. Two-year clinical response to brodalumab, an anti-IL-17 receptor antibody, in patients with psoriatic arthritis. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Mease PJ, Etzel CJ, Kremer JM, et al. Characteristics of a U.S. psoriatic arthritis/spondyloarthritis cohort: baseline data from the CORRONA PsA/SpA registry. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Mease P, Gladman DD, Ritchlin CT, et al. Therapeutic response in adalimumab-treated patients with psoriatic arthritis in relation to weight. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Gladman D, Kavanaugh A … Mease P. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase 3, randomized, controlled trials. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Kavanaugh A, Gladman D … Mease P. Clinical responses in joint and skin outcomes are associated with increased productivity in the workplace and at home in psoriatic arthritis patients treated with certolizumab pegol. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Gladman D, Mease P, Smolen J, et al. Impact of disease management by rheumatologists and dermatologists on patients’ attitude toward medication in psoriatic arthritis: results from the global align study. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Van den Bosch F, Mease P, Sieper J, et al. Early clinical response is a better predictor of long-term remission than baseline disease characteristics following adalimumab treatment in peripheral spondyloarthritis. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Lederman S, Clauw D … Mease P. TNX-102 SL for the treatment of fibromyalgia: role of nonrestorative sleep on pain centralization. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Van Der Heijde D, Landewé R, Mease P, et al. Secukinumab inhibits radiographic progression in patients with psoriatic arhtritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (FUTURE 1). The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Gottlieb A, McInnes IB, Mease P, et al. Secukinumab significantly reduces psoriasis burden in patients with psoriatic arthritis: results from the phase 3 FUTURE 2 study. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Kavanaugh A, Adebajo A, Mease P, et al. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomised, controlled trial and open-label expension (PALACE 1). The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Kirkham B, McInnes IB, Mease P, et al. Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arhtritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (FUTURE 2). The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

McInnes IB, Mease P, Kirkham B, et al. Secukinumab improves signs and symptoms of active psoriatic arhtritis in a phase 3 randomized, multicenter, double-blind, placebo-controlled study using a subcutaneous dosing regimen (FUTURE 2). The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Khraishi M, Hoepken B, … Mease PJ. Sustained improvements in skin outcomes following certolizumab pegol treatment of psoriatic arthritis patients with prior anti-TNF exposure or severe skin involvement at baseline. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Mease P, Adebajo A, Gladman D, et al. Long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Rome, Italy, June 2015.

Gottlieb A, Khraishi M, Mease PJ, et al. Improvements in skin outcomes over 96 weeks of certolizumab pegol treatment of psoriatic arthritis patients with and without prior anti-tumor necrosis factor exposure. European Academy of Dermatology and Venereology (EADV), 23rd World Congress of Dermatology, Vancouver Canada, June 2015.

Adebajo AO, Gladman DD, Mease PJ, et al. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (PALACE 1). Rheumatology 2015, British Society of Rheumatology (BSR), Manchester UK, Apr 2015.

Park W, Wollenhaupt J … Mease PJ. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in swollen and tender joint counts in psoriatic arthritis patients: results from 3 phase 3, randomized, controlled trials. Korean Congress of Rheumatology (KCR), Seoul, Korea, May 2015.

Park W, Adebajo AO, Mease PJ, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in psoriatic arthritis patients: pooled safety analysis of 3 phase 3, randomized, controlled trials. Korean Congress of Rheumatology (KCR), Seoul, Korea, May 2015.

Mease P, Ritchlin C, Rubant S, et al. Disconnect between radiographic progression and skin or arthritic outcomes in psoriatic arthritis patients treated with adalimumab. American Academy of Dermatology, AAD-W meeting, San Francisco CA, March 2015.

Mease P, Gladman DD, Ritchlin CT, et al. Therapeutic response in adalimumab-treated patients with psoriatic arthritis in relation to weight. American Academy of Dermatology (AAD) summer academy meeting, NY, NY, Aug. 2015.

Mease P, Kavanaugh A, Coates LC, et al. The prediction and benefits of minimal disease activity in patients with psoriatic arthritis in the ADEPT trial. American Academy of Dermatology (AAD) summer academy meeting, NY, NY, Aug. 2015.

Brown MA, Bird PA, Mease P, et al. Baseline MRI/CRP as predictors of response to etanercept in the management of patients with non-radiographic axial spondyloarthritis. Australian Rheumatology congress (ARA) Adelaide, Australia, May 2015.

Bird P, Adebajo AO, Mease PJ, et al. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial nd open-label extension (PALACE 1). Australian Rheumatology congress (ARA) Adelaide, Australia, May 2015.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Australian Rheumatology congress (ARA) Adelaide, Australia, May 2015.

van der Heijde D, Landewé R, Mease P, et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study. Australian Rheumatology congress (ARA) Adelaide, Australia, May 2015.

Gottlieb, Mease, McInnes et al. Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial. Australian Rheumatology congress (ARA), Adelaide, Australia, May 2015.

Strand, Mease, McInnes et al. Secukinumab, an Anti–Interleukin-17A Monoclonal Antibody, Improves Physical Function, Quality of Life and Work Productivity in Patients with Active Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial. Australian Rheumatology congress (ARA) Adelaide, Australia, May 2015.

Gomez-Reino JJ, Adebajo AO, Mease PJ, et al. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial nd open-label extension (PALACE 1). Spanish Rheumatology Congress (SER), Seville, Spain, May 2015.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. 23rd World Congress of Dermatology (WCD), Vancouver, Canada, June 2015.

Strand V, McInnes IB, Mease P, et al. Secukinumab treatment improved physical function, quality of life and fatigue in patients with active psoriatic arthritis in FUTURE 2, a phase 3, randomized, double-blind, placebo-controlled trial. 23rd World Congress of Dermatology (WCD), Vancouver, Canada, June 2015.

Gladman DD, Mease PJ, Kavanaugh A, et al. Long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial and open-label extension. Canadian Rheumatology Association (CRA) Annual Scientific Meeting, Quebec City, Canada, Feb. 2015.

van der Heijde D, Landewé R, Mease P, et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study. Winter Clinical Dermatology Conference (WCDC), Lahaina, Hawaii, Jan. 2015.

Gottlieb AB, Mease PJ, McInnes IB, et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial. Winter Clinical Dermatology Conference (WCDC), Lahaina, Hawaii, Jan. 2015.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Winter Clinical Dermatology Conference (WCDC), Lahaina, Hawaii, Jan. 2015.

Strand V, Mease P, McInnes IB, et al. Secukinumab, an anti–interleukin-17A monoclonal antibody, improves physical function, quality of life and work productivity in patients with active psoriatic arthritis: results from a phase 3, randomized, controlled trial. Spanish Rheumatology Congress (SER), Seville, Spain, May 2015.

van der Heijde D, Landewé R, Mease P, et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study. Spanish Rheumatology Congress (SER), Seville, Spain, May 2015.

Mease P, McInnes IB, Kirkham B, et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Spanish Rheumatology Congress (SER), Seville, Spain, May 2015.

Adams E, Mease P,Staud R, et al. Transitions among chronic pain and fibromyalgia patients: results from a two-year observational fibromyalgia study in the United States. American Pain Society (APS) annual meeting, Palm Springs CA, May 2015.

Sheeran T, van der Heijde D, Mease P, et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study. British Society of Rheumatology (BSR) 2015 Congress, Manchester, UK, April 2015.

Tahir H, Mease P, McInnes IB, et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. British Society of Rheumatology (BSR) 2015 Congress, Manchester, UK, April 2015.

Adebajo AO, Gladman DD, Mease PJ, et al. Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial nd open-label extension (PALACE 1). British Society of Rheumatology (BSR) 2015 Congress, Manchester, UK, April 2015.

Mease PJ, Hoepken B, Davies O, et al. Effect of certolizumab pegol on dermatological outcomes over 96 weeks in patients with psoriatic arthritis. American Academy of Dermatology (AAD), 73rd Annual Meeting, San Francisco, Mar. 2015.

Mease PJ, Fleischmann R, Wollenhaupt J, et al. Certolizumab pegol in patients with psoriatic arthritis, outcomes from RAPID-PsA to week 24, prior-TNF exposure (ACR response) and severity of baseline skin involvement (PASI). SOLAPSO 2nd congreso latinoamericano de psoriasis. Hacia una Nueva Dermatologia, Cancun, Mexico, Dec. 2014.

Lespessailles E ... Mease PJ. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoiatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. Société Française de Rhumatologie (SFR) Le 27e Congrès Français de Rhumatologie, Paris, December 2014.

Lespessailles E ... Mease PJ. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: results from 3 phase 3, randomized, controlled trials. Société Française de Rhumatologie (SFR) Le 27e Congrès Français de Rhumatologie, Paris, December 2014.

Mease PJ, Genovese MC, Greenwald MW, et al. Efficacy of brodalumab, an anti-IL17R antibody, in subjects with psoriatic arthritis. Society of Dermatologist Physicians Assistants (SDPA) 12th Annual Fall Dermatology Conference, San Diego CA, Nov. 2014.

CutoloM, MeasePJ, KavanaughA, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: pooled safety analysis of three phase 3, randomized, controlled trials (PALACE 1-3) . The 51st National Congress of the Italian Society of Rheumatology (SIR) in Nov. 2014.

Adebajo AO, Mease PJ, Kavanaugh A, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoiatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. 35th Scandinavian Congress of Rheumatology (SCR) Stockholm, Sweden, September, 2014.

Adebajo AO, Gomez-Reino JJ, Mease PJ, et al. Long-term 52-week results of PALACE 1, a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase inhibitor, in patients with psoiatic arthritis. 35th Scandinavian Congress of Rheumatology (SCR) Stockholm, Sweden, September, 2014.

Mease PJ, Fleischmann R, Wollenhaupt J, et al. Long-term safety and efficacy of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Sieper J, Rudwaleit M, MeasePJ, et al. Safety and efficacy of certolizumab pegol over 96 weeks in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Mease P, Fleischmann R, Davies O, et al. Disease activity and clinical response early in the course of treatment predict long-term outcomes in psoriatic arthritis patients treated with certolizumab pegol. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Gottlieb AB, Mease PJ, McInnes IB, et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Kavanaugh A, Cutolo M, Mease PJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: results from 3 phase 3, randomized, controlled trials. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Mease PJ, Genovese MC, MutebiA, et al. Reliability and construct validity of the psoriasis symptom inventory in subjects with psoriatic arthritis. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Strand V, Mease PJ, McInnes I, et al. Secukinumab, an anti–interleukin-17A monoclonal antibody, improves physical function, quality of life and work productivity in patients with active psoriatic arthritis: results from a phase 3, randomized, controlled trial. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

MeasePJ, Poddubnyy D, Chen S and Anderson JK. Therapeutic response in adalimumab-treated patients with non-radiographic axial spondyloarthritis is similar regardless of body mass index. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Ramiro S, Turina MC, Mease PJ, et al. A psychometric analysis of outcome measures in trials of peripheral spondyloarthritis. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Mease PJ, Gottlieb AB, Berman A, et al. A phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to evaluate the efficacy and safety of clazakizumab, an anti-IL-6 monoclonal antibody, in adults with active psoriatic arthritis. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

van der Heijde D, Landewé RBM, Mease PJ, et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Malm D, Bird P, Mease PJ, et al. Validation of the omeract psoriatic arthritis magnetic resonance imaging score for the hand and foot in a randomized placebo-controlled trial. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

van Vollenhoven R, Cohen SB, Mease PJ, et al. Efficacy and safety of MK-8457, a novel SYK inhibitor for the treatment of rheumatoid arthritis in two randomized, controlled, phase 2 studies. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Mease PJ, Van den Bosch F, Sieper J, et al. Better performance of the leeds and sparcc enthesitis indices compared to the mases in patients with peripheral spondyloarthritis during treatment with adalimumab. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Kavanaugh A, Gladman DD, Mease PJ, et al. Sustained improvements in workplace and household productivity and social participation with certolizumab pegol over 96 weeks in patients with psoriatic arthritis. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Genovese MC, Mease PJ, Greenwald MW, et al. Clinical response in subjects with psoriatic arthritis following one year of treatment with brodalumab, an anti-interleukin-17 receptor antibody. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Schett GA, Mease PJ, Gladman DD, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, and the impact of baseline weight and BMI on ACR20 and HAQ-DI response: pooled results from 3 phase 3, randomized, controlled trials. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Mease PJ, Adebajo AO, Gladman DD, et al. Long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial and open-label extension. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Gladman DD, Strand V, Mease PJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with improvement of pain, fatigue, and disability in patients with psoriatic arthritis: results from 3 phase 3, randomized, controlled trials. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Kavanaugh A, Mease PJ, Coates LC, et al. Value and prediction of minimal disease activity in patients with psoriatic arthritis. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Mease PJ, Gladman DD, Kavanaugh A, et al. Change in weight from baseline with apremilast, an oral phosphodiesterase 4 inhibitor: pooled results from 3 phase 3, randomized, controlled trials. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Kavanaugh A, Adebajo AO, Mease PJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Huynh DH, Etzel CJ, Mease PJ, et al. Persistence of low disease activity after tumor necrosis factor inhibitor withdrawal in patients with psoriatic arthritis. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Mease PJ, Collier D, Karki C, et al. Persistence and predictors of biologic TNFi therapy among biologic naïve psoriatic arthritis patients in a US registry. American College of Rheumatology (ACR) Annual Meeting, Boston MA, Nov. 2014.

Gladman D, Fleischmann R, Mease PJ, et al. Long-term maintenance of improvements in multiple facets of psoriatic arthritis with certolizumab pegol: 96-week patient-reported outcome results of the RAPID-PsA study. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress, Amsterdam, Nov. 2014.

Mease PJ, Fleischmann R, Wollenhaupt J, et al. Long-term safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without prior anti-tumor necrosis factor exposure: 96-week outcomes of the RAPID PsA trial. 9th International Congress on Spondyloarthropathies (ICS). Ghent, Belgium, October 2014.

Sieper J, Rudwaleit M, Mease P. J, et al. Long-term safety and efficacy of certolizumab pegol in patients with axial spondyloarthritis: 96-week outcomes of the RAPID AxSpA trial.-9th International Congress on Spondyloarthropathies (ICS). Ghent, Belgium, October 2014.

Wollenhaupt J … Mease PJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in swollen and tender joint counts in patients with psoiatic arthritis: results from three phase 3, randomized, controlled trials. 42nd Congress of the German Society of Rheumatology (DGRh), Dusseldorf, Germany, Sept. 2014.

Braun J … Mease PJ, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoiatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials.. 42nd Congress of the German Society of Rheumatology (DGRh), Dusseldorf, Germany, Sept. 2014.

Mease PJ, Fleischmann R, Wollenhaupt J, et al. OP0077 Long-term safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without prior anti-tumor necrosis factor exposure: 96 week outcomes from the RAPID-PsA trial. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Kavanaugh A, Cutolo M, Mease P, et al. OP0078 Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: results from 3 phase 3, randomized, controlled trials. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Kavanaugh A, McInnes I, Mease P, et al. OP0080 Impact of persistent minimal disease activity on long-term outcomes in psoriatic arthritis: results from 5 years of the long term extension of a randomized, placebo-controlled study. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Deodhar A, Mease PJ, Reveille JD, et al. THU0065 Prevalence of axial spondyloarthritis among undiagnosed chronic back pain patients in the United States. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Helliwell P, Mease PJ, Nurminen T, et al. SAT0403 Further analysis of psoriatic arthritis disease activity score (PASDAS) and composite psoriatic disease activity index (CPDAI) using data from a placebo-controlled trial of certolizumab pegol in psoriatic arthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Mease PJ, Kavanaugh A, Gladman D, et al. SAT0408 Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Mease P, Van den Bosch F, Baeten DL, et al. FRI0128 Utility of enthesitis assessments in peripheral spondyloarthritis– data from the ABILITY-2 trial. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Ramiro S, Turina M, Mease P, et al. FRI0138 A psychometric analysis of outcome measures in trials of peripheral spondyloarthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Sieper J, Rudwaleit M, Mease PJ, et al. SAT0351 Long-term safety and efficacy of certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 96 week outcomes of the RAPID-axSpA trial. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Mease PJ, Fleischmann R, Davies O, et al. SAT0405 Disease activity and clinical response early in the course of treatment predict long-term outcomes in psoriatic arthritis patients treated with certolizumab pegol. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Mease PJ, Dougados M, Davies O, et al. SAT0362 Certolizumab pegol rapidly reduces peripheral enthesitis and the incidence of tender and swollen joints in patients with active axial spondyloarthritis, including both ankylosing spondylitis and non-radiographic axial spondyloarthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Van den Bosch F, Mease P, Sieper J, et al. SAT0342 Arthritis and enthesitis remission during adalimumab treatment in peripheral spondyloarthritis: year 2 results from ABILITY-2. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Mease PJ, Genovese MC, Greenwald MW, et al. SAT0404 Fifty-two week clinical response to brodalumab, an anti-IL-17R antibody, in subjects with psoriatic arthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Weinblatt M, Mease P, Mysler E, et al. SAT0244 A phase IIB study of the efficacy and safety of subcutaneous clazakizumab (anti-IL-6 monoclonal antibody) with or without methotrexate in adults with moderate to severe active rheumatoid arthritis and an inadequate response to methotrexate. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Mease P, Karunaratne PM, Kupper H, et al. AB0757 Achievement of a combined clinical and radiographic endpoint in patients with psoriatic arthritis in the ADEPT trial. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Mease PJ, Genovese MC, Mutebi A, et al. AB0755 Reliability and construct validity of the psoriasis symptom inventory in subjects with psoriatic arthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Genovese MC, Mease PJ, Greenwald MW, et al. AB0752 Efficacy and safety of brodalumab over one year in patients with psoriatic arthritis with and without prior exposure to a biologic. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Kavanaugh A, Mease PJ, Strand V, et al. AB0372 Effect of certolizumab pegol on workplace and household productivity in US patients with rheumatoid arthritis with or without prior anti-tumor necrosis factor exposure: results from the PREDICT study. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Schett G, Mease P, Gladman D, et al. AB0746 Apremilast, an oral phosphodiesterase 4 inhibitor, and the impact of baseline weight and BMI on ACR20 and HAQ-DI response: pooled results from 3 phase 3, randomized, controlled trials. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Mease P, Gladman D, Kavanaugh A, et al. AB0758 Change in weight from baseline during the PALACE clinical trial program with apremilast, an oral phosphodiesterase 4 inhibitor: pooled results from 3 phase 3, randomized, controlled trials. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Paris, France, June 2014.

Adebajo A, Mease PJ, Kavanaugh A, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. 35th Scandinavian Congress of Rheumatology (SCR) Stockholm, Sweden, September, 2014.

Mease P, Masters E, McNett M, et al. An internet-based study characterizing the association between pain severity and the burden of fibromyalgia in the US. Society of General Internal Medicine ( SGIM), 37th Annual Meeting, San Diego, April 2014.

Mease P, Haraoui B, Kavanaugh A, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in swollen and tender joint counts in patients with psoriatic arthritis: results from three phase 3, randomized, controlled trials. Laurentian Conference of Rheumatology (LCR) 2014 congress, Tremblant, CA, May 2014.

Mease P, Boire G, Kavanaugh A, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an O=oral phosphodiesterase 4 inhibitor: pooled safety analysis of three phase 3, randomized, controlled trials. Laurentian Conference of Rheumatology (LCR) 2014 congress, Tremblant, CA, May 2014.

Mease PJ, Hoepken B, Davies O, et al. Effect of certolizumab pegol on dermatological outcomes over 96 weeks in patients with psoriatic arthritis. European Academy of Dermatology and Venereology (EADV), 23rd Congress, Amsterdam, Oct. 2014.

Mease P, Ritchlin C, Rubant S, et al. Disconnect between radiographic progression and skin or arthritic outcomes in psoriatic arthritis patients treated with adalimumab. European Academy of Dermatology and Venereology (EADV), 23rd Congress, Amsterdam, Oct. 2014.

Boulos PH, Cutolo M, Mease PJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in swollen and tender joint counts in patients with psoriatic arthritis: results from three phase 3, randomized, controlled trials. 45th Laurentian Conference of Rheumatology, Tremblant, May 2014.

Boire G, Mease PJ, Kavanaugh A, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: pooled safety analysis of three phase 3, randomized, controlled trials. 45th Laurentian Conference of Rheumatology, Tremblant, May 2014.

Bird P; Francisco J, Blanco FJ, Mease P, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results of Phase 3, Randomized, Placebo-Controlled Trials (PALACE 1, 2, and 3). Australian Rheumatology Association (ARA) 55th Congress, Hobart, Tasmania, May 2014.

Mease P,Fleischmann R,Wollenhaupt J, et al. Effect Of Certolizumab Pegol Over 48 Weeks On Signs and Symptoms In Patients With Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Exposure. Spanish Rheumatology Society National Congress, Santiago de Compostela, Spain, May 2014; and Portuguese Rheumatology National Congress , Algarve, Portugal, May 2014.

Mease PJ, Genovese MC, Greenwald MW, et al. Efficacy of brodalumab, an anti-IL-17R antibody, in subjects with psoriatic arthritis. Dermatology Nurses Association, Orlando FL, May 2014.

Mease PJ; Kavanaugh A, Gladman D, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-term (52-Week) Improvements in Enthesitis and Dactylitis in Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials. Canadian Rheumatology Association (CRA) Annual Scientific Meeting, Whistler BC Canada, Feb. 2014.

Mease PJ; Kavanaugh A, Gladman D, et al. Long-term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials. Canadian Rheumatology Association (CRA) Annual Scientific Meeting, Whistler BC Canada, Feb. 2014.

Cutolo M, Mease P, Gladman DD, et al. Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials. 16th Asia Pacific League of Associations for Rheumatology Congress (APLAR). Cebu City, Philippines, March 2014.

Mease PJ,Kavanaugh A, Gladman D, et al. Long-term safety and tolerability of apremilast, an an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. 16th Asia Pacific League of Associations for Rheumatology Congress (APLAR). Cebu City, Philippines, March 2014.

Landewé R, Rudwaleit M, Mease P, et al. Effect of certolizumab pegol over 48 weeks in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis. British Society of Rheumatology 2014 Congress, Liverpool, UK, April 2014.

Mease P,Fleischmann R,Wollenhaupt J, et al. Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure. British Society of Rheumatology 2014 Congress, Liverpool, UK, April 2014.

Keystone E, Landewé R, Mease P, et al. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from a 52-week randonized controlled trial and open-label extension study. British Society of Rheumatology 2014 Congress, Liverpool, UK, April 2014.

Kavanaugh A, Mease PJ, Adebajo AO, et al. Long-term 52-week results of PALACE 1, a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase inhibitor, in patients with psoriatic arthritis. British Society of Rheumatology 2014 Congress, Liverpool, UK, April 2014.

Mease PJ,Kavanaugh A, Gladman D, et al. Long-term safety and tolerability of apremilast, an an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. British Society of Rheumatology 2014 Congress, Liverpool, UK, April 2014.

van der Heijde D, Huang F, Mease P, et al. Comparison of Ankylosing Spondylitis in Chinese and Western Patients. Asia Pacific League of Associations for Rheumatology Congress (APLAR), Philippines, 2014.

Blanco F, Kavanaugh A, Mease P, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of phase 3, randomized, controlled trials (PALACE 1, 2, and 3) Congress of the Pan American League of Associations for Rheumatology (PANLAR), Punta del Este, Uruguay, 2014.

Gladman D, Fleischmann R … Mease PJ. Long-term maintenance of improvements in multiple facets of psoriatic arthritis with certolizumab pegol: 48-week patient-reported outcome results of the RAPID-PsA study. ISPOR 16th Annual European Congress, Dublin, Ireland, Nov. 2013.

Mease PJ, van Tubergen A, Deodhar A, et al. Comparing health-related quality of life across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: analyses from certolizumab pegol clinical trial baseline data. ISPOR 16th Annual European Congress, Dublin, Ireland, Nov. 2013.

Kavanaugh A, Gladman D ... Mease P, et al. Sustained improvements in productivity at paid work and within household, and increased participation in daily activities over time with certolizumab pegol in patients with psoriatic arthritis: 48-week results from the RAPID-PsA study. ISPOR 16th Annual European Congress, Dublin, Ireland, Nov. 2013.

Kavanaugh A, Adebajo AO … Mease PJ. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of phase 3, randomized, controlled trials (PALACE 1 and PALACE 3). 2013 Fall Clinical Dermatology Conference. Las Vegas. Oct. 2013.

Kavanaugh A, Gladman D ... Mease PJ, et al. Reduction of disease burden on workplace and household productivity in psoriatic arthritis over 48 weeks of treatment with certolizumab pegol. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Mease P, Fleischmann R, Wollenhaupt J, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure: 48-week results of a phase III study. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Landewé R, Deodhar AA … Mease PJ, et al. Effect of Certolizumab Pegol over 48 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Keystone E, Landewe R … Mease PJ, et al. Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Mease P, Masters ET, Zlateva G, et al. A Population-Based Survey and Physician Assessment Of The Characteristics and Prevalence Of Fibromyalgia. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Mease P, Kavanaugh A, Adebajo AO, et al. Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Cutolo M, Mease P, Gladman DD, et al. Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Genovese MC, Mease P, Visuanathan H, et al. Effect Of Brodalumab (AMG 827) On Pain and Physical Functioning In Patients With Psoriatic Arthritis. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Schett G, Mease P, Gladman DD, et al. Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Physical Function In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Gladman DD, Mease P, Kavanaugh A, et al. Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Helliwell PS, Mease P, Banalis E, et al. Baseline Characteristics and Treatment Outcomes In Psoriasis Patients With Polyarthritis Or Oligoarthritis. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Mease, P, Edson-Heredia E, Saunders KC, et al. Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Kavanaugh A, McInnes IB, Mease P, et al. Impact Of Persistent Minimal Disease Activity On Long-Term Outcomes In Psoriatic Arthritis: Results From 5 Years Of The Long Term Extension Of a Randomized, Placebo-Controlled Study. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Mease P, Kavanaugh A, Adebajo AO, et al. Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Genovese MC, Mease P, Greenwald MW, et al. Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Mease P, Coindreau J, Mallbris L, et al. Examining Phenotypes Of Patients With Psoriasis In The Prepare Study For Similarities Between Diagnosed Psoriatic Arthritis and Those With Signs Of Subclinical Psoriatic Arthritis Detected By Imaging. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Weinblatt M, Mease P, Mysler E, et al. A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Boyle DL, Wei N … Mease P. The Jak Inihibitor Tofacitinib Suppresses Synovial Jak-Stat Signalling In Rheumatoid Arthritis. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Deodhar A, Mease P, Curtis JR, et al. Prevalence Of Axial Spondyloarthritis In The United States Among Patients With Chronic Back Pain and Other Spondyloarthritis-Related Features. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Van der Heijde D, Mease P, Pangan AL, et al. Improvement In Physical Function, Health-Related Quality Of Life, and Work Productivity With Adalimumab Treatment In Non-Radiographic Axial Spondyloarthritis. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Mease P, Rao SA, Joshi AD, et al. Quality Of Life, Physical Function and Symptoms In Non-Radiographic Axial Spondyloarthritis:The Patient Perspective. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Silverman S, Masters ET … Mease P. Comparative Burden Of Chronic Widespread Pain and Fibromyalgia In The US Population. American College of Rheumatology Annual Meeting, San Diego CA, Oct. 2013.

Kavanaugh A, Mease PJ, Adebajo AO, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis. Psoriasis Congress. Paris, France. Sept. 2013.

Mease PJ, Kavanaugh A, Adebajo AO, et al. Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis. Psoriasis Congress. Paris, France. Sept. 2013.

Kavanaugh A, Mease P, Adebajo AO, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Mease PJ, Genovese MC, Greenwald MW, et al. Efficacy of broadalumab, an anti-IL-17R antibody, in subjects with psoriatic arthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Mease PJ, Rao S, Betts KA, et al. Effect of adalimumab on physical function, health-related quality of life, and work productivity in patients with peripheral spondyloarthritis: results from the ABILITY-2 clinical trial. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Smolen JS, Braun J, Mease P, et al. Treat-to-target recommendations for spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis: a consensus of an international task force. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Keystone E, Landewé R, Mease PJ, et al. 5-year results from the RAPID 1 trial and open-label extension: long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Van den Bosch F,Mease P, van der Heijde D, et al. Similar levels of disease activity in patients with oligoarticular vs. polyarticular peripheral spondyloarthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Kavanaugh A, van der Heijde D, Mease PJ, et al. 5 year safety, efficacy, and radiographic data in patients with active psoriatic arthritis treated with golimumab: long-term expansion results of the randomized, placebo-controlled study GO-REVEAL. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Kavanaugh A, Mease PJ, Purcaru O, et al. High economic burden of moderate to severe psoriatic arthritis on paid work and household productivity: baseline results from the RAPID-PsA study. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Kavanaugh A, Gladman D, Mease PJ, et al. Improvements in productivity at paid work and within household, and increased participation in daily activities after 24 weeks of certolizumab pegol in patients with psoriatic arthritis: results of RAPID-PsA study. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

van der Heijde D, Fleischmann R, Mease PJ, et al. Impact of imputation methodology on radiographic progression outcomes in the RAPID-PsA study of certolizumab pegol in patients with psoriatic arthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Mease PJ, Fleischmann R, Wollenhaupt J, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis from the RAPID-PsA study: impact of baseline skin involvement and prior anti-TNF therapy. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Mease PJ, Kavanaugh A, Adebajo AO, et al. Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Mease PJ, van Tubergen A, Deodhar A, et al. Comparing health-related quality of life across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis: analyses from certolizumab pegol clinical trial baseline data. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Gladman D, Fleischmann R, Mease PJ, et al. Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients with and without prior anti-TNF exposure: 24-week patient-reported outcome results of RAPID PsA study. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Mease P, Collier D, Saunders K, et al. Biologic therapy, time to low disease activity, and effect of mono vs. background oral DMARD therapy among psoriatic arthritis patients in a U.S. registry. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, Madrid, Spain, June 2013.

Gladman D, Fleischmann RM, Mease P, et al. Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients: 24 week patient reported outcome results of a phase 3 double-blind randomized placebo-controlled study. ISPOR (International Society for Pharmacoeconomics and Outcomes Research) 18th Annual International Meeting, New Orleans LA, May 2013.

Mease P, Fleischmann RM, Wollenhaupt J, et al. Effect of certolizumab egol on signs and symptoms in patients with psoriatic arthritis with and without prior anti-TNF exposure: 24 week results of a phase 3 double-blind randomized placebo-controlled study. British Society of Rheumatology 2013 Congress, Birmingham UK, April 2013.

Coates LC, FitzGerald OM, Mease P, et al. Reduced joint counts misclassify psoriatic arthritis patients with oligoarthritis and miss significant active disease. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Gladman DD, Fleischmann RM, Mease P, et al. Effect of certolizumab pegol on the multiple facets of psoriatic arthritis as reported by patients: 24 week patient reported outcome results of a phase 3 double-blind randomized placebo-controlled study. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Mease P, Sieper J, Van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with peripheral spondyloarthritis. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Revicki D, Chen W-H, Mease P, et al. Validation of the health assessment questionnaire for spondyloarthritis in patients with non-radiographic axial spondyloarthritis. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

van der Heijde D, Mease P, Pangan AL, et al. Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Nonradiographic Axial Spa: Wk-52 Results From Ability-1. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Gladman DD, Mease P, Faraawi RY, et al. The Prevalence of Psoriatic Arthritis Based On Rheumatologists’ Clinical Assessment Before and After Laboratory and Radiographic Tests in Psoriasis Patients in European/North American Dermatology Clinics. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Van den Bosch F, Mease P, van der Heijde D, et al. Similar Levels of Disease Activity in Patients with Oligoarticular Vs. Polyarticular Peripheral Spondyloarthritis. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Kavanaugh A, van der Heijde D, Mease P, et al. 5 year safety, efficacy, and radiographic data in patients with active psoriatic arthritis treated with golimumab: Results from the long-term extension of the randomized, placebo-controlled, GO-REVEAL study. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Maksymowych WP, van der Heijde D, Mease P, et al. Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Mease P, Bennett RM, Palmer RH, et al. Identifying Core Symptom Domains in the Fibromyalgia Impact Questionnaire: Principal Component Analysis of Data From Milnacipran Clinical Studies. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Mease P, Bennett RM, Palmer RH, et al. Clinical Outcome in Fibromyalgia Patients Treated with Milnacipran Is Largely Independent of Symptom Duration. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Mease P, Fleischmann RM, Wollenhaupt J, et al. Effect of Certolizumab Pegol On Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Anti-TNF Exposure: 24 Week Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study. American College of Rheumatology Annual Meeting, Washington DC, Nov. 2012.

Mease PJ, Papp KA, Gladman D, et al. The prevalence of rheumatologist-diagnosed psoriatic arthritis in psoriasis patients in European/North American dermatology clinics: Results of the PREPARE study. 3rd World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden July 2012. published in Dermatology and Therapy 2012;Vol 2;Supp 1, 10.

Wollenhaupt J, Mease PJ, Fleischmann R, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (RAPID PsA). 40th Congress of the German Society of Rheumatology (DGRh) Sept. 2012, Bochum, Germany.

Mease PJ, Gladman D, et al. Comparative performance of existing psoriatic arthritis screening tools in psoriasis patients in European/North American dermatology clinics: findings of the PREPARE study. 21st European Academy of Dermatology and Venereology (EADV) Congress, Prague, Sept. 2012.

Mease PJ, Papp KA, Gladman D, et al. The prevalence of rheumatologist-diagnosed psoriatic arthritis in psoriasis patients in European/North American dermatology clinics. 3^rd World Psoriasis & Psoriatic Arthritis Conference (WPPAC). Stockholm, Sweden July 2012.

Mease P, Sieper J, et al. Efficacy and safety of adalimumab in peripheral spondylarthritis patients: results from ABILITY-2. Spondyloarthropathies Congress, Gent, Belgium, 2012.

Mease P, Sieper J, et al. Efficacy and safety of adalimumab in patients with peripheral spondyloarthritis: results from a phase 3 study. EULAR 2012, Berlin.

Mease P, van Vollenhoven R, et al. Analysis of infection risk in patients with limited return of peripheral B cells after a period of 2 years or more following any rituximab treatment course in RA clinical trials. EULAR 2012, Berlin.

Mease PJ, Fleischmann R, Deodhar A, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (RAPID PsA) EULAR 2012, Berlin.

Mease P. Non-anti TNF biologics in PsA SP0147 EULAR 2012, Berlin. Invited Speaker Abstract.

Coates LC … Mease P, et al. Reduced joint counts misclassify PsA patients with oligoarthritis and miss significant active disease. EULAR 2012, Berlin.

Coates LC … Mease, et al. MDA criteria for PsA show good correlation with physician and patient opinions and with proposed composite measures. EULAR 2012, Berlin.

Mease P, Saunders K, et al. The effect of dactylitis and enthesitis on disease burden in patients with psoriatic arthritis in the CORRONA registry. EULAR 2012, Berlin.

Boonen A … Mease P, et al. Progression from undifferentiated spondyloarthritis to ankylosing spondylitis: is USPA a proxy for non-radiographic axial SpA? EULAR 2012, Berlin.

Mease P … Gladman D, et al. Comparative performance of existing psoriatic arthritis screening tools in psoriasis patients in European/North American dermatology clinics: findings of the PREPARE study. Fall EADV Congress, Prague, Sept. 2012.

Landewe R … Mease P, et al. Severity of baseline skin disease does not correlate with clinical, patient-reported, or radiographic responses in patients with psoriatic arthritis treated with Adalimumab. British Society for Rheumatology Annual Congress, Glasgow, May 2012.

Kavanaugh A … Mease P, et al. Early and Sustained Remission Associated with Normalized Physical Function, Health-Related Quality of Life & Significantly Improved Productivity in Patients with Active Psoriatic Arthritis Treated with Golimumab: 2-Year Data from Phase III GO-REVEAL Trial. 67th Canadian Rheumatology Association Annual Scientific Meeting. Victoria BC, March 2012.

Kavanaugh A … Mease P, et al. Long-term radiographic outcome in psoriatic arthritis patients treated with golimumab: 104 Week Results from the GO-REVEAL Study. 67th Canadian Rheumatology Association Annual Scientific Meeting. Victoria BC, March 2012.

van der Heijde D … Mease P, et al. Sustained Improvement of Spinal Mobility, Physical Function, and Quality of Life in Patients with Ankylosing Spondylitis: 5-Year Results. American College of Rheumatology Annual Meeting, Chicago, Illinois, Nov. 2011.

Gross RL … Mease P, et al. The Risk of Malignancy in a Large Cohort of Patients with Psoriatic Arthritis. American College of Rheumatology Annual Meeting, Chicago, Illinois, Nov. 2011.

Maksymowych WP, Mease P, Rao S, et al. Effect of Adalimumab on Function, Health-Related Quality of Life, Work Productivity, and Daily Activities in Patients with Non-Radiographic Axial Spondyloarthritis. American College of Rheumatology Annual Meeting, Chicago, Illinois, Nov. 2011.

Mease P, Clauw DJ, Ma Y, et al. Return of Pain and Functional Impairment After Discontinuation of Milnacipran in Patients with Fibromyalgia. American College of Rheumatology Annual Meeting, Chicago, Illinois, Nov. 2011.

Clauw DJ, Mease P, Ma Y, et al. Continuing Efficacy of Milnacipran Demonstrated After Long-Term Treatment of Fibromyalgia. American College of Rheumatology Annual Meeting, Chicago, Illinois, Nov. 2011.

Mease P, Palmer RH, Wang Y, and Gendreau RM. Improvements in Fatigue Are Incompletely Explained by Improvements in Pain in Fibromyalgia Patients Treated with Milnacipran. American College of Rheumatology Annual Meeting, Chicago, Illinois, Nov. 2011.

Rigby W, Mease P, Olech E, Ashby M and Tole S. Safety of Rituximab in Combination with Other Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: 48-Week Data From SUNDIAL. American College of Rheumatology Annual Meeting, Chicago, Illinois, Nov. 2011.

Robinson R … Mease P, et al. Six-Month Treatment Patterns and Outcomes for Patients with Fibromyalgia. American College of Rheumatology Annual Meeting, Chicago, Illinois, Nov. 2011.

Sieper J … Mease P, et al. Efficacy and Safety of Adalimumab in Patients with Non-Radiographic Axial Spondyloarthritis – Results From a Phase 3 Study. American College of Rheumatology Annual Meeting, Chicago, Illinois, Nov. 2011.

Mease P, Landewe R, Olds M, Lavie F. Severity of baseline skin disease does not correlate with clinical response in patients with psoriatic arthritis treated with adalimumab. EULAR, London, May 25-28, 2011.

Clauw DJ, Mease P, et al. Efficacy of milnacipran after long-term treatment in patients with fibromyalgia: A randomized double-blind, placebo-controlled discontinuation study. EULAR, London, May 25-28, 2011.

Strand V … Mease P. BMS-945429 (ALD518), a high-affinity anti-interleukin-6 monoclonal antibody, is associated with improvements in health-related quality of life in patients with rheumatoid arthritis and an inadequate response to methotrexate. EULAR, London, May 25-28, 2011.

Rigby W, Mease P, et al. An open-label study of the safety of rituximab (RTX) in combination with other biologic disease-modifying antirheumatic drugs (DMARDS) in patients with active rheumatoid arthritis (RA). EULAR, London, May 25-28, 2011.

Kavanaugh A … Mease P, et al. Early and sustained remission associated with normalized physical function, health-related quality of life and significantly improved productivity in patients with active psoriatic arthritis treated with golimumab: 2-year data from phase III GO-REVEAL trial. EULAR, London, May 25-28, 2011.

Kavanaugh A … Mease P, et al. Long-term radiographic outcome in psoriatic arthritis patients treated with golimumab: 104 week results from the GO-REVEAL study. EULAR, London, May 25-28, 2011.

Dougados M, Mease P, et al. Predicting joint and skin remission at 24 weeks in patients with psoriatic arthritis. EULAR, London, May 25-28, 2011.

Sieper J, van der Heijde D, Dougados M, Mease P, Pangan AL. Comparable levels of disease activity between axial spondyloarthritis patients classified through the MRI or HLA-B27 pathway of the ASAS criteria. EULAR, London, May 25-28, 2011.

Kavanaugh A … Mease P, et al. Early and sustained remission associated with normalized physical function, health-related quality of life and significantly improved productivity in patients with active psoriatic arthritis treated with golimumab: GO-REVEAL 2-year data. Academy of Managed Care Pharmacy Meeting, Minneapolis, Minnesota, April 27-29, 2011.

Mease P, Olds M, Kary S, et al. Modification of Minimal Disease Activity (MDA) score by replacement of PASI with PGA for patients with psoriatic arthritis treated with adalimumab. British Society of Rheumatology Annual Congress, Brighton, April 12-14, 2011.

Kavanaugh A … Mease P. High level responses in psoriatic arthritis patients treated with golimumab: results from week 104 of the GO-REVEAL study. British Society of Rheumatology Annual Congress, Brighton, April 12-14, 2011.

Kavanaugh A … Mease P, et al. Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52-week results from the GO-REVEAL study. British Society of Rheumatology Annual Congress, Brighton, April 12-14, 2011.

Mease P, Spera A, Palmer RH, et al. Improvements in fatigue with milnacipran treatment in patients with fibromyalgia: Pooled analysis from 3 randomized, placebo-controlled trials. Women’s Health Congress, Washington DC, April 1-3, 2011.

Mease P, Farmer MV, Trugman JM, et al. A randomized, open-label, controlled study evaluating the effect of adding milnacipran to pregabalin in patients with fibromyalgia. Women’s Health Congress, Washington DC, April 1-3, 2011.

Kavanaugh A ... Mease P, et al. Early and sustained remission associated with normalized physical function and health-related quality of life and significantly improved productivity in patients with active psoriatic arthritis treated with golimumab: Two year data from the phase III GO-REVEAL clinical trial. International Society for Pharmacoeconomics and Outcomes Research, Baltimore, Maryland, May 21 -25, 2011.

Robinson R ... Mease P, et al. Burden of illness for patients with fibromyalgia: Baseline findings from the REFLECTIONS study (Real World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments). American Pain Society Annual Meeting, Austin, Texas, May 19 -21, 2011.

Robinson R ... Mease P, et al. Treatment patterns for patients with fibromyalgia: Baseline findings from the REFLECTIONS study (Real World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments). American Pain Society Annual Meeting, Austin, Texas, May 19 -21, 2011.

Dougados M, Mease P, Olds M, et al. How early can we predict remission at 24 weeks in patients with psoriatic arthritis? French Rheumatology Congress, Paris, France, November 28 – December 1, 2010.

Mease P, D’Ambrosio L, Hareendran A, et al. Fatigue in fibromyalgia patients: A qualitative study exploring a conceptual framework. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Arnold L, Mease P, Williams D, et al. Development of responder definitions for fibromyalgia clinical trials. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Mease P, Arnold L, Wang F, et al. The effect of duloxetine on cognition in patients with fibromyalgia. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Wolfe F . . . Mease P, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: A modification of the ACR preliminary diagnostic criteria for fibromyalgia. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Strand V . . . Mease P, et al. ALD518 (BMS945429), a high-affinity anti-interleukin-6 monoclonal antibody, provides improvements in Health-Related Quality of Life (HRQoL) in patients with rheumatoid arthritis and an inadequate response to methotrexate. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Kavanaugh A . . . Mease P, et al. High level responses in psoriatic arthritis patients treated with golimumab: Results from week 104 of the GO-REVEAL study. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Kavanaugh A . . . Mease P, et al. Long-term radiographic outcome in psoriatic arthritis patients treated with golimumab: 104 week results from the GO-REVEAL study. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Kavanaugh A, Mease P, Olds M, et al. Correlation of disease activity, but not radiographic progression, with functional outcomes in adalimumab-treated patients with active psoriatic arthritis. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Mease P, Genovese M, Gladstein G, et al. Abatacept (ABA) in the treatment of Psoriatic Arthritis (PsA): 12-month results of a phase II study. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Mease P, Kavanaugh A, Genovese M, et al. Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Mease P, Ritchlin C, Olds M, et al. Disconnect between radiographic progression and clinical outcomes in psoriatic arthritis patients treated with adalimumab. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Mease P, Strand V, Shalamberidze L, et al. ALD518 (BMS945429) a High Affinity Monoclonal Antibody Directed Against Interleukin-6, Reduces Disease Activity and Achieves Remission in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Tak P, Mease P, Genovese M, et al. Efficacy and Safety of Ocrelizumab in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to at Least One TNF Inhibitor: Results from the Phase III SCRIPT Trial. American College of Rheumatology Annual Meeting, Atlanta, Georgia, November 7-11, 2010.

Kirkham B, Mease P, Robertson D. Improvement in enthesitis with etanercept therapy in patients with psoriasis and psoriatic arthritis (PRESTA trial). Asian Dermatology Satellite Meeting. November, 2010.

Kavanaugh A, Gladman D, van der Heijde D, Mease P, et al. Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results from the GO-REVEAL Study. International Congress on Spondyloarthropathies, Ghent, Belgium, October 7-9, 2010.

Dougados M, Mease P, Olds M, et al. How Early Can We Predict Remission at 24 Weeks in Patients With Psoriatic Arthritis? International Congress on Spondyloarthropathies, Ghent, Belgium, October 7-9, 2010.

Mease P, Olds M, Kary S, et al. Modification of Minimal Disease Activity (MDA) Score by Replacement of PASI With PGA for Patients With Psoriatic Arthritis Treated With Adalimumab. International Congress on Spondyloarthropathies, Ghent, Belgium, October 7-9, 2010.

Kavanaugh A, Gladman D, van der Heijde D, Mease P, et al. Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results from the GO-REVEAL Study. Belgium Congress on Rheumatology, G.D. Luxembourg, September 22-24, 2010.

Gladman D, Kavanaugh A, van der Heijde D, Mease P, et al. Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results from the GO-REVEAL Study. APLAR, Hong Kong, July 11-15, 2010.

Dougados M, Mease P, Olds M, et al. How early can we predict remission at 24 weeks in patients with psoriatic arthritis. EULAR, Rome, Italy, June 16-19, 2010.

Emery P, Mease P, Rubbert-Roth A, et al. Retreatment with Rituximab based on a treatment to target approach provides better disease control than treatment as needed in patients with RA. EULAR, Rome, Italy, June 16-19, 2010.

Kavanaugh A… Mease P, et al. Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study. EULAR, Rome, Italy, June 16-19, 2010.

Kavanaugh A… Mease P, et al. High level responses in psoriatic arthritis patients treated with golimumab: Results for week 104 of the GO-REVEAL study. EULAR, Rome, Italy, June 16-19, 2010.

Mease P, Genovese M, Ritchlin C, et al. Rituximab in psoriatic arthritis: Results of an open-label study. EULAR, Rome, Italy, June 16-19, 2010.

Mease P, Olds M, Kary S, et al. Modification of minimal disease activity (MDA) score by replacement of PASI with PGA for patients with psoriatic arthritis treated with adalimumab. EULAR, Rome, Italy, June 16-19, 2010.

Mease P, Strad V, Shalamberidze L, et al. Inhibition of IL-6 with ALD518 improves disease activity in rheumatoid arthritis in a randomized, double-blind, placebo-controlled, dose ranging phase 2 clinical trial. EULAR, Rome, Italy, June 16-19, 2010.

Mease P, Genovese M, Ritchlin C, et al. Abatacept in psoriatic arthritis: Results of a phase II study. EULAR, Rome, Italy, June 16-19, 2010.

Mease P, Clauw D, Fitzcharles MA, et al. Development of the fibromyalgia survey diagnostic criteria, a modification of the ACR (2010) preliminary diagnostic criteria for fibromyalgia. EULAR, Rome, Italy, June 16-19, 2010.

Mease P, Palmer RH, Wang Y et al. Effects of milnacipran treatment on fatigue in patients with fibromyalgia. EULAR, Rome, Italy, June 16-19, 2010.

Mease P, Rao S, Cifaldi M, et al. Impact of adalimumab on work and activity impairment for patients with psoriatic arthritis. EULAR, Rome, Italy, June 16-19, 2010.

Mease P, Rao S, Cifaldi M, et al. Impact of adalimumab treatment on physical function of patients with psoriatic arthritis with skin manifestations. EULAR, Rome, Italy, June 16-19, 2010.

Kirkham B, Mease P, Robertson D. Improvement in enthesitis with etanercept therapy in patients with psoriasis and psoriatic arthritis (PRESTA trial). 51st Annual Scientific Meeting of the Australian Rheumatology Association, Melbourne, Australia, May 22 – 25, 2010.

Emery P, Combe B, Mease P, et al. Re-treatment with rituximab (RTX) based on a treatment to target (TT) approach provides better disease control than treatment as needed (PRN) in patients (pts) with rheumatoid arthritis (RA). 51st Annual Scientific Meeting of the Australian Rheumatology Association, Melbourne, Australia, May 22 – 25, 2010.

Emery P, Mease P, Rubbert-Roth A, et al. Retreatment with rituximab based on a treatment to target (TT) approach provides better disease control than treatment administered as needed (PRN) in patients with rheumatoid arthritis (RA). 36^th Annual National Congress of the Sociedad Española de Reumatología, Tarragona, Spain, May 19-21, 2010.

Keystone EC… Mease P, et al. A faster clinical response to certolizumab pegol (CZP) treatment is associated with better 52-week outcomes in patients with rheumatoid arthritis (RA). British Society of Rheumatology Annual Congress, Birmingham, April 21-23, 2010.

Keystone EC… Mease PJ, et al. The efficacy of certolizumab pegol added to methotrexate in sustained over 2 years in the treatment of rheumatoid arthritis. British Society of Rheumatology Annual Congress, Birmingham, April 21-23, 2010.

Gladman D… Mease P, et al. Golimumab, A New, Human, TNF Alpha Antibody, Administered SC Every 4 Weeks in PsA Patients: 104-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-REVEAL Study. British Society of Rheumatology Annual Meeting, ICC, Birmingham, April 21-23, 2010.

Kavanaugh A . . . Mease P, et al. Golimumab Administered SC Every 4 Weeks in PsA Patients: 52-Week Health-Related Quality of Life, Physical Function and Health Economic Results of the Randomized, Placebo-Controlled GO-REVEAL Study. British Society of Rheumatology Annual Meeting, ICC, Birmingham, April 21-23, 2010.

Gladman D… Mease P, et al. Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study. Canadian Rheumatology Association Annual Meeting, Quebec, Canada, February 3-6, 2010.

Kavanaugh A, Mease P, Krueger GG, et al. Golimumab, A New, Human, TNF Alpha Antibody, Administered SC Every 4 Weeks in PsA Patients: 104-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-REVEAL Study. Canadian Rheumatology Association Annual Meeting, Quebec, Canada, February 3-6, 2010.

Gladman D…Mease P, et al. Golimumab administered every four weeks as a subcutaneous injection in psoriatic arthritis: Nail, enthesitis, and dactylitis response in the randomized, placebo-controlled, GO-REVEAL study. BSR Annual Meeting, Glasgow, Scotland, April 28-May 1, 2009.

Mease P, Coteur G, Keininger, D, et al. Improvements in physical function and pain relief were sustained in rheumatoid arthritis patients treated for 2 years with certolizumab pegol. Canadian Rheumatology Association Annual Meeting, Delta Kananaskis, Alberta, February 18-21, 2009.

Keystone E, Schiff M, Mease P, et al. Combination therapy with certolizumab pegol plus methotrexate maintains long-term efficacy in the treatment of rheumatoid arthritis: a two year analysis. Canadian Rheumatology Association Annual Meeting, Delta Kananaskis, Alberta, February 18-21, 2009.

Mease P, Palmer RH, Rao S, et al. Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: Results from a dose-controlled, extension study. American Pain Society, San Diego, May, 2009.

Arnold L… Mease P, et al. What makes fibromyalgia patients feel better? Correlation between patient global impressions and clinical symptoms and function. American Pain Society, San Diego, May, 2009.

Mease P, Palmer RH, Rao S, et al. Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: Results from a dose controlled, extension study. SGIM 32nd Annual Meeting, Miami Beach, May, 2009.

Mease P, Russell IJ, Kajdasz D, et al. Long-term safety, tolerability, and effectiveness of duloxetine in the treatment of fibromyalgia. American Academy of Pain Medicine, Hawaii, January, 2009.

McInnes I, Mease P, Kruger, G, et al. Golimumab administered every four weeks in psoriatic arthritis: 52 week efficacy and safety results of the GO-REVEAL study. British Society of Rheumatology Annual 2009.

McInnes I… Mease P, et al. Golimumab administered every four weeks as a subcutaneous injection in psoriatic arthritis: Nail, enthesitis, and dactylitis response in the randomized, placebo-controlled, GO-REVEAL study. British Society of Rheumatology Annual 2009.

Mease PJ, Duh MS, Vekeman F, et al. Evaluation of cardiovascular diseases (CVDs) risk in french patients receiving milnacipran (MLN) relative to patients receiving other antidepressants therapies. International Society of Pharmacoepidemiology conference, Providence, August, 2009.

Taylor WJ, Gladman DD, Mease PJ, et al. The impact of psoriatic arthritis (PsA) according to the International Classification of Functioning, Health and Disability (IFC). NZRA/ARA Combined Annual Scientific Meeting, Wellington, New Zealand, May, 2009.

Kavanaugh A, Mease P, Krueger GG, et al. Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis: 52 week efficacy and safety results of the GO-REVEAL study. NZRA/ARA Combined Annual Scientific Meeting, Wellington, New Zealand, May, 2009.

Kirkham B, Mease P, Robertson D, et al. Etanercept therapy improved enthesitis and dactylitis in subjects with psoriasis and psoriatic arthritis (PRESTA psoriasis trial). European Academy of Dermatology and Venereology, 2009.

Mease PJ, Duh MS, Vekeman F, et al. Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States. International Society of Pharmacoepidemiology, Stockholm, 2009.

Choy E, Mease P, Kajdasz D, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: Analysis of 5 studies. College of Psychiatric and Neurologic, Jacksonville, April 2009.

van der Heijde D, Pangan AL, Mease P, et al. Psoriatic spondylitis or ankylosing spondylitis with psoriasis: Insights from the SPARK international survey. Ann Rheum Dis 2009;68(Suppl3):347.

Mease P, Palmer RH, Hallman L, et al. Efficacy of milnacipran 200 mg/day in fibromyalgia patients who were nonresponders to milnacipran 100 mg/day: Results from a 6-month, randomized, doube-blind, extension study. Ann Rheum Dis 2009;68(Suppl3):692.

Mease P, Palmer RH, Chen W, et al. Day-to-day pain relief with milnacipran in fibromyalgia patients: Results from 2 clinical trials. Ann Rheum Dis 2009;68(Suppl3):692.

Dougados M… Mease PJ, et al. Nonsteroidal anti-inflammatory drugs (NSAID)-sparing effect of adalimumab treatment in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(Suppl3):632.

Kirkham B, Mease P, Robertson D. Improvement in enthesitis with etanercept therapy in patients with psoriasis and psoriatic arthritis (PRESTA trial). Ann Rheum Dis 2009;68(Suppl3):655.

Kavanaugh A, Mease P, Krueger GG, et al. Golimumab, a new, human, TNF-alpha antibody administered subcutaneously every 4 weeks in psoriatic arthritis patients: 107-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2009;68(Suppl3):136.

Dougados M… Mease PJ, et al. Intercountry variability of the relative percentage of rheumatoid arthritis versus spondyloarthritis in rheumatologic daily practice. Ann Rheum Dis 2009;68(Suppl3):531.

Mease P, et al. Fibromyalgia fatigue—development of a conceptual model based on qualitative patient interviews. Ann Rheum Dis 2009;68(Suppl3):759.

Gooch K… Mease P, et al. Relationship between spondyloarthropathies and impaired work productivity. Ann Rheum Dis 2009;68(Suppl3):356.

Keystone EC… Mease, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from RAPID 1 Trial. Ann Rheum Dis 2009;68(Suppl3):237.

Keystone EC… Mease, et al. A more rapid clinical response following certolizumab pegol treatment is associated with better 52-wekk outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68(Suppl3):225.

Mease PJ. Treatment of PsA; What is the optimal treatment algorithm. Ann Rheum Dis 2009;68(Suppl3):5.

Kavanaugh A, Gladman D, Mease P, et al. Golimumab administered subcutaneously every four weeks in psoriatic arthritis patients: 52-week health-related quality of life, physical function and health economic results of a randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2009;68(Suppl3):652.

Gooch K… Mease P, et al. Patients acceptable symptom state and work productivity in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(Suppl3):356.

van der Heijde D… Mease P, et al. Sustained clinical response and quality of life improvement through 4 years of adalimumab treatment in the ATLAS trial. Ann Rheum Dis 2009;68(Suppl3):624.

Keystone EC… Mease, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from RAPID 1 Trial. Congress of the German Society for Rheumatology, Köln, September, 2009.

Kavanaugh A, Mease P, Krueger, GG, et al. Golimumab, a new, human, TNF alpha antibody administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Belgium Rheumatology Conference, Mechelin, September, 2009.

Mease P, Geisser ME, Palmer RH, et al. Efficacy of milnacipran in two phase III fibromyalgia trials. Education Advisory Committee of the American Academy of Pain Management, Phoenix, Arizona, October, 2009.

Mease, P, Palmer RH, Wang Y, et al. Day-to-day pain relief with milnacipran in fibromyalgia. Education Advisory Committee of the American Academy of Pain Management, Phoenix, Arizona, October, 2009.

Kaiser MJ, Kavanaugh A, Mease P, et al. Golimumab, a New, Human, TNF Alpha Antibody, Administered Subcutaneously Every 4 Weeks in Psoriatic Arthritis Patients: 104-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-REVEAL Study. French National Rheumatology Congress. Paris, November 29-December 2, 2009.

Choy EH, Arnold LM, Mease PJ, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009;36(10):2330-4.

Kirkham B, Mease P, Robertson D. Improvement in enthesitis with etanercept therapy in patients with psoriasis and psoriatic arthritis (PRESTA trial). Fall Clinical Dermatology Conference, Las Vegas, October 15-18, 2009.

Wolfe F… Mease PJ, et al. The instability of the fibromyalgia diagnosis: Associations with measures of severity. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Kavanaugh A, Mease P, Krueger GG, et al. Golimumab, a new, human TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL Study. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Taylor WJ, Gladman DD, Mease PH, et al. The impact of psoriatic arthritis (PsA) according to the international classification of functioning, health and disability (ICF). American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Mease P, Perdoc R, Kary S, et al. Application of a new composite measures of minimal disease activity in patients with psoriatic arthritis treated with adalimumab: Subanalysis of the ADEPT trial. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Wolfe F… Mease PJ, et al. Clinical diagnostic and severity criteria for fibromyalgia. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Dougados M, Lavie F, Mease P, et al. Ds is associated with total hip replacement in patient with spondyloarthritis: Report for the SPARK international survey. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Keystone EC… Mease P, et al. A faster clinical response to certolizumab pegol (CZP) treatment is associated with better 52-week outcomes in patients with rheumatoid arthritis (RA). American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Mease P, Genovese M, Ritchlin C, et al. Abatacept in psoriatic arthritis: Results of a phase II study. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Kavanaugh A, Gladman D, Mease P, et al. Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-wek health-related quality of life, physical function and health economic results of the randomized, placebo-controlled GO-REVEAL study. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Swick TJ… Mease PJ, et al. Sodium oxybate improved fatigue, sleep disturbance, and PGIC in fibromyalgia—Results from a phase 3, 14-week, controlled trial. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Mease P, Palmer RH, Wang Y, et al. Milnacipran improves fatigue in fibromyalgia: Pooled analyses from 3 randomized, placebo-controlled clinical trials. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Keystone EC… Mease PJ, et al. The efficacy of certolizumab pegol added to methotrexate in sustained over 2 years in the treatment of rheumatoid arthritis. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Ritchlin C, Mease P, Perdok, R, et al. Is adalimumab an efficacious treatment for enthesitis of the achilles tendon in patients with spondyloarthritis? American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rituximab based on treatment to target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis. American College of Rheumatology Annual Meeting, Philadelphia, Pennsylvania, October 16-21, 2009.

Gottlieb AB…Mease PJ, et al. Malignancies from patients receiving etanercept across approved indications. EULAR, 2008.

Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia syndrome: A randomized, double-blind, placebo-controlled trial. College of Psychiatric and Neurologic Pharmacists (CPNP) meeting 2008.

Mease P, Clauw DJ, Palmer RH, et al. The efficacy and safety of milnacipran in the treatment of fibromyalgia syndrome. College of Psychiatric and Neurologic Pharmacists (CPNP) meeting 2008.

Goldenberg D…Mease P, et al. Milnacipran treatment for fibromyalgia syndrome: One-year durability of response. College of Psychiatric and Neurologic Pharmacists (CPNP) meeting 2008.

Anklesaria P, Heald AE, Mease PJ, et al. Intra-articular administration of a recombinant adeno-associated vector containing a TNF antagonist gene was safe, well tolerated and demonstrated clinical response in subjects with inflammatory arthritis. ASGT, Boston, May 2008.

Gendreau RM…Mease PJ, et al. Evaluating efficacy of milnacipran in fibromyalgia clinical trails: Comparisons of composite response and continuous endpoints. World Congress on Pain (WCP), 2008.

Clauw DJ…Mease PJ. Milnacipran for the treatment of fibromyalgia syndrome: results from a 3-month, double-blind, placebo-controlled, multicenter trial. World Congress on Pain (WCP), 2008.

Trifilo M…Mease PJ, et al. Milnacipran maintained treatment effect in patients with fibromyalgia syndrome: 12-month durability of response. World Congress on Pain (WCP), 2008.

Mease P, Clauw DJ, Palmer RH, et al. Treatment with milnacipran improves the symptoms of fibromyalgia syndrome: results from a 6-month, double-blind, placebo-controlled trial. World Congress on Pain (WCP), 2008.

Choy E, Mease P, Kajdasz D, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: Analysis of 5 studies. AAPM&R, San Diego, 2008.

Mease P, Clauw, D, Palmer RH, et al. The efficacy and safety of milnacipran in the treatment of fibromyalgia. AAPM&R, San Diego, 2008.

Goldenberg D…Mease P, et al. Milnacipran treatment for fibromyalgia: One-year durability of response. AAPM&R, San Diego, 2008.

Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia syndrome: A randomized, double-blind, placebo-controlled trial. AAPM&R, San Diego, 2008.

Choy E, Mease P, Kajdasz D, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: Analysis of 5 studies. Am Academy of Nurse Practitioners, National Harbor, 2008.

Clauw DJ, Mease P, Palmer R, et al. Milnacipran therapy for fibromyalgia: 15-week trial results. American Conference on Pain Medicine, 2008.

Mease P, Clauw DJ, Palmer RH. Efficacy and safety of milnacipran for fibromyalgia. American Conference on Pain Medicine, 2008.

Mease P, Gladman D, Keystone E, et al. Efficacy and safety of alefacept in combination with methotrexate in the treatment of psoriatic arthritis. Winter Clinical Dermatology Conference, 2008.

Goldenberg D…Mease P, et al. Milnacipran treatment for fibromyalgia: One-year durability of response. American Academy of Physical Medicine and Rehabilitation, 2008.

Mease P, Clauw D, Palmer RH, et al. The efficacy and safety of milnacipran in the treatment of fibromyalgia. American Academy of Physical Medicine and Rehabilitation, 2008.

Clauw D, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled trial. American Academy of Physical Medicine and Rehabilitation, 2008.

Kavanaugh A, Mease P, Krueger G, et al. Golimumab, a new, human, TNF alpha antibody administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. German Society of Rheumatology, 2008.

Gladman D…Mease PJ, et al. Golimumab, a new human TNF-alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Nail, enthesitis, and dactylitis response in the randomized, placebo-controlled, GO-REVEAL study. German Society of Rheumatology, 2008.

Clauw D…Mease PJ. Efficacy of milnacipran in the treatment of fibromyalgia: A 3-month, double-blind, placebo-controlled trial. American Pain Society, 2008.

Burmester G…Mease P, et al. Comprehensive safety profile and reductions in standardized mortality ratios from adalimumab (Humira®) global clinical trials in six autoimmune diseases. EULAR, Paris, France, June 2008.

Lin S…Mease P, et al. Malignancies from patients receiving etanercept across approved indications. EULAR, Paris, France, June 2008.

Mease P, Keystone E, Mason D, et al. Safety of certolizumab pegol with methotrexate in patients with active rheumatoid arthritis. EULAR, Paris, France, June 2008.

Heald A, Mease P, Wei N, et al. Safety, local tolerability and clinical response after intra-articular administration of a recombinant adeno-associated vector containing a TNF antagonist gene in inflammatory arthritis. EULAR, Paris, France, June 2008.

Heald A, Wei N, Mease P, et al. Single joint outcome measures: A comparison of patient reported outcomes, physical examination and MRI scans in a study of local delivery of a TNF antagonist gene in inflammatory arthritis. EULAR, Paris, France, June 2008.

Mease PJ, Keystone E, Kaell AT, et al. SDAI and CDAI for predicting outcome of a second course of Rituximab for patients with rheumatoid arthritis (RA). EULAR, Paris, France, June 2008.

Kavanaugh A…Mease P, et al. Golimumab, a new, human, TNF alpha antibody administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. EULAR, Paris, France, June 2008.

Mease P, Ory P, Sharp JT, et al. Adalimumab (Humira®) inhibits progression of joint damage for up more than weeks in patients with psoriatic arthritis (PsA). EULAR, Paris, France, June 2008.

Gladman D, Mease P, Choy E, et al. Risk factors for radiographic progression in psoriatic arthritis treated with adalimumab (Humira®) or placebo: Subanalysis of ADEPT. EULAR, Paris, France, June 2008.

Choy E, Gladman D, Mease P, et al. PASI 50 response is a sensitive indicator or reduced radiographic progression in psoriatic arthritis patients treated with adalimumab (Humira®) or placebo: Subanalysis of ADEPT. EULAR, Paris, France, June 2008.

Gladman D…Mease P, et al. Golimumab, a new human TNF-alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Nail, enthesitis, and dactylitis response in the randomized, placebo-controlled, GO-REVEAL study. EULAR, Paris, France, June 2008.

Gladman D, Farewell V, Mease, PJ, et al. Response criteria for psoriatic arthritis I: Derivation of models for response. EULAR, Paris, France, June 2008.

Gladman D…Mease, PJ, et al. Response criteria for psoriatic arthritis II: Developing and comparing response criteria for PsA. EULAR, Paris, France, June 2008.

McInnes I…Mease P. Golimumab, a new human TNF-alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Response to pneumococcal vaccine in the randomized, placebo-controlled, GO-REVEAL study. EULAR, Paris, France, June 2008.

Visvanathan S…Mease PJ, et al. Identification of serum markers associated with improvement in clinical response measures in PsA patients treated with golimumab EULAR, Paris, France, June 2008.

Arnold LM, Gendreau M, Mease P, et al. One-year durability of response to milnacipran treatment for fibromyalgia. EULAR, Paris, France, June 2008.

Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia syndrome: A 15-week, randomized, double-blind, placebo-controlled trial. EULAR, Paris, France, June 2008.

Mease P, Clauw DJ, Gendreau, et al. Milnacipran efficacy and safety in the treatment of fibromyalgia syndrome. EULAR, Paris, France, June 2008.

Strand V…Mease PJ, et al. Comparisons of composite responder and continuous endpoints to evaluate efficacy in a study of milnacipran for the treatment of fibromyalgia syndrome. EULAR, Paris, France, June 2008.

Walker D, Wiltse C, Mease P, et al. Long-term safety, tolerability and effectiveness of duloxetine in the treatment of fibromyalgia. EULAR, Paris, France, June 2008.

Hazes J…Mease P. Fatigue reduction and physical function improvements associated with increased productivity at work and at home in rheumatoid arthritis patients. EULAR, Paris, France, June 2008.

Mease P, Kavanaugh A, Livingstron J, et al. Golimumab significantly improves physical function, health-related quality of life, productivity and reduces time lost from work for caregivers in patients with active psoriatic arthritis. EULAR, Paris, France, June 2008.

Mease P, Klinkhoff A, Thomson G, et al. Psoriatic arthritis patients receiving adalimumab (Humira®) sustain improvement in health-related quality of life (HRQOL)—136-week results from a long-term open-label trial. EULAR, Paris, France, June 2008.

Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new, human, TNF-alpha antibody administered as a subcutaneous injection in psoriatic arthritis: 24-week results of the randomized, placebo-controlled GO-REVEAL study. Sixth International Congress on Spondylarthropathies (ICS), Gent, Belgium, October 2008.

Hazes J…Mease P. Fatigue reduction and physical function improvements associated with increased productivity at work and at home in rheumatoid arthritis patients. ISPOR 11th Annual European Congress, Athens, Greece, 2008.

Mease P, et al. The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both PS and psoriatic arthritis. American Academy of Dermatology 67^th Annual Meeting, San Francisco, 2008.

Mease P, et al. Adalimumab reduces symptoms of psoriatic arthritis (PsA) among psoriasis patients with comorbid PSA. American Academy of Dermatology 67^th Annual Meeting, San Francisco, 2008.

Gladman D, Tom B, Mease P, et al. Response criteria for psoriatic arthritis II: Developing and comparing response criteria for PsA. Arth Rheum 56 (Suppl 9): S363, 2008.

Ritchlin C…Mease P, et al. Treatment recommendations for psoriatic arthritis. Arth Rheum 56 (Suppl 9): S363, 2008.

Mease P, Palmer R, Qu P, et al. Milnacipran improves pain in fibromyalgia patients: Patient E-diary results over 15 weeks in two randomized, double-blind, placebo-controlled trials. Arth Rheum 56 (Suppl 9): S383, 2008.

Mease P, Palmer R, Rao S, et al. Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: Results from a dose-controlled, extension study. Arth Rheum 56 (Suppl 9): S383, 2008.

Mease P, Spaeth M, Clauw D, et al. Estimation of minimum clinically important difference of pain in fibromyalgia. Arth Rheum 56 (Suppl 9): S384-385, 2008.

Clauw D, Choy E, Mease P, et al. Impact of duloxetine treatment on concentration and mental fatigue in patients with fibromyalgia. Arth Rheum 56 (Suppl 9): S385-386, 2008.

Kavanaugh A, Mease P, Krueger G, et al. Golimumab administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Arth Rheum 56 (Suppl 9): S414, 2008.

Mease P, Wei N, Fudman E, et al. Safety and clinical outcomes after intra-articular administration of a recombinant adeno-associated vector containing a TNF antagonist gene. Arth Rheum 56 (Suppl 9): S719, 2008.

Dougados M…Mease P, et al. More rheumatoid arthritis or more spondyloarthritis? Preliminary results from the SPARK survey of US and european clinical practice. Arth Rheum 56 (Suppl 9): S455, 2008.

Mease P, McInnes I, Krueger G, et al. Golimumab significantly improves physical function, health-related quality of life, productivity, & reduces time lost from work for caregivers in patients with active psoriatic arthritis. Arth Rheum 56 (Suppl 9): S574-575, 2008.

Choy E, Gladman D, Mease P, et al. Improvement in psoriasis is associated with long-term inhibition of radiographic progression in patients with psoriatic arthritis receiving adalimumab (Humira®). Arth Rheum 56 (Suppl 9): S575-576, 2008.

van der Heijde D…Mease P, et al. Long-term spinal mobility in patients with ankylosing spondylitis (AS) – 3-year results from the adalimumab (Humira®) trial evaluating long-term efficacy and safety in AS (ATLAS). Arth Rheum 56 (Suppl 9): S578-579, 2008.

Kremer J…P Mease. Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: Results from long-term extension studies with a follow-up duration of 1.5 years. Arth Rheum 56 (Suppl 9): S783-784, 2008.

Mease P. PASI 100 is associated with better dermatology-specific patient reported outcomes compared with PASI 75–99 in adalimumab-treated patients with psoriatic arthritis: Subanalysis of ADEPT. EADV, 2007.

BurmesterG, MeasePJ, DijkmansBAC, et al. Adalimumab clinical trial safety in multiple indications and reduced mortality in rheumatoid arthritis. EADV, 2007.

Burmester GR… Mease PJ, et al.Safety of adalimumab across multiple indications. American Academy of Dermatology 2007.

Mease PJ, Florian H, Young JP, et al. Pregabalin as long-term treatment of fibromyalgia pain. American Academy of Pain Management, 2007.

Mease PJ, Simpson SL, Young JP, et al. Pregabalin for durability of meaningful relief of fibromyalgia syndrome. American Academy of Pain Management, 2007.

Tak PP, Carreno L, Mease PJ, et al. Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors. Spanish Congress of Rheumatology, 2007.

Gordon KB, Gottlieb AB… Mease PJ. Clinical trial safety data of events of interest in patients receiving etanercept across approved indications. American Academy of Dermatology, 2007.

Wohlreich MM, Kajdasz D…Mease PJ, et al. The safety and efficacy of duloxetine hydrochloride for the treatment of fibromyalgia: results from a 6-month randomized, double-blind, placebo-controlled, fixed dose trial. Academy of Psychosomatic Medicine, 2007.

Mease P, Ritchlin C, Wong R, et al. Sustained clinical efficacy and safety of alalimumab in patients with moderate to severe psoriatic arthritis (PsA): 2-year results for an open-label extension study. American Academy of Dermatology, 2008.

Gladman D, Mease P, Choy E, et al. Relationship between c-reactive protein (CRP) concentration and joint damage in psoriatic arthritis (PsA): Subanalysis of placebo and adalimumab-treated patients in ADEPT. Ann Rheum Dis 66 (Suppl 2): 98, 2007.

Fleischmann R…Mease P. Certolizumab pegol monotherapy 400 mg every 4 weeks improves physical functioning and reduces pain in patients with rheumatoid arthritis who have previously failed DMARD therapy. Ann Rheum Dis 66 (Suppl 2): 170, 2007.

Mease P, Wei N, Fudman E, et al. Local treatment for inflammatory arthritis: A phase ½ clinical study of intra-articular administration of a recombinant adeno-associated vector containing a TNF-alpha antagonist gene. Ann Rheum Dis 66 (Suppl 2): 182, 2007.

van der Heijde D…Mease P, et al. Adalimumab treatment maintains efficacy and safety in patients with ankylosing spondylitis (AS)—2-year results from ATLAS. Ann Rheum Dis 66 (Suppl 2): 411, 2007.

Mease PJ, Genovese M, Ritchlin CT, et al. Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis: 2-year results from PsA study MO2-537. Ann Rheum Dis 66 (Suppl 2): 419, 2007.

Mease PJ, Keystone E, Kaell A, et al. Predicting outcome of a second course of rituximab for rheumatoid arthritis. Ann Rheum Dis 66 (Suppl 2): 434, 2007.

Wohlreich M, Russell J, Mease P, et al. The safety and efficacy of duloxetine hydrochloride for the treatment of fibromyalgia: Results from a 6-month randomized, double-blind, placebo-controlled, fixed-dosed trial. ASPE National Pain Week Conference, 2007.

Russell J, Mease P, Smith T, et al. The safety and efficacy of duloxetine hydrochloride for the treatment of fibromyalgia: Results from a 6-month randomized, double-blind, placebo-controlled, fixed-dosed trial. AOA Conference, 2007.

Gordon KB….Mease PJ, et al. Clinical trial safety data of events of interest in patients receiving etanercept (Enbrel®) across approved indications. The Academy of Managed Care Pharma, 2007.

van der Heijde D…Mease PJ, et al. 2-year safety and efficacy results for the adalimumab trial evaluating long-term efficacy and safety in the ankylosing spondylitis (ATLAS). Arth Rheum 56 (Suppl): S252-253, 2007.

Gladman D, Mease PJ, Chou EHS, et al. Analysis of risk factors for radiographic progression in psoriatic arthritis (PsA): Subanalysis of ADEPT. Arth Rheum 56 (Suppl): S253-254, 2007.

Cauli A…Mease P. Patient and physician perception of disease in psoriatic arthritis (PsA). A multicenter GRAPPA and OMERACT study. Arth Rheum 56 (Suppl): S264, 2007.

Fleischmann RM…Mease PJ, et al. A new composite measure for assessing RA activity in clinical practice. Arth Rheum 56 (Suppl): S114, 2007.

Clauw DJ…Mease P, et al. The efficacy and safety of milnacipran in the treatment of fibromyalgia. Arth Rheum 56 (Suppl): S306, 2007.

Clauw DJ…Mease P. Milnacipran efficacy in the treatment of fibromyalgia syndrome: A 15-week randomized, double-blind, placebo-controlled trial. Arth Rheum 56 (Suppl): L1, 2007.

Mease P, Mason D, Kavanaugh A, et al. Efficacy and rapid response of certolizumab pegol liquid formation in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: Results from the RAPID 2 study. Arth Rheum 56 (Suppl): S391, 2007.

Burmester GR, Mease PJ, Dijkmans, BAC, et al. Adalimumab safety profile in global clinical trials and reduction in standardized mortality ratios (SMR) across multiple indications. Arth Rheum 56 (Suppl): S399, 2007.

Gordon KB…Mease PJ, et al. Clinical trial safety data of events of interest in patients receiving etanercept (Enbrel®) across approved indications. Arth Rheum 56 (Suppl): S399-S340, 2007.

van der Heijde D…Mease PJ, et al. Long-term spinal mobility in ankylosing spondylitis (AS) patients treated with adalimumab: 104-week results from ATLAS. Arth Rheum 56 (Suppl): S471-472, 2007.

Gladman D…Mease PJ, et al. Composite indices for disease activity in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Arth Rheum 56 (Suppl 9): S481-482, 2007.

Gendreau RM…Mease P, et al. Composite responder endpoints for fibromyalgia trials—experience with milnacipran. Arth Rheum 56 (Suppl 9): S603, 2007.

Goldenberg D… Mease P, et al. One-year durability of response to milnacipran treatment for fibromyalgia. Arth Rheum 56 (Suppl 9): S603, 2007.

Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new, human, TNF-alpha antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of the randomized, placebo controlled GO-REVEAL study. Arth Rheum 56 (Suppl): L14, 2007.

Mease PJ, Wei N, Fudman E, et al. Local treatment for inflammatory arthritis: A phase ½ clinical study of intra-articular administration of a recombinant adeno-associated vector containing a TNF-alpha antagonist gene. Arth Rheum 56 (Suppl 9): S793, 2007.

Chandran V…Mease PJ, et al. International multi-center psoriasis and psoriatic arthritis reliability trial (GRAPPA-IMPART): Assessment of skin, joints, nails, and dactylitis. Arth Rheum 56 (Suppl 9): S798-799, 2007.

Gordon KB…Mease PJ, et al. Clinical trial safety data of events of interest in patients receiving etanercept (Enbrel®) across approved indications. Academy of Managed Care Pharmacy (AMCP), 2007.

Goldenberg, D…Mease PJ, et al. Milnacipran treatment for fibromyalgia syndrome: One-year durability of response. The Academy of Managed Care Pharmacy (AMCP), 2007.

Wohlreich M…Mease PJ, et al. The safety and efficacy of duloxetine hydrochloride for the treatment of fibromyalgia: Results from a 6-month randomized, double-blind, placebo-controlled, fixed-dose trial. American Academy of Pain Medicine, 2007.

Clauw DJ…Mease PJ, et al. Efficacy of milnacipran in the treatment of the fibromyalgia syndrome among patients with varying degrees of depressed mood. American Psychiatric Assoc, 2007.

Kavanaugh A…Mease PJ, et al. Sustained improvement in clinical measures of psoriatic arthritis in infliximab-treated patients: 1 year results form IMPACT 2. EULAR, Amsterdam, June 2006.

van der Heijde D…Mease PJ, et al. Adalimumab enhances health-related quality of life in patients with active ankylosing spondylitis-results from the ATLAS trial. British Society of Rheumatology, 2006.

van der Heijde D…Mease P, et al. Improvements in Health Related Quality of Life (HRQL) correlate positively with clinical responses in ankylosing spondylitis (AS) patients-results from ATLAS. EULAR, Amsterdam, June 2006.

Mease P, Azechinski J, Greenwald M, et al. Improvements in patient-reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb (DANCER). EULAR, Amsterdam, June 2006.

Gottlieb AB…Mease PJ, et al. Clinical efficacy, safety, and patient-reported outcomes of EDUCATE, a multicenter, community-based, open-label study of the effect of Etanercept on skin and joint disease in patients with psoriatic arthritis. First World Congress of Psoriasis and Psoriatic Arthritis, Stockholm, May 2006.

Mease PJ, Ganguly R, Wanke L, Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: Applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Group Guidelines. First World Congress of Psoriasis and Psoriatic Arthritis, Stockholm, May 2006.

Fransen J…Mease PJ, et al. Response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of performance characteristics in two randomized, controlled trials of TNF inhibitors. First World Congress of Psoriasis and Psoriatic Arthritis, Stockholm, May 2006.

Mease PJ, Taylor WJ. The World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) as a framework for understanding the manifestations and consequences of psoriasis and psoriatic arthritis. First World Congress of Psoriasis and Psoriatic Arthritis, Stockholm, May 2006.

Mease PJ, Gladman D, Choy E, et al. Adalimumab is efficacious in treating skin disease of psoriatic arthritis patients with mild to severe baseline skin involvement: Subanalysis of ADEPT. First World Congress of Psoriasis and Psoriatic Arthritis, Stockholm, May 2006.

Ritchlin C, Mease PJ, Sasso E. Concurrent efficacy of adalimumab against skin and joint disease in psoriatic arthritis. First World Congress of Psoriasis and Psoriatic Arthritis, Stockholm, May 2006.

Mease PJ, Gladman D, Ritchlin C. Long-term efficacy, safety and inhibition of joint destruction by adalimumab in psoriatic arthritis: Results from ADEPT. Poster at First World Congress of Psoriasis and Psoriatic Arthritis, Stockholm, May 2006.

Burmester G, Gordon KB, Mease PJ, Kent JD. Safety of adalimumab in global clinical trials in multiple indications. Poster at Summer AAD, Annual Scientific Meeting, 2006.

Mease PJ, Hobbs K, Kivitz A, et al. Clinical studies of intra-articular administration of a recombinant adeno-associated vector containing a TNF-alpha antagonist gene in inflammatory arthritis. Ann Rheum Dis 65 (Suppl 2): 77, 2006.

Fransen J, Antoni C, Mease P, et al. Response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of randomized controlled trials of two TNF inhibitors. Ann Rheum Dis 65 (Suppl 2): 83, 2006.

Braun J…Mease P, et al. INSPIRE lateral flexion: a new method to measure lateral spinal mobility in patients with spondyloarthritis (SPA). Ann Rheum Dis 65 (Suppl 2): 208, 2006.

Gladman D…Mease PJ, et al. International spondyloarthritis inter-observer reliability exercise-The INSPIRE Study. Ann Rheum Dis 65 (Suppl 2): 217, 2006.

Kavanaugh A …Mease PJ, et al. Sustained improvement in clinical measures of psoriatic arthritis in infliximab-treated patients: 1 year results from IMPACT 2. Ann Rheum Dis 65 (Suppl 2): 220, 2006.

Tak P, Mease P, Bombardieri S, et al. Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors. Ann Rheum Dis 65 (Suppl 2): 503, 2006.

Burmester G, Mease P, et al. Adalimumab is safe in global clinical trials in multiple indications and reduced mortality in rheumatoid arthritis. Ann Rheum Dis 65 (Suppl 2): 181, 2006.

Giles JT, Mease PJ, et al. Application of the OMERACT filter to clinical assessments of arthritis of the knee. Ann Rheum Dis 65 (Suppl 2): 280, 2006.

Mease PJ, Szechiniski J, Greenwald M, et al. Improvements in patient-reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in the DANCER trial. Ann Rheum Dis 65 (Suppl 2): 332, 2006.

Maksymowych WP…Mease PJ, et al. INSPIRE hip mobility: a new method to measure hip mobility in patients with rheumatic diseases. Ann Rheum Dis 65 (Suppl 2): 534, 2006.

Mease PJ, Woolley M, Singh A, et al. Patient-reported outcomes in a randomized comparison of etanercept and placebo for treatment of psoriatic arthritis. Ann Rheum Dis 65 (Suppl 2): 535, 2006.

Ritchlin CT, Mease PJ, Sasso E. Correlation of skin and joint responses in psoriatic arthritis: a subanalysis of ADEPT. Ann Rheum Dis 65 (Suppl 2): 539, 2006.

van der Heijde D…Mease P, et al. Improvements in health related quality of life (HRQL) correlate positively with clinical responses in ankylosing spondylitis (AS) patients –results from ATLAS. Ann Rheum Dis 65 (Suppl 2): 546, 2006.

Gladman D, Mease P, Sasso E. Adalimumab is efficacious in treating skin disease in psoriatic arthritis: subanalysis by severity of psoriasis in ADEPT. Ann Rheum Dis 65 (Suppl 2): 639, 2006.

Mease P, Choy E, Atkins C, et al. Adalimumab efficacy in psoriatic arthritis patients with oligoarticular arthritis: subanalysis of ADEPT. Ann Rheum Dis 65 (Suppl 2): 640, 2006.

Mease PJ. Assessing patient-reported outcomes of patients with psoriatic arthritis treated with etanercept. AMCP Education Conference, Chicago, IL, Oct. 2006.

van der Heijde D…Mease PJ, et al. Adalimumab improves physical functioning and work productivity in ankylosing spondylitis (AS) Patients: Results from ATLAS. Arth Rheum 54 (Suppl): S99, 2006.

Gladman D, Mease PJ, Choy E, et al. Adalimumab radiographic efficacy in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use, and clinical response: subanalysis of ADEPT. Arth Rheum 54 (Suppl): S138, 2006.

Burmester GR, Mease PJ, Dijkmans BAC, et al. Adalimumab clinical trial safety in multiple indications and reduction in mortality in rheumatoid arthritis. Arth Rheum 54 (Suppl): S1232, 2006.

Mease P, Keystone E, Kaell A, et al. Recent disease activity affects outcome of second course of Rituximab for RA. Arth Rheum 54 (Suppl): S236, 2006.

Mease P, Wei N, Fudman E, et al. A phase ½ clinical study of intro-articular administration of a recombinant adeno-associated vector containing a TNf-α antagonist gene in inflammatory arthritis. Arth Rheum 54 (Suppl): S403, 2006.

Maksymowych W…Mease PJ, et al. INSIPRE hip mobility: A new method to measure hip mobility in patients with rheumatic diseases. Arth Rheum 54 (Suppl): S473, 2006.

Braun J…Mease PJ, et al. INSPIRE lateral flexion: A new method to measure lateral spinal mobility in patients with spondyloarthritis. Arth Rheum 54 (Suppl): S476, 2006.

Gardner JC, Mease PJ, Ory PA, et al. Automated assessment of synovitis in psoriatic arthritis wrist MRI using a multiscale, bayesian segmentation technique. Arth Rheum 54 (Suppl): S628, 2006.

Gladman D…Mease P, et al. Evaluating enthesitis in patients with spondyloarthritis (SpA). Arth Rheum 54 (Suppl): S724, 2006.

Gladman D…Mease P, et al. International spondyloarthritis inter-observer reliability exercise:

The INSPIRE study. Arth Rheum 54 (Suppl): S724, 2006.

Gladman D, Strand V, Mease PJ, et al. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis 64 (Suppl 2): ii115-116, 2005.

Mease PJ, Gottlieb AB, Yu EB, Wolley JM, Dunn M. Sustained improvements in patient-reported outcomes in psoriatic arthritis patients with etanercept. Presented at Am Acad Dermatol New Orleans, Feb 2005.

Mease P, Gladman D, Ritchlin C, et al. Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Presented at Am Acad Dermatol New Orleans, Feb 2005.

Mease P, Gottieb A, Wooley M, et al.: Sustained improvements in patient-related outcomes in psoriatic arthritis patients treated with etanercept. J Am Acad Dermatol 52 (suppl 3):P2, 2005.

Kavanaugh A, Mease P, Beutler A, et al.: Efficacy of infliximab in psoriatic arthritis-related dactylitis and enthesopathy: results from the IMPACT 2 trial. J Am Acad Dermatol 52 (suppl 3):P183, 2005.

Mease P, Gladman D, Ritchlin C, et al.: Adalimumab ion psoriatic arthritis: 24 week results of a phase III study. J Am Acad Dermatol 52 (suppl 3):P2, 2005.

Mease PJ, Rowbotham MC, Russell IJ, et al. Efficacy and safety of pregabalin for treatment of fibromyalgia syndrome. Presented at Anxiety Disorders Association of America: March 17-20, 2005.

Taylor W… Mease PJ. A validation of current classification criteria for the diagnosis of psoriatic arthritis-preliminary results of the CASPAR study. Ann Rheum Dis 64; OP0157, 2005.

Mease PJ, et al. Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: results from ADEPT. Ann Rheum Dis 64; FRI0212, 2005.

Mease PJ, et al. Psoriatic arthritis patients treated with etanercept experience sustained improvements in physical function. Ann Rheum Dis 64; FRI0217, 2005.

Marra C… Mease PJ. The cost-effectiveness of adding infliximab to usual therapy in the treatment of psoriatic arthritis. Ann Rheum Dis 64; FRI0252, 2005.

Mease PJ, Gladman D, Keystone E. Efficacy of alefacept in combination with methotrexate in the treatment of psoriatic arthritis. Ann Rheum Dis 64; FRI0224, 2005.

Van der Heijde D…Mease, PJ. Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis-The Atlas Trial. Arth Rheum: poster at ACR November 2005.

Gardner J…Mease PJ. Quantitative dynamic contrast-enhanced (DCE-MRI) wrist imaging in RA correlates with changes in clinical measures following initiation of anti-TNFα and MTX therapy. Arth Rheum 52 (Suppl 9): S109, 2005.

Mease PJ, Szechinski J, Greenwald M, et al. Improvements in patient reported outcomes over 24 weeks for rituximab and methotrexate in rheumatoid arthritis in patients in phase IIb trial (DANCER). Arth Rheum 52 (Suppl 9): S138, 2005.

Kavanaugh A…Mease PJ. Sustained improvement in clinical measures of psoriatic arthritis in infliximab-treated patients:1 year results from IMPACT 2. Arth Rheum 52 (Suppl 9): S210, 2005.

Van der Heijde D…Mease PJ. Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis-The ATLAS Trial. Arth Rheum 52 (Suppl 9): S211, 2005.

Mease PJ, Gladman D, Ritchlin C, et al. Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT. Arth Rheum 52 (Suppl 9): S215, 2005.

Mease PJ, Gladman D, Keystone E. Alefacept (Amevive®) in combination with methotrexate for the treatment of psoriatic arthritis. Arth Rheum 52 (Suppl 9): S280, 2005.

Singh A, Mease PJ, Yu H, et al. Health Assessment Questionnaire has similar psychometric properties in psoriatic arthritis and rheumatoid arthritis. Arth Rheum 52 (Suppl 9): S403, 2005.

Mease PJ, Sharp J, Ory P, et al. Inhibition of joint destruction in PsA with adalimumab:48-week results of ADEPT. Arth Rheum 52 (Suppl 9): S631, 2005.

Mease PJ. Adalimumab inhibits joint disease progression in PsA: 48-week results of ADEPT. British Society of Rheumatology, 2005.

Mease PJ. Adalimumab is effective in treating psoriatic arthritis: 48-week results of ADEPT. British Society of Rheumatology, 2005.

Mease PJ, Hobbs K, Chalmers A, et al. A phase 1 dose-escalation study of intra-articular administration of a recombinant adeno-associated vector containing the TNFR-Fc fusion gene, in inflammatory arthritis. European Society of Gene Therapy meeting. October 29, 2005.

Fleischmann RM, Cohen SB, Moreland LW, Schiff MH, Mease PJ, et al. Tapering methotrexate in patients with rheumatoid arthritis (RA) after response to therapy with the combination of Infliximab and MTX: The iRAMT Trial. Ann Rheum Dis 63(Suppl 1):FRI0101, 2004.

Mease P,Ganguly R, Wanke L, Singh A.How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 63(Suppl 1):39, 2004.

Mease P,Ganguly R, Wanke L, Singh A.How much improvement in pain is considered important by patients with active psoriatic arthritis? Ann Rheum Dis 63(Suppl 1):SAT0015, 2004.

Mease P, Ruderman E, Ritchlin C, Ory P, et al. Etanercept in psoriatic arthritis: Sustained improvement in joint and skin disease and inhibition of radiographic progression at 2 years. Ann Rheum Dis 63(Suppl 1):(OP0136)99, 2004.

Nash P, Kaltwasser J, Gladman D, Rosen C, Mease P, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis. Ann Rheum Dis 63(Suppl 1):SAT0074, 2004.

Moreland L, Fleischmann R, Cohen S, Mease P, et al. The effect of tumor necrosis factor a (TNFa) inhibition on bone mineral density (BMD) in rheumatoid arthritis (RA): the Infliximab rheumatoid arthritis methotrexate (MTX) tapering (iRAMT) protocol. Arth Rheum 50 (Suppl 9): S991, 2004.

Mease P, Kavanaugh A, Krueger G, et al. Infliximab improves psoriasis regardless of arthritis response in patients with active arthritis: results from the IMPACT 2 Trial. Arth Rheum 50 (Suppl 9): S1635, 2004.

Mease P, Gladman D, Ritchlin C, et al. Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum 50: 4097, 2004.

Petri M, Mease P, Merrill J, et al. Lupus disease activity and bone mineral density in patients with active lupus: Results of a double-blind, multicenter trial of prasterone vs. placebo. 7^th Intl. Congress on SLE and Related Conditions. New York, NY, May 9-13, 2004.

Petri M, Ramsey-Goldman R, Manzi S, Mease P, et al. Lupus disease activity and bone mineral density in women with active lupus: Results of a double-blind, multicenter trial comparing prasterone with placebo. British Society for Rheumatology, London, England, 2003.

Kaltwasser J, Nash P, Gladman D, Rosen C, Behrens F, Mease P, On behalf of the TOPAS Study Group: Leflunomide in the treatment of psoriatic arthritis and psoriasis: Data from a double-blind, randomized, placebo-controlled clinical trial. Eular, Lisbon, Portugal: 2003.

Mease P.J, Crofford L.J, Russell I, Young Jr. J.P, Sharma U, Knapp L. Pregabalin improves pain, sleep, and fatigue associates with fibromyalgia syndrome (FMS) in a multicenter, randomized, placebo-controlled, monotherapy trial. EULAR, Lisbon, Portugal: 2003.

Mease P.J, Ruderman E.M, Kivitz A.J, Burch F.X, Siegel E.L, Cohen S.B, Ritchlin C, Tsuji W, Burge D.J: Etanercept (Enbrel®) in patients with psoriatic arthritis and psoriasis: Continued observations. Eular, Lisbon, Portugal: 2003.

Ory P, Sharp J.T, Salonen D, Rubenstein J.D, Mease P.J, Ruderman E.M, Kivitz A.J, Burge D.J: Etanercept (Enbrel®) inhibits radiographic progression in patients with psoriatic arthritis. EULAR, Lisbon, Portugal: 2003.

Mease P, et al. Sustained improvement in activities of daily living in patients with psoriatic arthritis treated with etanercept. Arth Rheum 48 (Suppl 9): S167, 2003.

Mease P, et al. Leflunomide in the treatment of psoriatic arthritis and psoriasis: Joint and skin efficacy and safety in the TOPAS study. Arth Rheum 48 (Suppl 9): S169, 2003.

Mease P, et al. Continued efficacy and safety of etanercept (Enbrel®) in patients with psoriatic arthritis and psoriasis. Arth Rheum 48 (Suppl 9): S169, 2003.

Davis J…Mease P, et al. Effects of etanercept (Enbrel®) on spinal and hip bone mineral density in patients with ankylosing spondylitis: 24-week data. Arth Rheum 48 (Suppl 9): S177, 2003.

Gendreau RM, Mease P, et al. Milnacipran: A potential new treatment of fibromyalgia. Arth Rheum 48 (Suppl 9): S616, 2003.

Gardner J, Zierhut M, Gardner G, Mease P, Sharp J. Changes in MRI measures of synovial vascularity in the RA wrist at 1-2 months following Initiation of anti-TNFα and methotrexate therapy. Arth Rheum 48 (Suppl 9): S131, 2003.

Gottlieb AB, Mease PJ, Kivitz AJ, et al. Improvement in disease activity in patients with psoriatic arthritis receiving Etanercept (Enbrel®): Results of a phase 3 multicenter clinical trial. EULAR. Stockholm, Sweden, 2002.

Mease PJ, Ritchlin C, Martin RW, et al. Response to pneumococcal vaccination in psoriatic arthritis patients treated with Etanercept (Enbrel®). EULAR. Stockholm, Sweden, 2002.

Wanke LA, Gottlieb AB, Mease PJ, et al. Etanercept (Enbrel) improves health-related quality of life in psoriatic arthritis patients. EULAR. Stockholm, Sweden, 2002.

Mease PJ, Corbin AE, Young, Jr, JP, et al. Fibromyalgia Syndrome (FMS): Correlation of the triad of pain, sleep disturbance and fatigue. EULAR. Stockholm, Sweden, 2002.

Wanke LA, Gottlieb AB, Mease PJ, et al. Etanercept (Enbrel®) improves health related quality of life in patients with psoriatic arthritis. Arth Rheum (Suppl 9): S76, 2002.

Ory, P, Sharp J, Salonen D…Mease P, Etanercept (Enbrel®) inhibits radiographic progression in patients with psoriatic arthritis. Arth Rheum 46 (Suppl 9): S196, 2002.

Crofford L, Russell J, Mease P, et al. Pregabalin improves pain associated with fibromyalgia in a multicenter randomized placebo-controlled monotherapy trial. Arth Rheum (Suppl 9): S613, 2002.

Kaltwasser P, Nash P, Gladman, Mease P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis: Results from the TOPAS study. ACR, New Orleans, USA, 2002.

Mease PJ, Goffe B, Metz J, et al. Etanercept in patients with psoriatic arthritis and psoriasis. American Academy of Dermatology, 55^th Annual Meeting. Washington, DC. 3/2-7/01.

Mease PJ, Goffe B, Metz J, et al. Etanercept in patients with psoriatic arthritis and psoriasis. EULAR, Prague, 6/01.

Mease PJ, Goffe B, Metz J, et al. Etanercept in patients with psoriatic arthritis and psoriasis. International Symposium on Psoriasis and European Congress on Psoriasis. San Francisco, CA 6/01.

Mease P, Kivitz A, Burch F, et. al. Improvement in disease activity in patients with psoriatic arthritis receiving Etanercept (Enbrel®): Results of a phase 3 multicenter clinical trial. Arth Rheum 44 (Suppl 9): S90, 2001.

Mease P, Ritchlin C, Martin R, et. al. Response to pneumococcal vaccination in patients treated with Etanercept (Enbrel®) trial. Arth Rheum 44 (Suppl 9): S91, 2001.

Mease PJ, Goffe B, Metz J, Vanderstoep A. Phase II trial of Enbrel®™ (Etanercept) in patients with psoriasis and psoriatic arthritis (PsA). American Academy of Allergy Asthma & Immunology, 2000.

Mease PJ, Goffe B, Metz J, Vanderstoep A. Etanercept in patients with psoriatic arthritis and psoriasis. American Academy of Dermatology, San Francisco, CA. 3/00.

Mease PJ, Merrill J, Lahita R, et al. GL701 (Dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erythematosus. Autoimmunity: 2000 and Beyond. Eighth International Conference on Lymphocyte Activation and Immune Regulation, Newport Beach, CA, 2/00.

Mease PJ, Merrill J, Lahita R, et al. GL701 (Prasterone, Dehydroepiandrosterone) improves or stabilizes disease activity in systemic lupus erytematosus. Endocrine Society, 2000.

Mease PJ, Ginzler EM, Gluck OS. GL701 (prasterone, dehydroepiandrosterone) improves bone density in steroid-treated female lupus patients. Am Soc Bone Min Research, 2000.

Mease PJ, Goffe B, Metz J, et al. Enbrel® (Etanercept) in patients with psoriatic arthritis and psoriasis. Arth Rheum 43 (Suppl 9): S403, 2000.

Mease PJ, Merrill JT, Lahita RG, et al. GL701 (Prasterone, Dehydroepiandrosterone) improves systemic lupus erythematosus. Arth Rheum 43 (Suppl 9): S271, 2000.

Mease PJ, Ginzler EM, Gluck OS, et al. Improvement in bone mineral density in steroid-treated SLE patients during treatment with GL701 (Prasterone, Dehydroepiandrosterone). Arth Rheum 43 (Suppl 9): S206, 2000.

Fraser PA…Mease PJ, et al. TNF alpha-308 rather than HLA-DRB1 alleles are markers of early response to etanercept in Still’s disease in the adult. Arth Rheum 43 (Suppl 9): S228, 2000.

Weinblatt ME …Mease PJ, et al. Etanercept in Still’s disease in the adult. Arth Rheum 43 (Suppl 9): S391, 2000.

Schiff M, Mease PJ, Weinblatt M, et al. Randomized controlled trial of 25 Mg vs. 50 Mg Enbrel® (Etanercept) twice weekly in rheumatoid arthritis (RA). Arth Rheum 43 (Suppl 9): S391, 2000.

Mease PJ, Goffe B, Metz J, Vanderstoep A. Etanercept in patients with psoriatic arthritis and psoriasis. Arth Rheum 42 (Supp.), 1999.

Schiff MH, Moreland LW, Baumgartner SW…Mease P, et al. Quality of life (QOL) and laboratory measures in a phase III trial of TNF-receptor (p75):Fc fusion protein (TNFR:Fc; Enbrel®) in DMARD failing rheumatoid arthritis. Intl Soc Rheum Therapy, 1998.

Schiff MH, Moreland LW, Baumgartner SW…Mease P, et al. TNF receptor (p75): Fc Fusion Protein (TNFR: Fc: Enbrel®) results in improvement in clinical laboratory parameters in patients with rheumatoid arthritis (RA). Intl Soc Rheum Therapy, 1998.

Ehrich E…Mease P, et al. The effect of MK-0966 (VioxxÔ), a cox-2 specific inhibitor, on health related quality of life in osteoarthritis patients. EULAR, 1998.

Baumgartner SW… Mease PJ, et al. Response of elderly patients to TNF receptor p75 FC fusion protein TNFR:Fc; Enbrel®). Arth Rheum 41 (Supp. 9): 559, 1998.

Moreland LW … Mease PJ, et al. Optimal dose of TNF receptor p75 FC fusion protein (TNFR:Fc; Enbrel®). Arth Rheum 41 (Supp. 9): 559, 1998.

Moreland LW … Mease PJ, et al. Long term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc; Enbrel®) in DMARD refractory rheumatoid arthritis (RA). Arth Rheum 41 (Supp. 9): S364. 1998.

Moreland LW… Mease PJ, et al. Long-term treatment of rheumatoid arthritis (RA) with TNF receptor p75 Fc fusion protein (TNFR:Fc; Enbrel®). J Investig Med, 1998.

Moreland LW…Mease PJ, et al. Long-term treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc; Enbrel®). EULAR, 1998.

Moreland LW…Mease PJ, et al. Phase III trial of DMARD failing rheumatoid arthritis patients with TNF receptor p75 fusion protein (TNFR:Fc; Enbrel®). J Investig Med, 1998.

Moreland LW…Mease PJ, et al. Phase III trial of DMARD failing rheumatoid arthritis patients with TNF receptor fusion protein (TNFR:Fc; Enbrel®). EULAR, 1998.

Moreland LW…Mease PJ, et al. Long-term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc; Enbrel®) in DMARD refractory rheumatoid arthritis (RA). Ann Rheum Dis, 1998.

Weinblatt M, Moreland LW, Schiff M…Mease P, et al. Long-term and phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc Enbrel®), Arth Rheum 1997;40 (Supp.9):S126.

Baumgartner SW…Mease P, et al. Phase III and longterm treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc). Rheumatology in Europe, 1997.

Moreland LW…Mease PJ, et al. Long-term treatment of rheumatoid arthritis (RA) with p75 TNF receptor (TNFR:Fc; Enbrel®). 19^th International League of Associations for Rheumatology, 1997.

Blair J, Mease P, Buchwald D, et al. The use of acupuncture as an intervention in a fibromyalgia and chronic fatigue self-management program. J. Musculoskeletal Pain 3 (No. 1)(Supplement): 90, 1995.

Mease PJ, Driscoll P, Uslan D, et al. Multidisciplinary self-management and treatment program for patients with fibromyalgia and chronic fatigue syndrome. Arth Rheum 38 (No. 9) (Supplement): S271, 1995.

Mease PJ, Overman SS, Green DJ. Clinical symptoms/signs and laboratory features in symptomatic patients with silicone breast implants. Arth Rheum 38 (No. 9) (Supplement): S324, 1995.

Townes B, Mease P, Claypoole K, et al. Neurocognitive dysfunctioning in eosinophilia myalgia syndrome. Arth Rheum 35 (No. 9) (Supplement): S67, 1992.

Culpepper RC, Williams RG, Mease PJ, et at. Eosinophilia Myalgia Syndrome (EMS): Epidemiologic features, progression of disease, and therapeutic approaches. Arth Rheum 33(No. 9): 518, 1990.

Bowden RA, Mease PJ: Human Herpes Virus 6 (HHV6) infection in a patient with undifferentiated autoimmune disease; evidence for clinical infection? 28th ICAAC, Los Angeles, California, October 1988.

Mease PJ, Ochs HD: Successful treatment of the dermatomyositis/meningoencephalitis syndrome in X-linked agammaglobulinemia with intravenous immune globulin. Clinical Research 29 (No.1): 92A, 1981.

Mease PJ, Ochs HD, Wedgewood RJ: Successful treatment of the dermatomyositis/meningoencephalitis syndrome in X-linked agammaglobulinemia with intravenous immune globulin. Clinical Research 29 (No. 2): 372A, 1981.

Mease PJ, Ochs HD, Wedgwood RJ: Successful treatment of the ECHO-virus induced dermatomyositis/meningoencephalitis syndrome in X-linked agammaglobulinemia with intravenous immune globulin.15th International Congress of Rheumatology, Paris, France, June, 1981.

Ochs HD, Mease PJ, Wedgwood RJ, Rischer SH: Generalized Echo-11virus infection in X-linked agammaglobulinemia: Successful treatment with large doses of modified gammaglobulin given intravenously. Primary immunodeficiencies, Seligmann, Hitig (editor). INSERUM Symposium No. 16, The Netherlands: Elsevier, North Holland Biomedical Press, 513-514, 1980.

NEWSLETTERS and PERIODICAL ARTICLES

2005 Editor, Quarterly Newsletter on Rituximab, Genentech

1998-2001 Quarterly Q & A column, Lupus Foundation Newsletter, WA State Chapter.

1995 1995 DHEA and Lupus, Newsletter of the American Lupus Society - Seattle/Bellevue Chapter.

1996 1996 Rheumatological Disorders Associated with Celiac Sprue and Dermatitis Herpetiformis. Newsletter of the Gluten Intolerance Group of North America.

RESEARCH ACTIVITIES

2001-2014

ABT-981 (DMOAD0 in hand OA, PI (Abbvie)

ABT-981 (DMOAD) in knee OA, PI (Abbvie)

Tofacitinib in PsA, TNF IR (PI)(Pfizer)

Clazakizumab (IL 6i) in RA, TNF IR (PI) (BMS)

JAK 1i (ABT-494) in RA, TNF IR, Phase 2 (PI) (Abbvie)

JAK 1i (GLPG0634) in RA, MTX IR Phase 2 (PI) (Galapagos)

Secukinumab (IL17Ai) in PsA, Phase 3, TNF IR (PI)(Novartis)

Brodalumab in PsA (IL17Ri), Phase 3 TNF IR (PI) (Amgen)

Brodalumab in PsA (IL17Ri), Phase 3, MTX IR (PI)(Amgen)

Adalimumab in non-radiographic axial spondyloarthritis (PI)(Abbvie)

Cerephex NPT-301in FM (PI)(Cerephex)

Tonix-102 in fibromyalgia (PI)(Tonix)

Ixekizumab in PsA (PI) (Lilly)

GRT6005 in osteoarthritis of the knee (PI) (Forest)

TD-9855 in fibromyalgia (PI) (Theravance)

Abatacept SQ in PsA (PI) (BMS)

Ixekizumab (IL-17i) SQ in AS (PI) (Lilly)

Tofacitinib in PsA, MTX IR (PI) (Pfizer)

Tofacitinib in AS (PI)(Pfizer)

JAK inhibitor in RA (PI) (Vertex)

IL-20 inhibitor in RA (PI) (Novo Nordisk)

Adalimumab in peripheral spondyloarthritis (PI)(Abbvie)

Adalimumab in axial spondyloarthritis (PI) (AbbVie)

CORRONA Spondyloarthritis/Psoriatic Arthritis Effectiveness Registry

CORRONA Gout Effectiveness Registry

Prevalence of axial spondyloarthritis (SpA) in adults with chronic back pain (PI) (AbbVie)

Genetic analysis of psoriasis and psoriatic arthritis (Univ. of Michigan, Dept. of Dermatology)

Blood collection in systemic lupus erythematosus and Sjogren’s Syndrome (PI) (Resolve)

Blood collection in PsA, RA, SLE: Mechanistic and Biomarker studies (PI) (Novo Nordisk)

Biomarkers of anti-TNF therapy efficacy in RA (BATTER UP) (PI) (Crescendo)

RA BIODAM prospective validation of soluble biomarkers as predictors of

structural damage (PI) (OMERACT) (CaRE Arthritis)

Epidemiological study of fibromyalgia in the U.S. (PI) (Covance)

Blood collection in systemic lupus erythematosus (PI) (Amgen)

PREPARE (Prevalence of Psoriatic Arthritis in Adults with Psoriasis) (PI) (Pfizer)

CORRONA CERTAIN Effectiveness Registry – RA (CORRONA CERTAIN sub-study)

CORRONA RA and PsA effectiveness registries (CORRONA Data Collection Program)

PsA GRACE Registry (PI) (Group for Research and Assessment of Psoriasis and PsA)

Biomarkers in RA (PI) (Crescendo Bioscience)

IL-6 inhibitor in RA (PI) (BMS)

JAK inhibitor in RA (PI) (Lilly)

Epratuzumab in lupus (PI) (UCB)

BAFF inhibitor in lupus (PI) (Lilly)

Lupuzor in lupus (PI) (Cephalon)

IL-17 inhibitor in PsA (PI) (Novartis)

IL-17 inhibitor in PsA (PI)(Amgen)

Adalimumab in RA (ultrasound study) (PI)(Abbott)

Tocilizumab subcu in RA (PI) (Roche)

Certolizumab in PsA (PI)(UCB)

Certolizumab in AS (PI) (UCB)

Focus groups on fatigue in FM (PI) (Pfizer)

Golimumab comparator other anti-TNFs in RA (PI)(Centocor)

Apremilast in PsA (PI)(Celgene)

Milnacipran in combination with pregabalin (PI) (Forest)

Adalimumab in peripheral spondyloarthropathy – (International PI)(Abbott)

Adalimumab in axial spondyloarthropathy (non-AS) – (PI)(Abbott)

JAK inhibitor in RA (synovial biomarker study) – (PI)(Pfizer)

JAK inhibitor in RA (comparator to adalimumab) – (PI)(Pfizer)

Development of fibromyalgia questionnaire bank for the PROMIS Network (co-PI, NIH grant)

Development of a responder index for fibromyalgia (consultant, NIH grant)

JAK inhibitor in RA - 3 (PI) Pfizer

Criteria development for fibromyalgia (collaborative research with Wolfe, F, et al)

Milnacipran in fibromyalgia (sub-focus on fatigue) (PI)(Forest)

Sodium oxybate in fibromyalgia – (PI)(Jazz Pharma)

Rituximab combined with anti-TNF therapy in RA (PI)(Genentech)

Spondyloarthritis survey of US and European rheumatologists (PI) (SPARK)(Abbott)

Blood sampling re.lupus (Amgen)

Synovial fluid sampling in knee OA (Amgen)

Baminercept in RA (PI) Biogen-Idec

TRU-015 in RA (PI) Wyeth

Tocilizumab in RA – MTX IR (Roche)

Ocrelizumab in RA (PI) Genentech

Ocrelizumab in lupus (PI) Genentech

Fatigue questionnaire development (Forest)

Central Neural Pulse therapy in fibromyalgia (PI) Fralex

Pramipexole in fibromyalgia (PI) Boehringer-Ingelheim

JAK3 inhibitor in RA – 2B (PI) Pfizer

Milnacipran in fibromyalgia (PI) Cypress/Forest

Duloxotine in fibromyalgia (PI) Lilly

Pregabalin in fibromyalgia (PI) Pfizer

Partial alpha 2 agonist in fibromyalgia (PI) Allergan

Rituximab in psoriatic arthritis (Investigator initiated – PI) Genentech

Fatigue questionnaire development (Pfizer)

Anti-TNF (golimumab) in PsA (PI) Centocor

Anti-TNF (golimumab) in AS (PI) Centocor

Intra-articular gene therapy (anti-TNF) in RA/PsA(PI) Targeted Genetics

Anti-IL1 in osteoarthritis (PI) Amgen

Anti-IL1 in osteoarthritis (PI) Regeneron

Tocilizumab in RA – TNF IR (PI) (Roche)

Pregabalin in FMS (III) (PI) Pfizer

Duloxotine in FMS (III) (PI) Lilly

TACE inhibitor (anti-TNF) in RA (PI) (Wyeth)

Rituxan in SLE (PI) (Genentech)

Rituxan in PsA (PI-Lead independent investigator) (Genentech)

Intra-articular gene therapy (anti-TNF) in RA (IA)(Principal and National PI)(Targeted Genetics)

Anti-BLYS therapy in SLE (Safety Monitor)(Zymogenetics)

Expert Delphi in FMS domains (PI) (OMERACT)

5HT2 antagonist in fibromyalgia (Principal Investigator)(Sanofi)

Adalimumab in ankylosing spondylitis (Principal Investigator)(Abbott)

Milnacipran in Fibromyalgia (Phase III) (Principal Investigator)(Cypress Bioscience)

Prexige in knee OA (Phase III)(Principal Investigator)(Novartis)

Growth hormone secretagogue in Fibromyalgia (Principal Investigator)(Pfizer)

Pregabalin in FMS (III)(PI) Pfizer

Psoriatic Arthritis Clinical Registry and Genomics Project – National Psoriasis Foundation (PI)

Infliximab in Psoriatic Arthritis (Principal Investigator) Centocor

Adalimumab in Psoriatic Arthritis (Principal Investigator and National PI) Abbott

Efalizumab in Psoriatic Arthritis (Principal Investigator) Xoma, Genentech

Rituximab in RA (Principal Investigator) Genentech

Rituximab in RA (Principal Investigator) Idec

P38 MAP Kinase Inhibitor in RA (Principal Investigator) Scios

ICE compound in RA (Principal Investigator) Aventis

Clinical Criteria Development for Psoriatic Arthritis – CASPAR (PI)

DHEA in SLE bone density – Genelabs Technologies (PI)

MRI assessment of RA disease progression – Amgen (with John Sharp)

Autoimmune disease patient blood sampling – Zymogenetics (PI)

Autoimmune disease patient blood sampling – Seattle Genetics (PI)

Autoimmune disease patient blood sampling – XCYTE Therapies (PI)

Stem Cell Transplantation in Scleroderma – Fred Hutchinson Cancer Research Center CDX189 (COX-2 agent) in OA and RA – safety and efficacy (Principal Investigator) (Novartis)

Soluble IL-1 Receptor Type I in RA patients on Enbrel® (Principal Investigator) (Amgen)

National registry of RA, PsA, Osteoporosis (CORRONA)

RADIUS 2 – Natural history of RA in patients initiating Enbrel® (Principal Investigator) (Amgen)

Etoricoxib v. Diclofenac in OA – safety and efficacy (Principal Investigator) (Merck)

Milnacipran v. placebo in fibromyalgia (Principal Investigator) (Cypress Bioscience)

Pregabalin in fibromyalgia and diabetic peripheral neuropathy (Principal Investigator) (Pfizer)

Enbrel® in ankylosing spondylitis (Principal Investigator) (Immunex)

Soluble IL-1 Receptor Type II in RA (Principal Investigator) (Immunex)

Enbrel® in psoriatic arthritis and psoriasis (Principal Investigator/protocol development) (Immunex)

Duloxitene in fibromyalgia (Principal Investigator) (Lilly)

Enbrel® in RA – longterm safety and efficacy (Principal Investigator) (Immunex)

Choices – osteoporosis patient education research (Principal Investigator) (Procter & Gamble/Aventis)

Rheumatoid joint tissue sampling for genetic therapy development (Principal Investigator) (Targeted Genetics)

RADIUS I – Natural history study of RA treated with DMARDs or Biologics (PI) (Immunex)

Infliximab in RA – the iRAMT trial (Principal Investigator) (Centocor)

2000

Psoriasis skin transplantation to SCID mice (Principal Investigator/protocol development) (Zymogenetics)

Pregabalin in diabetic neuropathy (Principal Investigator) (Pfizer)

Enbrel® in psoriatic arthritis and psoriasis (Principal Investigator/protocol development) (Immunex)

Enbrel® in RA with co-morbid diseases (Principal Investigator) (Immunex)

Remicade in RA (Principal Investigator) (Centocor)

Anti-TNF (pegylated) in RA (Sub-Investigator) (Amgen)

Insulin growth factor 1 in OA (Principal Investigator) (Chiron)

Lupus patient blood sampling (Principal Investigator) (Cellpath)

Autoimmune disease patient blood sampling (Principal Investigator/protocol development) (Zymogenetics)

Enbrel® in RA – long term safety and efficacy (Principal Investigator) (Immunex)

Valdecoxib in OA and RA (Principal Investigator) (Searle)

Pregabalin in Fibromyalgia (Principal Investigator) (Parke-Davis)

Vioxx in RA (Principal Investigator) (Merck)

1999

Enbrel® in psoriatic arthritis and psoriasis (Principal Investigator/protocol development/FDA submission with Immunex support)

Enbrel® in RA: 25 vs. 50 mg dosing (Principal Investigator) (Immunex)

Anti-TNF (pegylated) in RA (Sub-Investigator) (Amgen)

Risedronate – weekly vs. daily dosing in Osteoporosis (Principal Investigator) (P&G/HMR)

Pregabalin in Fibromyalgia (Principal Investigator) (Parke-Davis)

Valdecoxib in OA and RA (Principal Investigator) (Searle)

Celebrex (Cox-2 NSAID) Gastrotoxicity (OA/RA) (Principal Investigator) (Searle)

D2E7(anti-TNF)in RA (Sub-Investigator) (Knoll)

DHEA in Lupus (Principal Investigator) (Genelabs)

Parathyroid Hormone in Osteoporosis (Principal Investigator) (Lilly)

Idoxifene in Postmenopausal Women with Vasomotor Symptoms (Principal Investigator) (SmithKline Beecham)

Idoxifene in Osteoporotic and Osteopenic Women (Principal Investigator) (SmithKline Beecham)

Anti-TNF in RA (Sub-Investigator) (Roche)

Enbrel® in RA (Principal Investigator) (Immunex)

UCLA RA Treatment Outcome Study

NSAID Gastrotoxicity (Principal Investigator) (Searle)

Vioxx in OA/RA (Sub-Investigator) (Merck)

Colloral in RA (Principal Investigator) (Autoimmune)

Bay 12-9566 (metalloproteinase inhibitor) in OA (Principal Investigator) (Bayer)

1998

Enbrel® in psoriatic arthritis and psoriasis (Principal investigator/protocol development/FDA submission with Immunex support)

Celebrex (COX-2 NSAID) Gastrotoxicity (OA/RA) (Principal Investigator) (Searle)

D2E7 anti-TNF DMARD in RA (Sub-Investigator) (Knoll)

RA Therapeutic Vaccine (Principal Investigator) (Anergen)

TAK-603 in RA (Principal Investigator) (TAP)

SN-2011 in Sjogren’s Syndrome (Principal Investigator) (Snow Brand)

DHEA in Lupus (Principal Investigator) (Genelabs)

Parathyroid Hormone in Osteoporosis (Principal Investigator) (Lilly)

Idoxifene in Postmenopausal Women with Vasomotor Symptoms (Principal Investigator) (SmithKline Beecham)

Idoxifene in Osteoporotic and Osteopenic Women (Principal Investigator) (SmithKline Beecham)

TNF in RA (Sub-Investigator) (Roche)

Enbrel® in RA (Principal Investigator) (Immunex)

UCLA RA Treatment Outcome Study

NSAID Gastrotoxicity (Principal Investigator) (Searle)

Vioxx in OA/RA (Sub-Investigator) (Merck)

Colloral in RA (Principal Investigator) (Autoimmune)

Bay 12-9566 (metalloproteinase inhibitor) in OA (Principal Investigator) (Bayer)

1997

DHEA in Lupus (Principal Investigator) (Genelabs)

Parathyroid Hormone in Osteoporosis (Principal Investigator) (Lilly)

Idoxifene in Postmenopausal Women with Vasomotor Symptoms (Principal Investigator) (SmithKline Beecham)

Idoxifene in Osteoporotic and Osteopenic Women (Principal Investigator) (SmithKline Beecham)

TNF in RA (Sub-Investigator) (Roche)

Enbrel® in RA (Principal Investigator) (Immunex)

UCLA RA Treatment Outcome Study

NSAID Gastrotoxicity (Principal Investigator) (Searle)

Anti-CD4 in RA (Sub-Investigator) (SmithKline Beecham)

1996

TNFR in RA (Principal Investigator) (Immunex)

DHEA in Lupus (Principal Investigator) (Genelabs)

Cox-2 Anti-inflammatory in OA (Principal Investigator) (Merck)

Idoxifene for Vasomotor Symptoms (Principal Investigator) (SmithKline Beecham)

Anti-CD4 in RA (Sub-Investigator) (SmithKline Beecham)

TNF in RA (Sub-Investigator) (Roche)

UCLA RA Treatment Outcome Study

1995

Cox-2 Anti-inflammatory (Principal Investigator) (Merck)

DHEA in Lupus (Principal Investigator) (Genelabs)

sTNFR-IgG in RA (Co-principal investigator) (Hoffmann-LaRoche)

Piroxicam B-cyclodextrin vs. Piroxicam in OA (Principal Investigator) (Pfizer)

Silicone-related rheumatic disorders, Fibromyalgia/CFS

Fibromyalgia/CFS

1994

sTNFR-IgG in RA (Roche)

Deflazacort in RA (Marion Merrell-Dow)

Silicone related rheumatic disorders

Fibromyalgia/CFS

H2B342 Ranitidine Bismuth Citrate Prophylaxis of NSAID-induced GU/DU (Glaxo)

1992–1993

Silicone related disorders

Eosinophilia Myalgia Syndrome (EMS)

Fibromyalgia/CFS

1989-1991

EMS

FM/CFS

CONTINUING MEDICAL EDUATION—FACULTY AND/OR CHAIR

“Fundamentals of Psoriatic Arthritis” Interdisciplinary Autoimmune Summit (CME), NYC 2016

“Spondyloarthritis: 2016 Update” Interdisciplinary Autoimmune Summit (CME), NYC 2016

“Psoriatic Arthritis: 2016 Update” Rheumatology CME, SPARTAN-GRAPPA Educational Symposia, Boise ID, March 2016

“Biologic Management of PsA and SpA” Utah Rheum Society CME, Salt Lake City, 2016

SPARTAN-GRAPPA Educational Symposia, Panama, Program Co-Chair and Faculty, April 2016.

National Psoriasis Foundation - GRAPPA, Dermatology / Rheumatology CME, Program Co-Chair and Faculty, April 2016

“Interdisciplinary Autoimmune Summit” North American Center for Continuing Medical Education (NACCME), Steering Committee and Faculty, April 2016

“Interdisciplinary Autoimmune Summit 2015” North American Center for Continuing Medical Education (NACCME), Co-Program Chair, NY, NY. 2015.

“PsA Update” SPARTAN-GRAPPA Educational Symposia, San Antonio TX, Feb 2015.

SPARTAN-GRAPPA Educational Symposia, Chicago IL, Oct 2014.

“Comorbidities of PsA and SpA” SPARTAN-GRAPPA Educational Symposia, Rheumatology CME, Washington DC, Sep 2014.

“Clinical Presentation of PsA and SpA” SPARTAN-GRAPPA Educational Symposia, Rheumatology CME, Washington DC, Sep 2014.

“Physical Examination of PsA and SpA” SPARTAN-GRAPPA Educational Symposia, Rheumatology CME, Washington DC, Sep 2014.

“Update on Spondyloarthritis” Rheumatology Fellows National CME (Annennberg), Roanoke, VA

“PsA: Past, Present and Future” Rheumatology Fellows National CME (Annennberg), Roanoke, VA

“Physical Examination of Psoriatic Arthritis and Ankylosing Spondylitis” Rheumatology CME, Sacramento, CA

“Psoriatic Arthritis: Management”, SPARTAN-GRAPPA Educational Symposia, Rheumatology CME, Sacramento, CA

“Physical Examination of PsA and SpA”, SPARTAN-GRAPPA Educational Symposia, Rheumatology CME, Sacramento, CA

“Psoriatic Arthritis: Clinical Features and Assessment” Rheumatology CME, Sacramento, CA

“Advances in Spondyloarthritis: Translational biology, Classification, and Therapy Symposium.” CME provider: Cleveland Clinic Center for Continuing Education. Faculty. October 27, 2013.

Point of Care360 Rheumatoid Arthritis. Editor in Chief: Philip J. Mease, MD.
CME provider: Projects in Knowledge. October 2013:

Chapter 1.1 Epidemiology of Rheumatoid Arthritis. Faculty: Jon T. Giles, MD. MPH & Philip J. Mease, MD.

Chapter 2.1 Etiology of Rheumatoid Arthritits. Faculty: Eric L. Matteson, MD, MPH & Philip J. Mease, MD.

Chapter 2.2 Pathophysiology of Rheumatoid Arthritis: Implications for Therapy. Faculty: Eric L. Matteson, MD, MPH & Philip J. Mease, MD.

Chapter 3.1 Optimizing Early and Accurate Diagnosis of Rheumatoid Arthritis. Faculty: Philip J. Mease, MD.

Chapter 4.1 Achieving and Measuring Remission and Minimal Disease in Rheumatoid Arthritis. Faculty: Philip J. Mease, MD.

Chapter 4.2 Where Are We After More Than a Decade of TNF Inhibitor Therapy in Rheumatoid Arthritis? Faculty: Eric M. Ruderman, MD & Philip J. Mease, MD.

Chapter 4.3 Currently Available Non-TNF-Targeting Biologics for Rheumatoid Arthritis. Faculty: Leonard H. Calabrese, DO & Philip J. Mease, MD.

Chapter 4.4 Emerging Oral Biologic Therapies for Rheumatoid Arthritis. Faculty: Mark D. Cohen, MD & Philip J. Mease, MD.

Chapter 4.5 Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis. Faculty: Kathryn F. Hobbs, MD & Philip J. Mease, MD.

Chapter 4.6 Optimizing and Individualizing Treatment. Faculty: Philip J. Mease, MD.

Chapter 4.7 Comparative Effectiveness: Evaluating Safety and Efficacy. Faculty: Marc D. Cohen, MD & Philip J. Mease, MD.

Chapter 5.1 Management of Established Disease: Monitoring and Treatment of Comorbid Conditions. Faculty: M. Elaine Husni, MD, MPH & Philip J. Mease, MD.

7th Annual Mentoring in Rheumatology, Advancing the Care and Treatment of Rheumatologic Diseases. Presenter and Mentor: “Psoriatic Arthritis and Ankylosing Spondylitis: New Developments,” “Case Presentations.” CME provider: Annenberg Center for Health Sciences. Phoenix AZ, Sept 27-28, 2013.

“Current and Future Directions of the Diagnosis, Assessment and Treatment of Psoriatic Arthritis.” CME Provider: Penn State College of Medicine. Course Director. 2013.

Series: Spondyloarthritis Reseach and Treatment Network and Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (SPARTAN-GRAPPA) Educational Symposia on Axial Spondyloarthritis and Psoriatic Arthritis. Program co-chairs: Philip Mease and Atul Deodhar.

Mease P: “Screening and Assessment of Spondyloarthritis and Psoriatic Arthritis,” “Management of Spondyloarthritis and Psoriatic Arthritis: Biologics,” “Epidemiology and Classification of Spondyloarthritis and Psoriatic Arthritis,” “SpA and PsA Physical Exam - Spine, Enthesitis, Skin & Nails.” CME provider: Oregon Health Sciences University. Seattle WA, Sept. 2013.

Mease P: “Co-morbidities and Management of PsA,” “SpA and PsA physical exam: spine, enthesitis, skin & nails.” CME provider: Oregon Health Sciences University. Santa Monica CA, Feb. 2013.

Mease P: “SpA and PsA physical exam: spine, enthesitis, skin & nails.” CME provider: Oregon Health Sciences University. San Francisco CA, March 2013.

Mease P: “Pathogenesis and Genetics of Spondyloarthritis and Psoriatic Arthritis,” “Screening and Assessment of Spondyloarthritis and Psoriatic Arthritis,” “SpA and PsA physical exam: spine, enthesitis, skin & nails.” CME provider: Oregon Health Sciences University. Glendale AZ, Jan. 2013.

Mease P: “Epidemiology and Classification of Spondyloarthritis and Psoriatic Arthritis,” “Screening and Assessment of Spondyloarthritis and Psoriatic Arthritis,”

‘Co-morbidities in Spondyloarthritis and Psoriatic Arthritis,” “SpA and PsA physical exam: spine, enthesitis, skin & nails.” CME provider: Oregon Health Sciences University. La Jolla CA, June 2013.

Mease P: “Assessment of Spondyloarthritis and Psoriatic Arthritis,” “Treatment of Spondyloarthritis and Psoriatic Arthritis.” CME provider: Rocky Mountain Rheumatology Society annual meeting. Sun Valley ID, 2013.

Mease P: “Epidemiology and Classification of Spondyloarthritis and Psoriatic Arthritis - Biologics,” “SpA and PsA physical exam: spine, enthesitis, skin & nails.” CME provider: Oregon Health Sciences University. Portland OR, July 2012.

Mease P: “Clinical Aspects of Spondyloarthritis and Psoriatic Arthritis,” “Management of Spondyloarthritis and Psoriatic Arthritis: Biologics,” “SpA and PsA physical exam: spine, enthesitis, skin & nails.” CME provider: Oregon Health Sciences University. Houston TX, Dec. 2012.

Rheumatology Living Medical eTextbook. Editor in Chief: Philip J. Mease, MD.
Released: April 2011, Updated Sept 2012. CME provider: Projects in Knowledge:

Chapter 1 - Pathophysiology of Rheumatoid Arthritis: Implications for Therapy.

Faculty: Philip J. Mease

Chapter 2 - Optimizing Early and Accurate Diagnosis of Rheumatoid Arthritis.

Faculty: Philip J. Mease

Chapter 3 - Achieving and Measuring Remission and Minimal Disease in Rheumatoid

Arthritis.

Faculty: Philip J. Mease

Chapter 4 - Where Are We After More Than a Decade of TNF Inhibitor Therapy in

Rheumatoid Arthritis?

Faculty: Eric M. Ruderman and Philip J. Mease

Chapter 5 - Currently Available Non-TNF-Targeting Biologics for Rheumatoid

Arthritis.

Faculty: Leonard H. Calabrese and Philip J. Mease

Chapter 6 - Emerging Oral Biologic Therapies for Rheumatoid Arthritis.

Faculty: Mark D. Cohen and Philip J. Mease

Chapter 7 - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis.

Faculty: Kathryn F. Hobbs and Philip J. Mease

Chapter 8 - Management of Established Disease: Monitoring and Treatment of

Comorbid Conditions.

Faculty: M. Elaine Husni and Philip J. Mease

“Rheumatology Highlights Report - Advances in Psoriatic Arthritis.” Faculty.
Webcast available January 12, 2012 through January 12, 2013. CME provider: Cleveland Clinic Center for Continuing Education.

“Use of Biomarkers to Individualize RA Management” Peer View Press. 2012 Podcastdirectory.com

“Update on Psoriatic Arthritis and Spondyloarthritis” Annenberg Foundation Program for Rheumatology Fellows. San Francisco, CA, 2012.

“Pain Management in the Rheumatology Setting: Individualized Multimodal Therapies for Improved Patient Function.” www.medscape.org. March 7, 2012 through March 7, 2013. CME provider: PainTopics.org

“Update on Psoriatic Arthritis and Spondyloarthritis” CME provider: Annenberg Foundation Program for Rheumatology Fellows. San Francisco, CA, 2012.

“New GRAPPA Recommendations for Managing Psoriatic Disease.” CHICAGO, IL Sept. 2010. CME provider: PESI, LLC is accredited by the Accreditation Council for Continuing Medical Education.

“Strategies to Maintain Tight Control of Rheumatoid Arthritis.” April 2009 through April 30, 2010. raoutlook.org. CME provider: Curatio CME Institute.

“Medical Case Views: A Case-Based Approach to Discuss the Diagnosis and Treatment of Patients With Fibromyalgia.” Presented by Temple University School of Medicine and HealthcareFirst. June 2010 through June 2011. CME provider: Medical Crossfire. Faculty.

Cecentral.com. Rheumatoid Arthritis Educational Challenge (RAEC) Faculty. University of Kentucky. RA: Educational challenge.

Clinical Updates for Nurse Practitioners and Physician Assistants: Dec. 2011 Seattle, WA. CME provider: Naceonline.com

Three patient visits CORE CME provider: NACCME. July 2010 – Sept 2011.

“Using Patient Encounters to Demonstrate Best Practices in Patient Management Among the Rheumatoid Arthritis Clinical Community.” PRIME 3/29/11 and 6/7/11.

“Rheumatology Highlights Report – Post 2009 National Meeting: Psoriatic Arthritis.” Webcast available December 3, 2009 through December 3, 2010. CME provider: Cleveland Clinic Center for Continuing Education. Faculty.

“Improving Patient Outcomes in Fibromyalgia: A Clinical Update on Appropriate Diagnosis, Adequate Treament, and Proper Management of Comorbid Conditions.” Webcast available October 26, 2009 through October 25, 2010. CME provider: Semel Institute for Neuroscience and Human Behavior at UCLA and PVI, PeerView Institute for Medical Education. Faculty.

“Strategies for Improving Treatment Outcomes in Patients with Rheumatoid Arthritis: An Interactive, Virtual, Case-Based Exploration.” Workshop, October 18, 2009. CME provider: Temple University School of Medicine. Faculty.

“Barriers to Recognition and Diagnosis of Fibromyalgia in the Primary Care Setting.” Webcast, October 7, 2009. CME provider: University of Michigan Medical School and the National Fibromyalgia Association. Faculty.

“Exploring Psoriatic Arthritis: Bridging Dermatology and Rheumatology.” Webcast available July 2, 2009 through July 2, 2010. CME provider: The Cleveland Clinic Foundation Center for Continuing Education and DIME. Steering Committee Member.

“Management Challenges in Rheumatic Diseases: An Update on Best Practices.” Workshop, June 30, 2009. CME provider: NACCME. Faculty.

“Strategies to Maintain Tight Control of Rheumatoid Arthritis.” Webcast available April 2009 through April 30, 2010. CME provider: Curatio CME Institute. Faculty.

“Management Challenges in Rheumatic Diseases: An Update on Best Practices.” Workshop, March 31, 2009. CME provider: NACCME. Faculty.

“Rheumatoid Arthritis Educational Challenge Webcast - a 1-hour presentation from the live regional meetings.” Webcast available January 22, 2009 through January 22, 2010. CME provider: University of Kentucky and Gullapalli & Associates. Faculty.

“Milestones in Rheumatoid Arthritis.” Webcast available January 20, 2009 through January 20, 2010. CME provider: Temple University School of Medicine. Faculty.

“Continuing Medical Education: Rheumatology CME 2009: Latest Developments in Biologics for Rheumatoid Arthritis: From Science to Practice: Scientific Congress Update.” Webcast available December 19, 2008 through December 18, 2009. CME Provider: Scientific Congress Update. Course Director and Program Chair.

"Treating to remission in rheumatoid arthritis." Achieving therapeutic targets to improve quality of life. PCME Potomac Center for Medical Education. Chairperson. 8/2011

“Individualizing Rheumatoid Arthritis Management: A Practice-Based Approach.” Webcast available Dec 17, 2008 through Dec 17, 2009. CME provider: University of Kentucky and Gullapalli & Associates. Faculty.

“Rheumatology Arthritis Educational Challenge: Case Study.” Webcast available Dec 15, 2008 through Dec 15, 2009. CME provider: Potomac Center for Medical Education. Faculty.

“Fibromyalgia: Managing the Syndrome of Abnormal Pain Processing.” Webcast available through December 12, 2009. CME provider: Pri-Med Institute. Faculty.

“Emerging Novel Biologic Agents for Inflammatory Joint Diseases – Role in Clincal Practice: An Expert Interview with Philip J. Mease, MD.” Interview, December 11, 2008. CME provider: Medscape Rheumatology.

“A Closer Look at Diagnosing and Treating Fibromyalgia.” Webcast available November 28, 2008 through November 28, 2009. CME Provider: NACCME. Faculty.

“Expert Insights: New Frontiers in the Treatment of Fibromyalgia.” Article available for credit November 14, 2008 through November 13, 2009. CME provider: Indiana University School of Medicine and Health Focus, Inc. Executive Editor.

“Individualizing Rheumatoid Arthritis Management: A Practice-Based Approach.” Workshop, October 28, 2008. CME provider: Potomac Center for Medical Education. Faculty.

“Seminar in Advanced Rheumatology: Selected Proceedings of a Live Symposium held March, 2008. Bulletin of the NYU Hospital of Joint Diseases.” Article available for credit October 15, 2008 through October 14, 2009. CME Provider: NYU Post-Graduate Medical School. Faculty.

“New Frontiers in the Treatment of Fibromyalgia: Treatment Options: Current, Emerging, and Future Promise.” Articles, September 2008. CME Provider: Indiana University School of Medicine and Health Focus, Inc. Executive editor and author.

“Putting Together the Fibromyalgia Puzzle: New Understandings in Pathophysiology and Management.” Webcast available September 18, 2008 through September 18, 2009. CME provider: INNOVIA Education Institute, LLC. Author.

“Recognizing Fibromyalgia Syndrome as a True Disease Entity.” Presentation available for credit August 29, 2008 through August 29, 2009. CME provider: Medscape. Author.

“Treating Fibromyalgia Pain and Beyond: Pathophysiology and Management of Multiple Symptom Domains.” Article available for credit July 31, 2008 through July 31, 2009. CME provider: Medscape. Author.

“Exploring Fibromyalgia: Expert Perspectives on Diagnosis and Impact.” Webcast available July 18, 2008 through July 17, 2009. CME provider: University of Michigan Medical School. Faculty.

“Beyond Efficacy and Safety in Rheumatoid Arthritis Treatment: Quality-of-Life Outcomes With Newer Biologics in RA.” Webcast available April 10, 2008 through April 9, 2009. CME provider: University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. Course Director.

“Can HRQOL Be Sustained in the Long Term With Abatacept and Rituximab?” Webcast available April 10, 2008 through April 9, 2009. CME provider: the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. Course Director.

“Long-Term Data on Abatacept and Rituximab Show Continued Efficacy in Rheumatoid Arthritis.” Webcast available April 10, 2008 through April 9, 2009. CME provider: University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. Course Director.

“Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis.” Webcast available February 18, 2008 through May 26, 2010. CME provider: Cleveland Clinic Foundation Center for Continuing Education. Faculty.

“Current Concepts in Psoriasis and Psoriatic Arthritis.” Webcast available February 14, 2008 through May 26, 2010. CME provider: Cleveland Clinic Richard J. Fasenmyer Center of Clinical Immunology Biologic Therapies for Autoimmune and Inflammatory Disease States Summit. Faculty.

Mease PJ. ACR 2007: Fibromyalgia. Medscape CME Review of ACR 2007, 2007.

“Fibromyalgia: Mechanisms, Clinical Aspects and Efficacy and Safety of Treatments.” Article available for credit December 21, 2007. CME provider: Medscape. Author.

“Novel Therapies in the Treatment of Rheumatoid Arthritis.” Webcast available December 18, 2006. CME Provider: Scinexa, LLC. Faculty.

“Psoriatic Arthritis Therapy Advances.” Article available August 3, 2005 through August 3, 2006. CME provider: Medscape. Author.

“Psoriatic Arthritis: Understanding Its Pathophysiology and Improving Its Diagnosis and Management.” Article available for credit July 28, 2005 through July 28, 2006. CME provider: University of New Mexico School of Medicine. Author.

Making a Difference in Rheumatology: Early and aggressive treatment, better outcomes for today’s patients. Editor: M. Schiff, MD. A CME Textbook. 2004. CME provider: Rheumatology Educational Initiative (REDI). Veritas Institute for Medical Education and MedLearning Inc.

Chapter 7 - Psoriatic Arthritis Update. Philip Mease, MD

Chapter 8 – The Pathogenesis and Treatment of Psoiasis. Alan Menter, MD and Philip Mease, MD

“New Horizons in TNF Inhibition – Topic 1: Treating Ankylosing Spondylitis.” Webcast available December 17, 2003 through December 17, 2004. CME provider: Discovery Institute of Medical Education. Co-Chair.

“National Pain Forum, Fibromyalgia: What is it? How is it managed? Can clinical trials be performed? A rheumatologist’s perspective.” Philadelphia PA Oct 2004. CME Sponsor: Academy for Healthcare Education and Beth Israel Medical Center.

INVITED PRESENTATIONS & SYMPOSIA

2016

“Emerging Therapies for Psoriatic Arthritis and Axial Spondyloarthritis” PANLAR, Panama

“Psoriatic Arthritis: Epidemiology, Assessment, and Management” PANLAR, Panama

“Psoriatic Arthritis, Overview” Investigator meeting, Mainz, Germany

“PsA: Physical Examination” Investigator meeting, Mainz, Germany

“Psoriasis: Skin and Nail Examination” Investigator meeting, Mainz, Germany

“Fundamentals of Psoriatic Arthritis” Interdisciplinary Autoimmune Summit (CME), NYC

“Spondyloarthritis: 2016 Update” Interdisciplinary Autoimmune Summit (CME), NYC

“Psoriatic Arthritis: 2016 Update” Rheumatology CME, Boise, ID

“Psoriatic Arthritis: 2016 Update” Rheumatology GR, Cerrahpasa University, Istanbul

“PsA Overview” Investigator meeting, NYC

“PsA: Physical Examination” Investigator meeting, NYC

“Psoriasis Skin and Nail Examination” Investigator meeting, NYC

“Biologic Rationale for Hyaluronate Therapy in OA” Rheumatology CE, webinar

“Psoriatic Arthritis: Diagnosis and Treatment” Rheumatology CE, Seattle

“Psoriatic Arthritis: Diagnosis and Management” Dermatology CE, AAD, NYC

“Biologic Rationale for Hyaluronate Therapy in OA” Rheumatology CE, Webinar

“GRAPPA Educatoinal Objectives” Derm-Rheum CE, Seoul, Korea

“PsA Management” Derm-Rheum CE, Seoul, Korea

“Treating to Target in PsA” Derm-Rheum CE, Seoul, Korea

“PsA: Physical Examination” Derm-Rheum CE, Seoul, Korea

“Future of PsA Management” Derm-Rheum CE, Seoul, Korea

“Biologic Management of PsA and SpA” Utah Rheum Society CME, Salt Lake City

“Fundamentals of PsA” Dermira meeting, Portland, OR

“Biologic Rationale for Hyaluronate Therapy in OA” Rheumatology CE, webinar

“TH17 and IL-17 Pathway in PsA and Psoriasis” SpA Research Symposium, Berlin

2015

“TH17 and IL-17 Biology in Psoriasis and PsA” Rheumatology CE, ACR, SF, CA

“JAK Inhibition in RA” Rheumatology CE, ACR SF, CA

“Psoriatic Arthritis Update” Meet the Professor session, ACR, SF, CA

“Multidisciplinary Care of PsA” Rheum-Derm CE, ACR, SF, CA